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Dihydrolipoamide dehydrogenase (DHlipDH) has been discovered in the 
mammalian bloodstream form of the protozoal parasite Trypanosoma brucei brucei 
(Danson, M J., Conroy, K., McQuattie, A. & Stevenson, KJ. (1987) Biochem. J. 243, 661- 
665). This organism has a repressed mitochondrion which does not contain the 2-oxo acid 
dehydrogenase complexes, of which DHlipDH is normally a component part.
Within the cell, DHlipDH has been located to the whole surface of the plasma 
membrane, including the flagellar pocket region, by subcellular fractionation. Latency 
studies demonstrated that it is at the cytoplasmic face of this membrane. Using Triton X- 
114 phase partitioning, this DHlipDH was shown not to be attached to the membrane by any 
form of direct lipid or hydrophobic anchorage. This is the first report of a eukaryotic extra- 
mitochondrial DHlipDH.
Lipoic acid, the presumed substrate of DHlipDH, has been detected in acid 
hydrolysates of bloodstream form cells at a level of 1.7 (± 0.2) ng of the cofactor/mg 
protein. Its chemical identity has been confirmed by gas chromatography/mass 
spectrometry.
In the procyclic (Tsetse fly midgut) stage of the parasite, DHlipDH is 13-fold more 
active than in the bloodstream form, and there is also 10-fold more lipoic acid at this stage. 
These increases are coincident with the activation of the mitochondrion and expression of 
the 2-oxo acid dehydrogenase complexes. In agreement with this, the majority of DHlipDH 
in these cells was shown to be intra-mitochondrial by subcellular fractionation.
The DHlipDH of bloodstream form cells has been purified to homogeneity by Triton 
X-l 14 phase partitioning, heat treatment, chromatofocussing and gel filtration. It appears to 
be a dimer of similar molecular weight sub-units (Mj. = 53 kDa). In terms of size and 
kinetics, this enzyme is similar to those isolated from the mitochondria of other species.
The active site vicinal dithiol of DHlipDH is susceptible to inactivation by arsenical 
reagents. As these are also the drugs of choice for late-stage African trypanosomiasis, 
DHlipDH has been assessed as a possible target for chemotherapy. Die enzyme was not 
inactivated at arsenical concentrations required to immobilise cells, and was particularly 
insensitive to the drug melarsen oxide, indicating that it may not be a major target for these 
compounds.
The possible functions of the plasma membrane DHlipDH are discussed together 
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1CHAPTER 1 : INTRODUCTION
1.1 The trvpanosomes
1.1.1 Classification of the trvpanosomes
Trypanosomes are parasitic protozoan haemoflagellates (class Zoomastigophora, 
order kinetoplastida) which infect humans and domestic animals in tropical Africa and South 
America. The genus Trypanosoma is divided into two groups on the basis of the mode of 
transmission of the parasite by the insect vector the stercoraria (faecal transmission) and the 
salivaria (salivary transmission) (Fairlamb, 1982).
1.1.2 The stercoraria
The most prominent stercorarian trypanosome is Trypanosoma cruzi, the causative 
agent of Chagas' disease in humans in South America. The parasite is transmitted between 
hosts by the Reduviid bug, which ingests the trypanosome during a blood meal, and excretes 
it in the faeces, from where it enters the host by being rubbed into skin abrasions or mucous 
membranes. Young children die of infection in the acute febrile stage, whilst adults who 
survive to the chronic phase suffer parasite-induced heart muscle and autonomic nervous 
tissue damage, leading to congestive heart failure and dilatation of the oesophagus, 
respectively (Boreham, 1979). The disease is very prevalent in South America, with 35 
million people exposed to infection, and 13-14 million possibly carrying the parasite 
(Fairlamb, 1982). At present, there is no effective treatment available (Gutteridge, 1985).
1.1.3 The salivaria
The salivarian trypanosomes that infect humans are Trypanosoma brucei gambiense 
and Trypanosoma brucei rhodesiense. These cause African sleeping sickness, 10,000 new 
cases of which are reported every year. In total, 45 million people are at risk from infection, 
and the disease constantly threatens to reach epidemic proportions (Goodwin, 1985). Acute 
infection is characterised by a swollen chancre at the site of inoculation, and by general 
oedema of the face. If the infection is not treated after several weeks of intermittent and 
irregular fever, invasion of the central nervous system (CNS) is inevitable and rapidly fatal 
(Fairlamb, 1982).
Treatment regimens have not altered significantly over many years, with suramin or 
pentamidine employed for early-stage sleeping sickness; combinations of these with 
aromatic arsenicals such as melarsoprol and tryparsamide are required when the CNS 
| becomes involved, because the former compounds cannot cross the "blood-brain barrier" 
(Raseroka & Ormerod, 1985; Thomson, 1989). Such treatment is highly unsatisfactory as the 
arsenicals cause serious encephalopathy even at therapeutic doses.
2The diseases of domestic animals caused by salivarian trypanosomes include nagana 
in cattle {T.b.brucei, T.vivax & T.congolense), surra in horses and camels (‘T.evansi) and 
dourine in horses {T.equiperdum). Over 3 million cattle die from animal trypanosomiasis 
each year, and the prevalence of the Tsetse fly, the major insect vector, means that 10 million 
square kilometres of land cannot be farmed in Africa.
The lack of effective cure for any of the trypanosomiases, together with the associated 
economic and nutritional problems and the possibilities of epidemics, led the World Health 
Organisation, in 1979, to rate trypanosomiasis among the top six tropical diseases for study 
with a view to developing more effective treatments (Trigg, 1979). In response to this, the 
last decade has seen a rapid increase in biochemical research into the trypanosomiases, with 
much work concentrating on the exploitation of biochemical differences between the parasite 
and its mammalian host.
TJ).brucei has become the main organism for the study of African trypanosomiasis, 
and its particularly interesting biochemistry has drawn many workers into this field of 
research.
1.2 Trvpansoma brucei brucei
1.2.1 Life-cvcle of T.b.brucei
TJ>.brucei undergoes a cyclical transmission from mammal to mammal effected by 
the insect vector, the Tsetse fly {Glossina spp.) (Fig. 1.1). Different developmental stages of 
the life-cycle are accompanied by markedly different morphology and biochemical activities. 
Most notable among these changes are those of the mitochondrion and the surface of the 
flagellate, which must undergo alterations in order for the parasite to survive in the two very 
different environments of the mammalian host and the insect vector (Vickerman, 1965 &
1985).
In the mammalian bloodstream, a pleomorphic population of trypanosomes is 
observed, ranging from the long, slender (LS) form, which has a free flagellum at its anterior 
end, to the short stumpy (SS) form, which has no free flagellum (Vickerman, 1965). It is the 
LS form which is the most abundant when parasitaemia is rising. This form is able to divide 
rapidly (doubling time = 6 h), and evades the host immune system by antigenic variation of 
its surface coat (Vickerman, 1985). Parasitaemia occurs in waves, with each peak appearing 
to coincide with the expression of one specific antigenic variant. As trypanosomes bearing a 
particular variant antigen are eliminated from the population by the host immune system, a 
; new variant type arises to take its place as the principal surface antigen (Boothroyd, 1985). 
The mitochondrion of the LS form is poorly developed as the parasite has a plentiful supply
3Fig. 1.1. Schematic diagram of Trypanosoma brucei brucei developmental cycle in 
mammal and tsetse fly, showing changes in cell surface, mitochondrion, glycosomes and 
receptor-mediated endocytosis, and relative sizes of different stages. Stages possessing 
the variable antigen coat lie to the right, and uncoated stages to the left The 
mitochondrion is depicted in section to show changes in its cristae (from Vickerman, 
1985).
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4of blood glucose, and is therefore able to meet all of its energy requirements through 
glycolysis, thus obviating the need for a citric acid cycle.
During periods of low parasitaemia, the SS form predominates. For many years, this 
has been thought to be a pre-adaption to life in the insect, mainly because of the state of its 
mitochondrion, which is intermediate between those of the LS and procyclic insect forms. 
There is some doubt, however, about whether this form, or a closely related intermediate is 
the true form that is able to infect the Tsetse fly (Giffin & McCann, 1989; Bienen et al.9 
1991).
Following a blood meal, ingested trypanosomes enter the Tsetse fly midgut lumen. 
Transformation to the procyclic form occurs within the endoperitrophic space in the posterior 
of the midgut This insect form has lost the variable surface antigen coat, which has been 
replaced by a procyclic antigen (Roditi et al., 1989). The mitochondrion has become a fully- 
developed, highly-branched network with many plate-like cristae (Fairlamb, 1982).
From 4 days onwards, procyclics invade the ectoperitrophic space by penetrating the 
peritrophic membrane. During the following week this space becomes packed with dividing 
trypanosomes. As they move to the proventriculus, they become longer (up to 60 Jim) and 
cease to divide. Mitochondrial regression begins at this stage. Proventricular mesocyclics 
re-invade the endotrophic space and journey via the oesophagus, mouthparts and salivary 
ducts to the salivary glands (Vickerman, 1985).
In the salivary gland, the proliferative form is the epimastigote, which becomes 
attached by its flagellum to the microvilli of the epithelial cells. Here it undergoes 
metacyclogenesis, a process requiring the formation of junctional complexes with the 
epithelial cells. As cells become premetacyclics they lose their ability to divide, and during 
maturation, the metacyclic acquires an antigenic coat (Vickerman, 1985; Donelson, 1988).
When an infected Tsetse fly bites, metacyclic forms are injected into the mammalian 
host along with the salivary secretions. These enter the draining lymphatics, and from there 
infiltrate the bloodstream. Further mitochondrial regression accompanies these movements, 
producing the LS form to complete the life-cycle of T.b.brucei (Vickerman, 1985).
1.2.2 The structure and metabolism of T.b.brucei
The trypanosome is characterised by 5 main structural features: a single flagellum, a 
single mitochondrion containing a very large network of DNA (the kinetoplast), a complex 
network of subpellicular microtubules, glycosomes (microbody-like organelles) and a surface 
coat.
The ultrastructure of the trypanosome through all the various stages of its life-cycle 
has been described in detail by Steiger (1973), and the structure and role of the kinetoplast 
DNA has been reviewed by Simpson (1987). Of the remaining features, the glycosome and 
the surface coat have attracted a great deal of interest in the last few years, partly because
5they are potential sites for chemotherapy. Furthermore, the pathways of purine, polyamine, 
thiol and carbohydrate metabolism and terminal oxidation, with their unique features, have 
been extensively investigated, as has the overall nutrition throughout the life-cycle of the 
trypanosome.
1.2.2.1 The glvcosome
Glycosomes are found in all members of the family of Trypanosomatidae. They are 
ellipsoid or circular organelles of 0.3 Jim diameter bounded by a single membrane. Each 
T.b.brucei cell has 200-300 such microbodies, which make up approximately 6 % of the cell 
volume (Hart etal.y 1984; Opperdoes, 1988). They contain the first nine glycolytic enzymes, 
enzymes of pyrimidine and ether-lipid biosynthesis, of glycerol metabolism and of carbon 
dioxide fixation, and adenylate kinase (Fairlamb & Opperdoes, 1986).
The high degree of compartmentalisation of the glycolytic enzymes is thought to be 
of considerable benefit to the trypanosome, which is totally dependent upon substrate-level 
phosphorylation for ATP synthesis. The glycosomal membrane probably acts as a selective 
permeability barrier, allowing the entry and exit of metabolites, whilst maintaining high 
concentrations of the glycolytic enzymes (up to 1 mM; Fairlamb, 1989). Despite the capacity 
for free diffusion through the glycosomal membrane, metabolites are concentrated within the 
organelle to five times their levels in the cytosol, and are postulated to be channelled through 
a complex of the enzymes. This channelling may be facilitated by the very high isoelectric 
points of the enzymes (the highest found in nature !), which could play a role in ionic binding 
of phosphorylated intermediates (Fairlamb, 1989).
The biogenesis of the glycosomes has come under particular scrutiny as a possible site 
for chemotherapeutic intervention because of the dependence of the trypanosome upon 
glycolysis (Michels, 1988). These organelles possess no DNA, with all their proteins being 
manufactured in the cytosol on free ribosomes. Proteins are imported into the glycosome 
within 1-3 min of completion (Opperdoes, 1987 & 1988).
Several of the glycolytic enzymes have 2 "hotspots” of positive charges separated by 
40 A, which are thought to be an internal import motif. This suggestion has been borne out 
by experiments in Wang's laboratory using chimaeras of glycosomal and cytosolic 
phosphoglycerate kinase to investigate the structural basis for import in in vivo assays (Wang,
1988). Suramin, one of the major trypanocidal drugs, has two negatively-charged domains 
separated by a distance of 40 A. This compound has a high affinity for several glycolytic 
enzymes, and could be inhibiting glycolysis by interacting with the "hot spots" (Fairlamb,
1989). Due to the lack of hotspots in some glycosomal proteins (Kendall et al., 1990), 
current theory has had to be modified to include other possible signal sequences, including 
the C-terminal peroxisomal import sequence (SKL) (Fung & Clayton, 1991).
61.2.2.2 The surface coat
The surface coat of the bloodstream form of T.b.brucei consists of a unique variable 
surface glycoprotein (VSG), which has a protective function in enabling the parasite to evade 
the host immune system. The surface of the trypanosome is covered by 1.2 x 10^ tightly- 
packed molecules of VSG, forming a 15 nm thick coat The glycoprotein comprises a 450- 
480 amino acid polypeptide with 2 or more attached carbohydrate chains, linked to the 
plasma membrane by a glycosylphosphatidyl inositol (GPI) anchor containing dimyristoyl 
fatty acid (Boothroyd, 1985; Low, 1989).
The trypanosomal genome has a repertoire of over 1000 possible antigenic variants of 
VSG, only one of which is expressed at any one time. It is the switching between different 
VSGs that enables the parasite to escape destruction by the host immune system (see section 
1.2.1). Expression occurs at specific telomeric sites, to which new VSG genes are transferred 
by homologous recombination. Towards the start of an infection, switching proceeds 
according to an ordered program, but with later gene conversions and mutations, the order 
becomes less predictable (Donelson, 1988; Pays, 1988).
Trypanosomes are able to transfer their VSGs to host cells, which are then destroyed 
by their own immune system, resulting in the anaemia often observed with trypanosomal 
infection (Rifkin & Landsberger, 1990).
Upon entering the Tsetse fly, the VSG coat is shed (Seyfang et al., 1990) and is 
replaced by one of a group of GPI-anchored procyclic acidic repeat proteins (PARPs; Clayton 
& Mowatt, 1989). The most well characterised of these is procyclin, which has an unusual 
14-18 nm long rod-like structure (Richardson et al., 1988; Rodid et al., 1989).
Once the trypanosome reaches the metacyclic stage, it re-acquires the VSG coat, often 
displaying the last coat which was expressed in the mammalian bloodstream, though only a 
small fraction (14-17 in Tb.brucei) of the VSGs are available for expression at this stage 
(Pays, 1988).
Vaccine development to early bloodstream and metacyclic VSGs may eventually 
prove effective, but blocking the biosynthesis of the glycoprotein, through an understanding 
of the component enzymes in the pathway, should be a more successful strategy for surface 
coat-directed chemotherapy (Pays, 1988).
1-2.2.3 Eming salvage
All members of the Trypanosomatidae are unable to synthesize purines de novo, and 
depend upon active salvage mechanisms for purine incorporation. A diversity of enzyme 
! pathways can be involved in salvage, so it is difficult to design specific therapeutic agents. 
Allopurinol, however, is active as a substrate for salvage enzymes, being accumulated in and 
lethal to trypanosomes (Opperdoes, 1985).
71.2.2.4 Polvamine metabolism
Polyamines have been implicated in many vital cellular processes, and are 
significantly elevated in rapidly growing cells (Fairlamb, 1989). In T.b.brucei the major 
polyamines are putrescine and spermidine, produced via the same biosynthetic routes as in 
mammals. Putrescine is produced from ornithine by ornithine decarboxylase (ODC), which 
is the controlling enzyme in the formation of polyamines (Wang, 1988). ODC is specifically 
inhibited by a-difluoromethylornithine (DFMO), causing depletion of polyamines. The 
trypanosome treated with this drug is transformed from the long slender to short stumpy 
bloodstream form (Giffin & McCann, 1989). This form is unable to change its surface coat, 
and is caught up by the host immune system. The particular effectiveness of DFMO against 
trypanosomes appears to be because ODC has a low turnover rate in vivo, and is structurally 
different from the mammalian enzyme (Wang, 1988). DFMO is currently undergoing 
clinical evaluation against African trypanosomiasis.
1.2.2.5 Thiol metabolism
Most eukaryotic and prokaryotic cells contain high concentrations of at least one low 
molecular weight thiol. In eukaryotes, the principal thiol is glutathione (GSH), which is 
involved in maintenance of correct intracellular thiol redox balance, enzymatic removal of 
hydrogen peroxide, scavenging of free radicals, detoxification of xenobiotics and control of 
protein synthesis. It also produces deoxyribonucleotides (via ribonucleotide reductase) for 
DNA synthesis (Meister & Anderson, 1983). GSH is maintained in its reduced form within 
the cell by glutathione reductase.
In trypanosomatids, glutathione has been detected in a unique conjugate with 
spermidine, termed trypanothione (N ^  ,N^-bis(glutathionyl)spermidine; Fairlamb & 
Henderson, 1987). This performs an analogous role to that of glutathione in mammals, and is 
kept in its reduced state by trypanothione reductase, which is located in the cytosol of the cell 
(Smith et 0/., 1991) and shows close homology to glutathione reductase. Trypanothione 
peroxidase is also active in these cells, and, together with the reductase, it ensures low 
intracellular concentrations of H2O2 (Fairlamb & Henderson, 1987).
The enzymes trypanothione reductase, peroxidase and synthetase are all unique to 
trypanosomatids, and, because of their role in reducing oxidative stress, may provide 
excellent targets for chemotherapeutic drug design. Indeed, one of the major drugs for late- 
stage sleeping sickness, melarsen oxide, has been shown to form a stable adduct with 
trypanothione (Fairlamb et al., 1989). The selective toxicity of this arsenical may result from 
sequestration of intracellular trypanothione and/or inhibition of trypanothione reductase. 
Progress has also been made in the use of "subversive substrates" for trypanothione reductase 
(Henderson et al., 1988). These substances, when reduced, undergo redox cycling processes 
to produce toxic metabolites of oxygen. Therefore, this enzyme, which normally reduces
oxidative stress, has had its function subverted to produce a cytotoxic effect. Preliminary 
studies with T.cruzi have demonstrated that a number of these compounds are trypanocidal 
(Henderson et al., 1988).
1.2.2.6 Terminal respiratory systems
Bloodstream forms of T.b.brucei have very high rates of respiration, with whole cell 
suspensions using 70-140 nmol C^/min/mg protein with glucose as the oxidisable substrate. 
This respiration rate is up to 50 times that observed in mammalian tissues. In the absence of 
any cytochromes or lactate dehydrogenase, the trypanosomes use a novel L-glycerol-3- 
phosphate oxidase to re-oxidise NADH generated from glycolysis (Grant & Sargent, 1960; 
Bowman & Flynn, 1976). This terminal oxidase is in the mitochondrion, and, together with 
the glycosomal NAD+-dependent glycerophosphate dehydrogenase, it forms a shunt for 
reducing equivalents into the mitochondrion (Opperdoes et al., 1977b). By the concerted 
action of these two components, dihydroxyacetone phosphate (DHAP) is first reduced to 
glycerol-3-phosphate, which is then re-oxidised to DHAP by the glycerophosphate oxidase. 
This re-oxidation allows the quantitative conversion of glucose to pyruvate and the 
maintenance of redox balance in the cell (Fig. 1.2; Bowman & Flynn, 1976).
The bloodstream form terminal oxidase resembles those of some plants and fungi, and 
is inhibited by metal-chelating compounds such as salicylhydroxamic acid (SHAM), but not 
cyanide (Opperdoes, 1985).
Transformation to the insect form of the parasite is a two-stage process for terminal 
oxidation. Firstly, new dehydrogenases appear, capable of transferring reducing equivalents 
from succinate, proline and NADH to O2 via the alternative oxidase. This process occurs 
during the development of the short-stumpy bloodstream forms (Bienen et al., 1991). The 
second stage is the emergence of a complete cytochrome chain, and the partial attenuation of 
the glycerophosphate oxidase, which may still account for up to 30 % of terminal oxidation 
in procyclics (Opperdoes, 1985; Fairlamb & Opperdoes, 1986). The cytochrome chain 
appears branched, with cytochromes aa3 and o as oxygen acceptors. Cytochrome c has a 
particularly unusual structure in trypanosomes, resulting in a change in its absorbance 
maximum from 550 nm (mammalian) to 558 nm (Opperdoes, 1985). The cytochrome chain 
is inhibited by cyanide, but not SHAM.
In addition, Turrens (1989) has recently demonstrated that the NADH-Ubiquinone 
segment of the respiratory chain of procyclics is replaced by direct formation of succinate 
from fumarate reduction (by fumarate reductase). Succinate dehydrogenase also passes 
electrons to the respiratory chain, regenerating fumarate from succinate.
T.b.brucei represents the most extreme case of mitochondrial repression and 
transformation of all the trypanosomatids, as many others still possess active mitochondria in 
their bloodstream forms (Vickerman, 1965).
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In the mammalian bloodstream, T.b.brucei circulates in an extremely rich 
environment, capable of supplying all its metabolic needs. Glucose, its primary energy 
source, is present at high concentrations ( S mM in plasma), and is acquired by facilitated 
diffusion into the cell (Fairlamb & Opperdoes, 1986). A series of transporters exist for the 
amino acids (Voorheis, 1971), and fatty acids are imported into the cell because they cannot 
be synthesized de novo (Gilbert et al., 1983). TJb.brucei is, however, capable of chain 
elongation of fatty acids, for which a ready supply of acetyl-CoA is available from the 
oxidation of threonine. In plentiful supply in the blood, threonine is transported into the 
trypanosome through the Nj-amino acid transporter, and broken down by threonine 
dehydrogenase and acetyl-CoA : glycine acetyltransferase to acetyl-CoA (solely available for 
lipid biosynthesis) and glycine (exported into the medium) in the mitochondrion (Linstead et 
al., 1977; Gilbert et a l , 1983).
Macromolecular material is taken up by receptor-mediated endocytosis in the flagellar 
pocket (Opperdoes et al., 1987). Receptors for transferrin and host low density lipoprotein 
(LDL) have been identified (Opperdoes et al., 1987; Coppens et al., 1988). LDL is of 
particular importance in providing cholesterol, the major membrane sterol, to bloodstream 
forms of T.b.brucei.
Endocytosis ceases in the more self-sufficient procyclic form (Vickerman, 1985). 
Energy metabolism switches from a carbohydrate to an amino acid base, with proline 
replacing glucose as the major energy source. Proline is present in high concentrations in the 
Tsetse fly haemolymph as a fuel for flight (Bursell, 1978). Within the trypanosome, it is 
oxidised with ring opening to glutamate followed by transamination to 2-oxoglutarate, which 
enters the citric acid cycle (Bowman & Flynn, 1976). Threonine metabolism is an order of 
magnitude more active than in the bloodstream form, but procyclics are also only capable of 
chain elongation of fatty acids (Klein, 1981).
1.2.3 Carbohydrate metabolism
1.2.3.1 Long-slender bloodstream forms
Glucose is the major respiratory substrate for the long-slender (LS) bloodstream form 
of TJ).brucei. It is quantitatively converted to pyruvate by a standard glycolytic pathway, the 
majority of which is located in the glycosomes of the parasite (Fig. 1.2; see section 1.2.2.1; 
Fairlamb & Opperdoes, 1986). The action of the glycerophosphate shunt allows the 
production of 2 moles of 3-phosphoglyceric acid from 1 mole of glucose under aerobic 
conditions. Net ATP and NADH production is zero within the glycosome, the glycolytic 
energy yield of 2 moles of ATP coming from the action of pyruvate kinase in the cytosol. 
Pyruvate is excreted into the surrounding medium because the pyruvate dehydrogenase
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complex and the majority of the citric acid cycle enzymes are absent from LS forms 
(Fairlamb & Opperdoes, 1986). The rate-limiting step of glycolysis is thought to be the 
transport of glucose across the plasma membrane of the trypanosome (Eisenthal et al., 1989). 
The oxidative branch of the pentose phosphate pathway is present in both this and the 
procyclic form of T.b.brucei (Hunt etaL, 1986).
Under anaerobic conditions, or in the presence of glycerophosphate oxidase inhibitors 
such as SHAM, glucose is converted to equimolar amounts of pyruvate and glycerol 
(Fairlamb & Opperdoes, 1986).
1.2.3.2 Short-stumpv bloodstream forms
The major end-product of glucose metabolism in short-stumpy (SS) forms is 
pyruvate, but CO2, acetate and succinate are also formed (Flynn & Bowman, 1973). This is 
because, whilst the glycolytic metabolism of the LS form is still predominant, the 
mitochondrion of the cell has begun activation. Most CO2 is produced from the 
decarboxylation of pyruvate by the pyruvate dehydrogenase complex (PDHC). Cells are also 
able to respire on 2-oxoglutarate (Vickerman, 1965), but the citric acid cycle is still thought 
to be inoperative due to the low levels of succinate oxidase and citrate synthase (Flynn & 
Bowman, 1973).
1.2.2.3 Procvclic forms
The state of carbohydrate metabolism in procyclic T.b.brucei is less well understood 
than in the bloodstream form. Therefore parts of the metabolic scheme shown in Fig 1.3 are 
constructed with data from T.b.rhodesiense. This trypanosome is closely related to 
T.b.brucei, but does have some subtle differences in the contribution of different pathways to 
its glucose catabolism (Bowman & Flynn, 1976; Fairlamb & Opperdoes, 1986).
With a reduction in the oxygen tension of the surrounding medium and a change from 
a glucose- to proline-based metabolism, the glycolytic pathway is less important to the 
procyclic cell (Fairlamb & Opperdoes, 1986). The specific activities of glycolytic enzymes 
are 30-70 % of their respective levels in the bloodstream form, except hexokinase, which is 
reduced 25-fold (Opperdoes et al., 1981).
Despite the reduced activity of the glycerophosphate shunt, there remain no net 
changes in ATP/ADP or NAD+/NADH ratios in the glycosome. To maintain this balance, 
1,3-diphosphoglycerate leaving the glycosome must re-enter as phophoenolpyruvate (PEP). 
To this end, phosphoglycerate kinase is expressed in the cytosol (it is in the glycosome of the 
bloodstream form) and pyruvate kinase (which, in the bloodstream form, catalyses the 
conversion of PEP to pyruvate) is absent (Fig. 1.3; Fairlamb & Opperdoes, 1986). There are 
large increases in PEP carboxykinase and malate dehydrogenase in the glycosome. PEP 
carboxykinase enables CO2 fixation, as well as maintaining the ATP balance. Malate
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dehydrogenase reduces oxaloacetate, making NADH available for glycerol-3-phosphate 
dehydrogenase, and producing malate, the final product of glycosomal metabolism 
(Opperdoes etal., 1981; Fairlamb & Opperdoes, 1986).
Malate from the glycosome has a number of possible metabolic routes. In the cytosol, 
it can be converted by malate dehydrogenase to oxaloacetate, followed by transamination to 
aspartate, or, through the malic enzyme, it can be oxidised to pyruvate. A proportion of this 
pyruvate is transaminated to alanine, the major free amino acid in procyclics, but the majority 
is converted to acetyl-CoA by the PDHC (Opperdoes et a/., 1981; Fairlamb & Opperdoes,
1986). Malate can also enter the mitochondrion. In this way it acts as a shunt for reducing 
equivalents from the other two metabolic compartments. In the mitochondrion, malate can 
be oxidised to oxaloacetate or reduced to fumarate depending on the metabolic requirements 
of the organelle. With the proposed absence of the NADH-Ubiquinone segment of the 
respiratory chain, it has been suggested that the majority of the reducing equivalents from 
NADH are fed into the respiratory chain by the action of the fumarate reductase and 
succinate dehydrogenase (Turrens, 1989). Of the other enzymes of the citric acid cycle, 
aconitase and the 2-oxoglutarate dehydrogenase complex (20GDHC) have been identified 
(Ryley, 1962), but an NAD+-dependent isocitrate dehydrogenase (NAD-IDH) has never been 
detected (Ryley, 1962; Evans & Brown, 1972), and there remains only one report of citrate 
synthase activity, which was at a very low level (Jenkins et al., 1988). Another indicator of 
an inoperative citric acid cycle has been the inability to detect citrate as a metabolic 
intermediate in both T.b.brucei and T.b.rhodesiense (Evans & Brown, 1972; Fairlamb & 
Opperdoes, 1986). With 3-10 % of glucose carbon being converted to acetate through an 
active deacylase (Fairlamb & Opperdoes, 1986), and glycosomal malate and proline-derived 
2-oxoglutarate entering midway through the citric acid cycle to be converted to CO2  and 
succinate (Ryley, 1962), it is perhaps not surprising that the cell does not require a full citric 
acid cycle.
This incomplete oxidation of glucose appears to be a feature of most parasitic 
protozoa (see Marr, 1980). In Leishmania, pyruvate is mostly converted to succinate, with 
the parasite containing only low levels of PDHC and pyruvate carboxylase. Citrate synthase 
activity is very low, NAD-IDH is absent, and 20GDHC and succinate dehydrogenase levels 
are low (Marr, 1980). Therefore, this cell has many similarities to procyclic TJ).brucei. 
T.cruzi epimastigotes, which have an amino acid-based metabolism, also have low citrate 
synthase activity and no NAD-IDH, and, in addition, they lack the 20GDHC (Adroher et al.,
1988).
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1.3 Biochemical research into trypanosomiasis
From a biochemical point of view, it is clear that the trypanosome is a fascinating 
organism, with some features which are unique, and others which are very different from 
those of other eukaryotic cells. The parasite also represents a significant health hazard in 
Africa and South America. These two motivating factors have led to a considerable amount 
of research in recent years. From a chemotherapeutic point of view, much of this research 
has been aimed at identifying and characterising specific biochemical differences between 
trypanosomal cells and those of its mammalian host Previous work from our laboratory has 
identified one such peculiarity, namely the enzyme dihydrolipoamide dehydrogenase 
(Danson etal., 1987). The investigation of the cellular location(s) and characteristics of this 
enzyme is the subject of this thesis, and our current knowledge of dihydrolipoamide 
dehydrogenase will now be discussed.
1.4 Dihydrolipoamide dehydrogenase
1.4.1 Catalytic function
Dihydrolipoamide dehydrogenase (DHlipDH) catalyses the NAD+-dependent 
oxidation of dihydrolipoamide:
Dihydrolipoamide + NAD+ = Lipoamide + NADH + H+
Catalysis proceeds via alternate oxidation and reduction of the enzyme's active-site dithiol, as 
shown in Fig. 1.4. The first step is the oxidation of dihydrolipoamide to lipoamide. Two 
electrons are removed, and shared between the active-site dithiolate anion and a molecule of 
FAD in a charge-transfer complex. NAD+ accepts the electrons from this complex, and, in 
being reduced to NADH, re-oxidises the enzyme in preparation for another catalytic cycle 
(for Reviews see Guest, 1978).
1.4.2 Role in multienzvme complexes
DHlipDH performs its catalytic role as part of the pyruvate dehydrogenase complex 
(PDHC), 2-oxoglutarate dehydrogenase complex (20GDHC), branched chain 2-oxo acid 
dehydrogenase complex (BCKDHC) and the glycine cleavage system (GCS) (Yeaman,
1989). All of these complexes have been found in prokaryotic systems, and are 
intramitochondrial in eukaryotes. They consist of multiple copies of several component 
enzymes. Each complex is situated at a key position in carbon and energy metabolism (see 
Fig. 1.5), and they are of particular importance because the PDHC, 20GDHC and BCKDHC
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catalyse irreversible catabolic steps. Molecular studies on these complexes have been 
recently reviewed in detail (Perham, 1991).
1.4.2.1 Pyruvate dehydrogenase complex
The pyruvate dehydrogenase complex (PDHC) is the most studied of the 2-oxo acid 
dehydrogenase complexes (see Patel & Roche, 1990 for Review). It catalyses the following 
enzyme reaction:
Pyruvate + CoA + NAD+ = Acetyl-CoA + CO2  + NADH + H+
The PDHC is a multimer [Mr (3-10) x 10^] the size of a ribosome, and has a pivotal role in 
the utilisation of pyruvate by most cells, producing acetyl-CoA for energy or biosynthesis.
As can be seen from Fig. 1.6, it consists of 3 catalytic components, denoted E l, E2 and E3, 
which have similar properties in all species :
E l (pyruvate decarboxylase) catalyses the thiamin pyrophosphate-dependent 
decarboxylation of pyruvate to a hydroxyethyl group followed by reductive acetylation of the 
lipoamide coenzyme of E2. In eukaryotes and Gram positive eubacteria, the enzyme consists 
of 2 subunits forming an (X2 P2  oligomer, whereas in Gram negative bacteria there is a single 
E l chain type forming a homodimer.
E2 (dihydrolipoyl transacetylase) possesses a lipoamide coenzyme bound to a lysyl 
e-amino group at the end of a 1.4 nm swinging arm. This arm is thought to be able to rotate 
among the catalytic centres of the 3 component enzymes (Guest, 1978; Perham, 1991). As a 
transacetylase, E2 hands the acetyl group, derived from pyruvate, to CoA. In doing this, it 
maintains the energy-rich thioester bond, produced upon decarboxylation of the pyruvate, in 
the acetyl-CoA product
E3 (dihydrolipoamide dehydrogenase) oxidises the reduced lipoamide coenzyme in 
preparation for receiving another acetyl group, and hands the reducing equivalents to NAD+.
E2 forms the structural core of the complex, with the mammalian PDHC possessing 
60 copies arranged in icosahedral symmetry (Patel & Roche, 1990). To this core are bound 
20-30 oligomers of E l and 6  molecules of E3. E3 dimers are arranged in identical non­
interacting sites, with each one extending across 2  of the 12  faces of the transacetylase core. 
In addition, the mammalian complex has 6  copies of a lipoyl-bearing component, Protein X, 
the role of which is not precisely known, although it appears to act as a high affinity binding 
site for E3 and may have a critical role in the transmission of reducing equivalents to the E3 
component (Patel & Roche, 1990). This protein is unique to the mammalian PDHC.
The mammalian PDHC is regulated by phosphorylation, there being specific E l- 
kinases and El-phosphatases which are bound to the complex, and phosphorylate and 
dephosphorylate, respectively, the E la  subunit (Yeaman, 1986 & 1989). The kinase is more
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tightly bound than the phosphatase, which can be lost during purification (Guest, 1978).
Three serine residues arc available for phosphorylation, but 60-70 % inhibition occurs with 
phosphorylation of just one residue (Patel & Roche, 1990).
Neither protein X nor phosphorylation are features of the bacterial PDHC, and their 
presence in other eukaryotic systems such as yeast has not been proved. In Gram-negative 
bacteria the PDHC possesses octahedral symmetry, with 24 copies of E2 forming its core 
(Yeaman, 1989).
1.4.2.2 2-Oxoglutarate dehydrogenase complex
The 2-oxoglutarate dehydrogenase complex (20GDHC) is of the same basic structure 
as the PDHC, but has an E2 octahedral core in all species, and is not regulated by 
phosphorylation. One further difference is that the El component is a homodimer as opposed 
to a hetero-oligomer. The 20GDHC is part of the citric acid cycle of the cell, in which it 
catalyses the irreversible oxidative decarboxylation of 2-oxoglutarate to succinyl-CoA in a 
reaction analogous to that of the PDHC.
1 *4.2.3 Branched-chain 2-oxo acid dehydrogenase complex
The BCKDHC catalyses the oxidative decarboxylation of branched-chain amino acids 
including ketoleucine, ketoisoleucine and ketovaline (Patston et al., 1988). The process is 
thiamin pyrophosphate- and Mg^+-dependent, and can be summarised by the following 
general reaction mechanism:
R-CO-COOH + CoA + NAD+ = R-CO-CoA + CO2  + NADH + H+
The eukaryotic BCKDHC is similar in structure to the PDHC, having an El component that 
is Ct2 p2 » and being regulated by phosphorylation (Patston et al., 1988). Its metabolic 
importance is as the first committed step in branched-chain amino acid catabolism. Acyl- 
CoA products arc fed into the citric acid cycle through acetyl-CoA or succinyl-CoA (Fig. 1.5; 
see Yeaman, 1986). In oxidising the branched chain amino acids, it is able to prevent their 
otherwise toxic effects on the cell (Harris et al., 1986). The complex is found in eukaryotic 
systems and in those bacteria that utilise branched chain amino acids (e.g. Pseudomonas 
putida; Bums et al., 1989a).
1.4.2.4 Glvcine cleavage system
The glycine cleavage system (GCS) consists of four protein components: P-protein 
(pyridoxal-phosphate-containing glycine decarboxylase), H-protein (lipoyl-bearing 
aminomethyltransferase), T-protein (N^, methylene tetrahydrofolate synthetase) and L-
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protein (DHlipDH) (Kikuchi & Hiraga, 1982; Olson et al., 1986). It catalyses the pyridoxal 
phosphate-dependent decarboxylation of glycine :
Glycine + H^folate + NAD+ = 5 ,10 -methylene-H4 -folate + NH3  + CO2  + NADH + H+
This complex is also capable of glycine synthesis from methylene-tetrahydrofolate, 
ammonia and CO2  in the reverse of the above reaction (see Kochi & Kikuchi, 1974). 
Therefore, in contrast to the 2-oxo acid dehydrogenase complexes, it catalyses a reversible 
reaction.
The GCS forms the major pathway for the catabolism of glycine and serine in 
vertebrates (Kikuchi & Hiraga, 1982) and for the breakdown of glycine by certain anaerobic 
glycine-utilising bacteria, including Clostridium cylindrosporum (Dietrichs & Andreesen, 
1990).
1-4.2.5 Other multienzvme complexes
In addition to the complexes mentioned above, DHlipDH has also been found as a 
component of the complex catalysing the NAD+-dependent conversion of lactate to pyruvate 
in Butyribacterium rettgeri (Wittenberger & Haaf, 1964), and in the acetoin dehydrogenase 
enzyme system of Pelobacter carbinolicus (Oppermann et al.t 1991).
1.4.3 Diversity of dihydrolipoamide dehydrogenase
DHlipDHs have been isolated from a number of sources. They are all homodimers 
containing 1 mol of FAD and two redox-active cysteine residues per subunit The sizes of 
individual subunits vary in the range 49,000 to 58,000 Daltons (see Dietrichs & Andreesen, 
1990). DHlipDHs from different species are highly homologous, with human DHlipDH 
displaying 44 % identity to the E.coli enzyme (Pons et al., 1988), and the human and pig 
enzymes being 96 % identical (Otulakowski & Robinson, 1987).
It is now accepted that eukaryotic PDHC, 20GDHC and BCKDHC all contain the 
same E3 component (i.e. the product of one gene), but recent immunological observations 
have suggested that a different DHlipDH is involved in the GCS (Carothers etal., 1987). On 
the other hand, some prokaryotes possess several different DHlipDHs that are thought to 
function in different multienzyme complexes. In this respect, three DHlipDHs have been 
characterised in Pseudomonas putida (Burns et al., 1989a & b). One is part of the 20GDHC 
and probably also the PDHC, the second is part of the BCKDHC, and the function of the 
third is unknown.
E.coli is thought to have one gene for DHlipDH, although a second protein has been 
identified, which is not involved in any of the complexes (Richarme, 1989). In this organism, 
DHlipDH has been implicated in both ubiquinone-mediated transport of proline (Owen et al.,
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1980) and binding protein-dependent transport of maltose, ribose and galactose (Richarme, 
1988). In other organisms, DHlipDH may be involved in the link between the mitochondrial 
ATPase and the respiratory chain (Partis et al., 1977). These other possible roles for 
DHlipDH are discussed in more detail in chapter 8.
A crystal structure has now been solved for the DHlipDH from Azotobacter vinelandii 
(Schierbeek et al., 1989), and this has now been refined to 2.2 A (Mattevi et al., 1991).
1.4.4 Other reactions of dihydrolipoamide dehydrogenase
In addition to performing its normal function as an NAD+-dependent dehydrogenase, 
DHlipDH is also capable of mediating other NADH-linked reactions (see Tsai, 1980; 
Carothers et al., 1989), including: (a) hydrogen transfer to nicotinamide nucleotides. This 
tranhydrogenase activity may effect hydride ion translocation across the mitochondrial inner 
membrane in certain organisms (Komuniecki & Saz, 1979) (b) electron transfer to inorganic 
acceptors, and (c) reduction of quinone dyes such as nitro-blue tetrazolium (the basis of 
diaphorase activity, a common histochemical test for mitochondria [Vickerman, 1965]).
1.4.5 The disulphide oxidoreductases
DHlipDH belongs to the family of enzymes, the flavin-containing pyridine nucleotide 
disulphide oxidoreductases (see Carothers et al., 1989 for review), which includes 
thioredoxin reduptase (Gleason & Holmgren, 1988), dihydroasparagusate dehydrogenase 
(Yanagawa & Egami, 1976), glutathione reductase (Pigiet & Conley, 1977), trypanothione 
reductase (Shames et al., 1986), bis-y-glutamylcysdne reductase (Sundquist & Fahey, 1988), 
pantethine 4’,4"-diphosphate reductase (Swerdlow & Setlow, 1983) and mercuric reductase 
(Fox & Walsh, 1982). These enzymes show considerable homology around their common 
active site dithiols, FAD binding sites, NAD(P) binding sites and subunit interfaces 
(Carothers et al., 1989). In illustration of this fact, human and pig DHlipDHs show 30 and 28 
% identity to glutathione reductase and mercuric reductase, respectively (Otulakowski & 
Robinson, 1987).
1.5 DHlipDH in T.b.brucei
With the bloodstream form of T.b.brucei having a highly repressed mitochondrion 
containing no detectable 2-oxo acid dehydrogenase complexes, it was a surprise when 
Danson et al. (1987) discovered DHlipDH in these cells. They added further intrigue to their 
discovery by finding that this DHlipDH co-purified with T.b.brucei plasma membranes.
It has been the goal of this project to continue on from the work of Danson et al. 
(1987) by
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a) providing further information about the subcellular location of DHlipDH in 
bloodstream forms
b) looking at the procyclic form, in which a more active mitochondrion might result 
in altered levels and locations of DHlipDH and the 2-oxo acid dehydrogenase complexes
c) searching in the bloodstream and procyclic forms for lipoic acid, the presumed 
substrate of DHlipDH, as a first step towards elucidating the function of the enzyme in vivo
d) analysing the properties of the bloodstream form DHlipDH to see if there are any 
differences from other DHlipDHs, and purifying and N-terminal sequencing the enzyme to 
enable a gene cloning approach to structural and functional studies
e) investigating the inactivation of the bloodstream form DHlipDH by arsenicals in 
order to elucidate the role of this enzyme in the toxicity of arsenicals towards trypanosomes, 
and possibly to develop these compounds for in vivo functional studies on DHlipDH
These five areas of work are described in chapters 3 to 7 (a to e respectively).
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CHAPTER 2 : MATERIALS AND GENERAL METHODS
2.1 Materials
2.1.1 Chemicals and enzymes
Chemicals used were of analytical grade or the finest grade commercially available. 
NAD+, 3-acetyl-NAD+ and NADH were from Boehringer Mannheim, Lewes, E.Sussex. 
High purity Triton X-100 was from Pierce and Warriner (U.K.), Chester. D,L-Lipoamide, 
5,5'-dithio-bis-(2-nitrobenzoic acid) (DTNB) and Triton X-l 14 were obtained from Sigma 
Chemical Co., Poole, Dorset Of the components of the SDM-79 medium (see table 2.1), 
Dulbecco's modified Eagle medium, Medium 199, MEM amino acid solution, MEM non- 
essential amino acids, Penicillin/Streptomycin and Gentamycin were from Gibco, Uxbridge, 
Middlesex. The remainder were purchased from Sigma. Protein assay reagent was 
purchased from Bio-Rad Laboratories, Hemel Hempstead, Herts. The arsenical 
phenylarsenoxide was from Sigma or Aldrich Chemical Co., Poole, Dorset, and Melarsen 
oxide was provided by Specia, Paris, France. p-Aminophenyldichloroarsine and p- 
acetylaminophenyldichloroarsine were kind gifts from Prof. K. J. Stevenson (University of 
Calgary, Canada); these had been synthesized as described by Stevenson et al. (1978). DE- 
52 (DEAE-cellulose) was purchased from Whatman, Maidstone, Kent Vitamin assay 
casamino acids and LB medium were from Difco Laboratories, West Moseley, Surrey. SDS- 
PAGE low molecular weight markers and 8-25 % gradient gels were obtained from 
Pharmacia LKB Biotechnology, Milton Keynes. Of the markers used for gel filtration, 2,4- 
dinitrophenyl-L-lysine, Dextran Blue, bovine liver catalase and bacteriorhodopsin were from 
Sigma, and pig heart malate dehydrogenase, citrate synthase and lactate dehydrogenase were 
obtained from Boehringer. Acetyl-CoA was produced by the method of Stadtman (1957) 
from CoA purchased from Boehringer. Unheparinised microhaematocrit tubes, for storing 
trypanosome stabilates, were purchased from Bilbate Ltd., Daventry, England.
2.1.2 Organisms
Monomorphic long-slender bloodstream forms of Trypanosoma brucei brucei strain 
EATRO 427 were obtained from Dr H. P. Voorheis (Trinity College, Dublin, Eire). These 
cells had been rendered monomorphic by syringe passage in laboratory animals (see 
Vickerman, 1965). No short-stumpy forms were ever seen when cells were counted prior to 
use in experiments. Procyclic forms of EATRO 427 were originally supplied by Dr W. 
Gibson (Tsetse Research Centre, Langford, Bristol, U.K.). They were grown by Marjan 
Kasraeian (Dept of Biochemistry, University of Bath). Escherichia coli strain TGI (an 
EcoK derivative of JM101) was a gift from Dr A. Bankier (MRC Laboratory of Molecular
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Table 2.1 SDM-79 Medium for the growth of procyclic forms of T.b.brucei
INGREDIENTS per Litre
Dulbecco's modified Eagle medium powder 7.0 g
Medium 199 powder 2 .0  g
MEM amino acid solution 8 .0  ml
MEM non-essential amino acids 6 .0  ml
Glucose 1 .0  g
HEPES 8 .0  g
MOPS 5.0 g
NaHC03 2 .0  g
L-Alanine 0 .2  g
L- Arginine HC1 0 .1  g
L-Methionine 0.07 g
L-Phenylalanine 0.08 g




L-Tyrosine 0 .1  g
Adenosine 10  mg
Guanosine 10  mg
D(+)Glucosamine H Q 50 mg
Folic acid 4 mg
p-Aminobenzoic acid 2  mg
Biotin 0 .2  mg
Penicillin (5U/ml)/Streptomycin (5 mg/ml) 12  ml
Gentamycin 2 0  mg
Hemin solution (2.5 mg/ml) 2  ml
Fetal calf serum 1 0  % (v/v)
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Biology, Cambridge, U.K.). The lipoic acid-requiring mutant E.coli K12 (W1485 lip2) was a 
kind gift from Prof J. R. Guest (University of Sheffield, U.K.).
2.2 General Methods
2.2.1 Growth and harvesting of bloodstream forms of Trypanosoma brucei brucei
Stocks of Trypanosoma brucei brucei (strain EATRO 427) were stored in the form of 
stabilates in microhaematocrit tubes under liquid nitrogen. These stabilates were produced 
from whole rat blood containing trypanosomes, to which 10-15% (w/v) glycerol was added. 
Haematocrit tubes were filled with blood by capillary action and sealed at both ends over a 
Bunsen flame. The process of glycerol addition to the blood was carried out slowly at 4°C 
due to the inhibition of glycolysis in bloodstream forms of T. brucei by high concentrations 
of glycerol (Fairlamb & Opperdoes, 1986). This was also the reason for using less glycerol 
than is common for the storage of other cells.
For the inoculation of rats, stabilate tubes were thawed, opened at each end, and the 
blood expelled by passing through Krebs Ringer Buffer (KRB: 98 mM NaCl, 22 mM 
KH2 PO4 , pH 8.0,1 mM MgS0 4 » 2 mM KC1) containing 10 mM glucose and 3 % (w/v) 
sucrose (denoted KRBG). The number of live trypanosomes present was measured using a 
Neubauer haemocytometer. Male Wistar or Sprague-Dawley rats were inoculated 
intraperitoneally with 1.7-1.9 x 10^ cells per rat (see Eisenthal & Panes, 1985). 
Approximately seventy-two hours post-infection, rats were exsanguinated from the heart or 
common ileac artery, and the blood was rapidly mixed with 1 ml heparin solution (200 U/ml 
in KRB). Infected blood was centrifuged at 1000 x g (4°C) for 10 min in an IEC-CENTRA- 
3R bench centrifuge. The serum supernatant was discarded and the upper white layer 
containing trypanosomes and white blood cells was resuspended in a minimum volume of 
KRBG. Inevitably, a few red blood cells were also resuspended by this process, so a further 
one or two washes of the cells (by centrifugation and resuspension as before) was carried out 
prior to loading the cell suspension onto a DE-52 (DEAE-cellulose) column pre-equilibrated 
with KRBG. The column had a bed volume of 10 ml, and one column was used for every 3-4 
rats bled. Uncharged trypanosomal cells passed straight through the column, while 
negatively charged blood cells were adsorbed (Lanham & Godfrey, 1970). The 
trypanosomes were washed through with 30-40 ml KRBG.
2.2.2 Growth of other cells
Escherichia coli strain TGI was grown in LB (Luria-Bertani) medium according to 
Maniatis et al. (1982).
Trypanosoma brucei brucei procyclic forms were grown at 26°C in SDM-79 medium 
(Table 2.1; Brun & Schonenberger, 1979). In preparing this medium, hemin and fetal calf
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serum were sterilised separately from the other components. Procyclic cells were harvested 
by centrifugation at 600 x g and washed in phosphate-buffered saline.
2.2.3 Preparation of sonic extracts
Sonic extracts of either form of Tb.brucei or E.coli were prepared by sonicating cells 
in Eppendorf microfuge tubes for 3 x 30 s at 40 W using a 3 mm probe. Sonication tubes 
were incubated at 4°C to minimise headng effects, and each 30 s sonicadon was separated by 
a 30 s time period to allow maintenance of the temperature at 4°C.
2.2.4 Preparation of dihydrolipoamide
Dihydrolipoamide was synthesized from D ,L-lipoamide by reduction with sodium 
borohydride (Reed et al.> 1958). 800 mg DJL-lipoamide were dissolved in 20 ml methanol: 
water (4:1) over ice. Sodium borohydride (800 mg) was added in 4 ml cold distilled water, 
and the mixture stirred over ice for 1 h. The solution was acidified with 1 M HC1 until 
effervescence stopped. The product was extracted three times with 50 ml chloroform 
(bottom layer), transferred to a round-bottom flask, and rotary evaporated to dryness. The 
resulting crystals were dissolved in toluene (40 ml) with gentle warming. Hexane (16 ml) 
was added, and the precipitate collected by filtration under vacuum and dried in a desiccator.
The purity of the product (dihydrolipoamide) was assessed by titration with DTNB. 
Reaction with DTNB is described by the following equation :
Dihydrolipoamide + DTNB = Lipoamide + 2TNBS
The reaction was carried out in 50 mM sodium phosphate buffer (pH 7.0), containing 
0.2 mM DTNB and 0.05 mM dihydrolipoamide (assuming 100 % purity). Em TNBS at 412 
nm is 13,600 M~* cm"^, so the expected absorbance at 412 nm produced by a solution of 0.1 
mM SH groups (0.05 mM dihydrolipoamide) reacting with DTNB is 1.36.
2.2.5 Protein determination
Protein determination was carried out by the method of Markwell et al. (1981). 
Staining solution was either purchased from Bio-Rad or made according to Bradford (1976). 
The Bradford method involved dissolving 100 mg Coomassie G-250 in 50 ml 95 % ethanol, 
adding 100 ml 85 % (w/v) orthophosphoric acid, and making up to 1 litre with distilled water. 
The reagent was filtered prior to use. The assay was carried out in 1 ml cuvettes, to which 
were added 100 pi sample/standard BSA (0-25 pg when using Bio-Rad solution, or 0-10 pg 
when using reagent produced by the Bradford method) and 900 pi Bio-Rad reagent (1 in 5 
dilution of stock solution in distilled water) or Bradford reagent Protein content was 
assessed by measuring A5 9 5  at 10 min to 1 h after mixing by inversion.
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2.2.6 Enzvme assays
(a) Dihydrolipoamide dehydrogenase was assayed at 30*C in 50 mM potassium 
phosphate (pH 7.0)/2 mM EDTA containing 0.4 mM dihydrolipoamide and 1 mM NAD+. 
The reaction, in a final volume of 1 ml, was started with enzyme and its progress was 
monitored by the increase in A3 4 Q.
(b) Malate dehydrogenase was assayed at 30#C in 50 mM potassium phosphate (pH
7.0)/ 2 mM EDTA containing 0.1 mM NADH and 0.2 mM oxaloacetate. The reaction, in a 
final volume of 1 ml, was started with enzyme and its progress monitored by the decrease in
a 340-
(c) Lactate dehydrogenase was assayed by adding samples from fractions to a 
reaction mixture containing 20 mM Tris-HCl, pH 8.0,1 mM EDTA, 0.2 mM pyruvate and
0.2 mM NADH. The reaction was monitored by following the decrease in A3 4 0  due to the 
oxidation of NADH.
(d) Control assays for the above dehydrogenases were carried out in the absence of 
substrates to ensure that no NADH oxidase activity was present.
The molar extinction coefficient for NADH at 340 nm is 6.22 x 10^ M'^cm- .^ 
Therefore, a 1 mM solution of NADH will have an A3 4 Q of 6.22.
(e) Citrate synthase activity was detected by measuring the increase in absorbance at 
412 nm due to the reaction of DTNB with the product CoA to liberate the yellow-coloured 
thionitrobenzoate. Samples were added to an assay mixture containing 20 mM Tris-HCl, pH
8.0,1 mM EDTA, 0.2 mM oxaloacetate, 0.2 mM acetyl-CoA and 0.1 mM DTNB.
(f) Catalase was detected by adding hydrogen peroxide to eluted fractions. The 
generation of bubbles of oxygen indicated the presence of the enzyme.
2.2.7 PhastSvstem SDS-PAGE
Samples for SDS-PAGE were mixed with sample buffer (10 mM Tris-HCl, pH 8.0,1 
mM EDTA, 2.5 % (w/v) SDS, 5 % (v/v) 2-mercaptoethanol, 0.01 % (w/v) bromophenol blue) 
and boiled for 3 min. These were loaded onto a sample applicator (8  wells; 1 ill per well) 
that was automatically lowered onto the gel surface during electrophoresis. The molecular 
weight markers used were phosphorylase b (94 kDa), bovine serum albumin (67 kDa), 
ovalbumin (43 kDa), carbonic anhydrase (30 kDa), soybean trypsin inhibitor (20.1 kDa) and 
a-lactalbumin (14.4 kDa). Gels were stained with Coomassie blue R and silver.
2.2.8 Coomassie staining
Stain : 0.1 % (w/v) Coomassie Blue R in 30 % (v/v) methanol /1 0  % (v/v) acetic acid 
Destain : 30 % (v/v) methanol /10  % (v/v) acetic acid
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Procedure:
1. Stain for 8 min @ 50°C
2. Destain for 5 min @ 50°C
3. Destain for 8  min @ 50°C
4. Destain for 10 min @ 50°C
2.2.9 Silver staining (Pharmacia PhastSystem Owners Manual, 1987) 
Solutions
1 50 % (v/v) ethanol, 10 % (v/v) acetic acid (90 ml)
2 10 % (v/v) ethanol, 5 % (v/v) acetic acid (400 ml)
3 distilled H20  (400 ml)
4 8.2 % (w/v) glutaraldehyde (90 ml)
5 0.25 % (w/v) silver nitrate (90 ml)
6  0.04 % (v/v) formaldehyde in 2.5 % (w/v) Na2 CC>3 (180 ml)
7 5%  (v/v) acetic acid (90 ml)
8 10 % (v/v) acetic acid, 5 % (v/v) glycerol (90 ml)
ElPgfidgig
Step Solution Time (min) Temp. (°C)
1 1 2 50
2 2 2 50
3 2 4 50
4 4 6 50
5 2 3 50
6 2 5 50
7 3 2 50
8 3 2 50
9 5 13 40
10 3 0.5 30
11 3 0.5 30
12 6 0.5 30
13 6 4 30
14 7 2 50
15 8 3 50
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CHAPTER 3 : SUBCELLULAR LOCALISATION OF DIHYDROLIPOAMIDE 
DEHYDROGENASE
3.1 Introduction
The dihydrolipoamide dehydrogenase of the bloodstream form of Trypanosoma 
brucei brucei was first identified and localised to the plasma membrane of the organism by 
Danson et al. (1987) using the method of Voorheis et al. (1979) to purify plasma membranes. 
In this method, live trypanosomes were swollen to turgidity and homogenised with a tight- 
fitting Dounce homogeniser. Following treatment with leupeptin and DNAase, the 
homogenate was subjected to sucrose-density-gradient centrifugation (Voorheis et al., 1979). 
A prominent dense band was extracted from the gradient, which contained plasma 
membranes as evidenced by their characteristic subpellicular microtubular array, identified 
by electron microscopy. Enzymatic analysis of these membrane fragments indicated that 
they contained the majority of the DHlipDH (only 10 % being found in the initial 
supernatant), up to 60 % of a plasma membrane marker, the ouabain-sensitive Na++K+- 
stimulated ATPase, and a negligible amount of malate dehydrogenase contamination (< 2 %) 
(Danson et al., 1987). The recovery of DHlipDH in these membranes was much higher than 
those of the two membrane markers adenylate cyclase (47 %) and the ouabain ATPase (58 
%), measured by Voorheis etal.{1979).
Whilst this membrane purification provided evidence of a plasma membrane location 
for the DHlipDH of bloodstream form T.b.brucei, we felt it necessary to prove conclusively 
whether or not the enzyme was present only in this location within the cell. This was 
important because the possibility of contamination of the plasma membrane preparation with 
other cellular membranes was not ruled out by Danson et al. (1987), who used malate 
dehydrogenase, which is 90 % cytosolic and 10 % mitochondrial in bloodstream 
trypanosomes (Opperdoes et al., 1981) as an indicator of contamination from other 
organelles. With residual amounts of other citric acid cycle enzymes having been detected in 
the bloodstream form promitochondrion by Jenkins et al. (1988) and Durieux et al. (1991), 
DHlipDH could also be mitochondrial, and its recovery with plasma membranes could be a 
result of contamination or adventitious adherence. An additional source of concern about the 
Voorheis method (Voorheis et al., 1979) is the low recovery of marker enzymes, all were less 
than 60 % of their initial levels, and glycolytic marker enzyme contamination (Conroy,
1988), in the purified plasma membranes. Either a considerable proportion of the membranes 
have been lost, or the enzymes may have become detached during purification.
Alternatively, these enzymes may not be good markers for the plasma membrane.
A number of other methods have been used to purify plasma membranes from 
Trypansomatids. Rovis and Baekkeskov (1980) disrupted T.b.brucei cells by nitrogen 
cavitation, and separated their components by differential centrifugation. They obtained
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plasma membrane vesicles free of microtubules and organelles, and were able to maintain the 
intact nature of nuclei and mitochondria during their separation. Whilst mitochondrial 
contamination was negligible, the yield of plasma membranes, as assessed by enzyme 
recoveries, was very low (9.3 % of the ATPase and 7.6 % of adenylate cyclase). Hunt and 
Ellar (1974), who purified plasma membranes by blending a cell suspension of Leptomonas 
collosoma (a trypanosomatid) with glass beads, differential centrifugation and further 
separation on a sucrose gradient, had problems with contamination from other cellular 
compartments.
The only method to deal adequately with problems of recovery and contamination 
would be one which did not require full separation of cellular organelles. Subcellular 
fractionation partially separates organelles on a linear sucrose gradient, and the location of a 
particular enzyme can be investigated by comparing its distribution across the gradient with 
those of organelle markers (Beaufay and Amar-Costesec, 1976). This method should 
unambiguously determine the cellular location(s) of DHlipDH in the bloodstream form of 
TJ}.brucei. It is also able to distinguish between the plasma membrane and flagellar pocket 
membrane of the trypanosome.
In addition to determining the cellular location of DHlipDH within the trypanosome 
by subcellular fractionation, it is possible to ascertain whether it is located at the cytoplasmic 
or external face of the plasma membrane by measuring the latency of the enzyme, which is 
the amount of enzyme accessible to externally-applied substrates in whole cells. This has 
been carried out as described by Steiger et al. (1980).
The third method used in this chapter to investigate the DHlipDH of the bloodstream 
form T.b.brucei is Triton X-l 14 phase partitioning. This has been used extensively to 
determine the form of attachment of proteins to membranes. Triton X-l 14 is a nonionic 
detergent which forms clear micellar solutions in aqueous buffer below 20*C. Above this 
temperature (the cloud point), a microscopic phase separation occurs in solution, which 
proceeds with increasing temperature until two distinct phases are produced (Bordier, 1981).
This detergent phase partitioning was first applied to the analysis of proteins by 
Bordier (1981), who demonstrated the partitioning of human erythrocyte membrane 
acetylcholinesterase, bacteriorhodopsin and cytochrome c oxidase into the detergent phase 
upon raising the temperatures of their solutions from 0°C to 30°C. Serum albumin, catalase, 
ovalbumin, concanavalin A, myoglobin and cytochrome c all remained within the aqueous 
phase. Subsequently, Balber & Ho (1988) applied this technique to the Variable Surface 
Glycoprotein (VSG) of T.b.brucei, showing that its membrane form partitioned into the 
detergent phase, whilst the phospholipase C-cleaved soluble form remained in aqueous 
solution.
With the trypanosomal DHlipDH, three forms of cellular material were chosen for 
partitioning. The use of sonicated material would reveal any anchorage following cell
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disruption. Plasma membranes (prepared according to Voorheis et al. [1979]) allow the 
analysis of only that DHlipDH which is attached to the plasma membrane, and whole cells 
give the nearest to in vivo conditions for the enzyme.
To confirm that DHlipDH is not participating in any of the 2-oxo acid dehydrogenase 
complexes in long-slender bloodstream forms, assays using pyruvate, 2 -oxoglutarate and 
branched-chain 2 -oxo acids as substrates have been carried out.
3.2 Methods
3.2.1 Subcellular fractionation
The subcellular fractionation of bloodstream form T.b.brucei was carried out by Mr J. 
Van Roy in the research group of Dr F. Opperdoes (International Institute for Cellular and 
Molecular Pathology, Brussels).
Trypanosomes were homogenized by grinding with silicon carbide grain until more 
than 90 % were broken (Opperdoes et dl.t 1977a). Homogenization was carried out in two 
different buffering systems: (a) 0.25 M sucrose, 1 mM imidazole-HCl and 1 mM EGTA (pH
7.0) and (b) 0.25 M sucrose, 25 mM Tris-HCl and 1 mM EDTA (pH 7.2). Following 
homogenization, the silicon carbide was removed by centrifugation, and the supernatant was 
subjected to differential centrifugation. Unbroken cells, nuclei and debris were removed by 
centrifugation at 1000 x g for 10 min, and a large-granule fraction was separated at 5,000 x g 
for 10 min. The post-large-granule extract was applied to a linear sucrose gradient (density = 
1.10-1.26 g/cm^) using an E-40 automatic zonal rotor and accelerated to 40,000 rpm for 140 
min according to the method of Beaufay and Amar-Costesec (1976; see also Steiger et al.y 
1980). A series of fractions were removed from the gradient and assayed for marker 
enzymes, protein and DHlipDH.
The marker enzymes a-glucosidase (plasma membrane), acid phosphatase (flagellar 
pocket), 3'-nucleotidase (plasma membrane), isocitrate dehydrogenase (mitochondrion), a- 
mannosidase (lysosomes), hexokinase (glycosomes) and adenylate cyclase (flagellar pocket) 
were assayed by Mr J. Van Roy according to the methods of Gbenle et al. (1986) and Walter 
& Opperdoes (1982). Protein was determined as described by Stein et al. (1973). These 
assays were performed at the International Institute for Cellular and Molecular Pathology, 
Brussels. Individual fractions from the gradient were frozen in liquid nitrogen, stored frozen, 
and sent to Bath. The assay of DHlipDH was carried out in Bath as described in section 
2.2.6.
3.2.2 Latency studies
Gbenle etal. (1986) measured the latencies of RNase, 3'-nucleotidase, aryl 
acylamidase and alanine aminotransferase by determining their activities in the presence and
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absence of 0.1 % (w/v) Triton X-100. For this method, they supplemented the normal assay 
buffers with 0.25 M-sucrose, 5 mM-glucose and 0.05 % bovine serum albumin. For 
DHlipDH, the method of Gbenle et al. (1986) was adapted for live, respiring trypanosomes 
by using KRBG containing 1 mM NAD+. For these studies, the known intracellular enzyme 
malate dehydrogenase (Voorheis et al., 1979) was used as a positive control to determine 
whether the cells were intact. This enzyme was assayed according to the procedure detailed 
in section 2.2.6, replacing assay buffer with KRBG.
3.2.3 Triton X-l 14 phase partitioning
Triton X-l 14 phase partitioning was carried out according to the method of Bordier 
(1981). Bacteriorhodopsin and citrate synthase were chosen as membrane and soluble 
protein controls, respectively.
(a) Preparation of samples. To investigate the phase partitioning of DHlipDH, 
three different forms of T.b.brucei cellular material were examined: whole cells, sonicated 
cells (3 x 30 s @ 40 W), and plasma membranes prepared by the method of Voorheis et al. 
(1979) and stored frozen at -80*C.
Each sample was suspended, to a total volume of 800 pi, in 10 mM Tris-HQ, pH 7.4, 
150 mM NaQ (partitioning buffer) at 0’C. Triton X-l 14 was added to a final concentration 
of 1 % (w/v), and the sample mixed by vortexing.
Bacteriorhodopsin was dissolved to a final concentration of 4 mg/ml in 25 mM 
potassium phosphate buffer, pH 6 .8 8 , containing 0.1 % (w/v) Triton X-100 according to the 
method of Dencher & Heyn (1978). A 10 |il sample was added to 190 |il partitioning buffer 
containing 1 % (w/v) Triton X-l 14.
Citrate synthase (2 mg/ml) was diluted 20-fold into partitioning buffer containing 1 % 
(w/v) Triton X-l 14.
(b) Phase partitioning. To carry out the phase separation, each sample was layered 
onto a 300 pi sucrose cushion (Tris buffer containing 6  % (w/v) sucrose and 0.06 % (w/v) 
Triton X-l 14) in a conical Eppendorf microfuge tube. Each tube was incubated at 30*C for 3 
min, and centrifuged for 20 s in an MSE bench microfuge at 8,500 x g. The separation was 
then repeated by removing the aqueous phase, adding to it a further 0.5 % (w/v) Triton X-
114, cooling, layering back onto the cushion, incubating and centrifuging as before. The 
aqueous phase was removed once more and 2 % (w/v) Triton X-l 14 added. Following 
incubation and centrifugation, the separated detergent was discarded.
Buffer and detergent were added to the detergent and aqueous phases, respectively, 
to give the same salt/surfactant contents. Protein and DHlipDH activities were determined as 
in sections 2.2.5 and 2.2.6, respectively. Bacteriorhodopsin and citrate synthase were 
detected by SDS-PAGE (section 2.2.7).
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3.2.4 Determination of DHlipDH and 2-oxo acid dehydrogenase complex levels
The assay for DHlipDH is described in section 2.2.6. Determination of the 2-oxo acid 




The distribution profiles for DHlipDH and the marker enzymes in post-large-granule 
extracts of T.b.brucei homogenates after isopycnic centrifugation in linear sucrose gradients 
are shown in Fig. 3.1.
DHlipDH shows three clear peaks of activity in the imidazole-containing gradient at
1.05 g/cm^, 1.14 g/cm^ and 1.20 g/cm^. The two outer peaks coincide with those of the 
enzymes a-glucosidase and 3’-nucleotidase which have been shown by Steiger et al. (1980) 
and Gbenle et al. (1986) to be markers for the plasma membrane in T.b.brucei. Upon 
changing to the Tris-containing buffer, the peak at 1.20 g/cm^ was replaced by one at 1.15 
g/cm^ both for DHlipDH and the two marker enzymes. This shift in density is due to the 
detachment of the subpellicular microtubular array from the plasma membrane, and provides 
an unambiguous confirmation of the location of the three enzymes at the plasma membrane 
(Opperdoes & Steiger, 1981).
The additional peak of DHlipDH activity at 1.14 g/cm^ in sucrose/imidazole/EGTA 
buffer was not present in the profiles of either of the two plasma membrane markers. This 
peak is at the same density as those of acid phosphatase and adenylate cyclase, which are 
located in the flagellar pocket membrane (Walter & Opperdoes, 1982; Gbenle et al., 1986).
3.3.2 Latency studies
The activity of malate dehydrogenase in 4.5 x 10^ trypanosomes in the presence of 
0.1 % (w/v) Triton X-100 was 6.2 (± 0.3) nmol NADH oxidised/min. In the absence of 
Triton, none of this activity could be detected. Malate dehydrogenase is a known 
intracellular enzyme in T.b.brucei, and the fact that no enzyme activity could be detected 
without the presence of detergent indicates that all the cells in the assay tube were intact
DHlipDH activity in Triton-treated cells was 0.8 (± 0.2) nmol NADH produced/min. 
Without Triton, no enzyme activity could be detected, indicating that DHlipDH is probably 
located at the inner surface of the plasma membrane of bloodstream T.b.brucei, and hence is 
not accessible to externally supplied substrate in the whole organism.
3.3.3 Triton X-l 14 phase partitioning
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Fig. 3.1. Distribution profiles of marker enzymes and protein from post-large-granule 
extracts of bloodstream form T.b.brucei homogenates after isopycnic centrifugation in 
linear sucrose gradients. The marker enzymes present are : ot-glucosidase and 3'-nucleo- 
tidase for plasma membrane; acid phosphatase and adenylate cyclase for flagellar pocket; 
ot-mannosidase for lysosomes; isocitrate dehydrogenase for mitochondrion, and 
hexokinase for glycosomes. Thick lines represent the distribution in an imidazole- 
containing gradient, and thin lines that in a Tris-containing gradient. The recovery of 
marker enzymes and protein for both gradients was greater than 85 %; the recovery of 
dihydrolipoamide dehydrogenase was 95 %.
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It was judged (from SDS-PAGE) that greater than 95 % of the bacteriorhodopsin 
partitioned solely into the detergent phase, and greater than 95 % of the citrate synthase was 
recovered in the aqueous phase following phase separation.
3.3.4 Determination of DHlipDH and 2-oxo acid dehydrogenase complex levels
The specific activity of DHlipDH in cell-free extracts of bloodstream form cells was 
0.029 ± 0.003 U/mg protein. The pyruvate dehydrogenase, 2-oxoglutarate dehydrogenase 
and branched chain 2 -oxo acid dehydrogenase complexes were undetectable in cell-free 
extracts. The validity of each assay was confirmed by the demonstration that each of the 2- 
oxo acid dehydrogenase complexes were active in the procyclic form of T.b.brucei (section 
4.3.1).
3.4 Discussion
The location of dihydrolipoamide dehydrogenase to the plasma membrane of the 
bloodstream form of T.b.brucei was first reported by Danson et al. (1987) using the method 
of Voorheis et al. (1979) to purify plasma membranes. This method has a few limitations 
and a number of possible inaccuracies that have already been described in the introduction to 
this chapter (section 3.1).
Full subcellular fractionation of bloodstream forms of TJ).brucei has proved 
successful in confirming the intracellular location of a number of enzymes (Steiger et al., 
1980). The results presented in this chapter demonstrate that DHlipDH is located over the 
whole surface of the plasma membrane, including the flagellar pocket region. This is the first 
report of an enzyme located over the whole surface of the trypanosome, and also the only 
known example of an extra-mitochondrial eukaryotic DHlipDH.
Other enzymes located to the plasma membrane include a-glucosidase, which is on 
the external face of the membrane, and possibly galactosyl transferase, both of which may be 
involved in the turnover of variable surface glycoproteins (Cross et al., 1975; Steiger et al., 
1980). 3-Nucleotidase is buried within the plasma membrane of the bloodstream form of 
T.b.brucei, and is probably involved in the salvage of external purines (Gbenle et al., 1986).
The flagellar pocket contains acid phosphatase, acid phosphodiesterase and acid 
pyrophosphatase (Steiger etal., 1980; Opperdoes et al., 1987). Adenylate cyclase has also 
been localised to this region (Walter & Opperdoes, 1982), as have receptors for host low 
density lipoproteins and transferrin (Opperdoes et al., 1987; Coppens et al., 1988). It is 
therefore thought that the flagellar pocket is the site for uptake of macromolecular material 
into the trypanosome (Opperdoes et al., 1987).
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Table 3.1. Phase partitioning of dihydrolipoamide dehydrogenase (DHlipDH) and protein 
with Triton X-l 14
% Initial Material 
Detergent Phase Aqueous Phase
DHlipDH
Whole Cells 0 69





Cell sonicate 2 2 63
Controls
Bacteriorhodopsin >95 <5
Citrate synthase <5 >95
For DHlipDH and protein, the data are mean results obtained from 3 separate experiments. 
Phase partitioning was carried out according to section 3.2.3.
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The assay of the enzyme in intact trypanosomes in the presence and absence of 
detergent indicates that DHlipDH is present on the inner surface of the plasma membrane, so 
it is probably involved with cellular processes concerning the plasma membrane.
The DHlipDH of Clostridium cylindrosporum has been located to the plasma 
membrane of the cell by immunocytochemical techniques (Dietrichs et al., 1991), and the 
enzyme has also been demonstrated to be an antigen in membrane vesicles of E.coli (Owen et 
al.y 1980). These are the only other examples of plasma membrane locations for DHlipDH.
In our laboratory, we have also attempted an immunocytochemical localisation of the 
trypanosomal DHlipDH by producing rabbit polyclonal antibodies to the pig heart enzyme. 
Unfortunately, the serum obtained did not significantly cross-react with the trypanosomal 
enzyme on Western blots. Until sufficient quantities of the trypanosomal enzyme become 
available either by large-scale purification or the expression of a cloned gene, this 
confirmatory experiment is not possible.
Experiments carried out with Triton X -l 14 indicate that DHlipDH is probably not 
attached to the plasma membrane of T.b.brucei via a hydrophobic domain or a lipid anchor. 
Although 63 % of protein partitioned into the detergent phase, only 6 % of DHlipDH from 
sonicated cells was detected in this phase. As whole cells have not been disrupted prior to 
partitioning, and the plasma membranes also have attached DHlipDH, it is evident that the 
small DHlipDH content of the detergent phase from sonicates, in which cellular material has 
been more brutally treated, is probably the result of contamination. In the 2-oxo acid 
dehydrogenase complexes, DHlipDH is bound non-covalently to the E2 or protein X 
components by proteimprotein interactions (Yeaman, 1989). Although the 2-oxo acid 
dehydrogenase complexes are absent from the bloodstream form of T.b.brucei, it is possible 
that the DHlipDH may exist as part of another multienzyme complex which could have a 
similar attachment to the plasma membrane as the pyruvate and 2-oxoglutarate 
dehydrogenase complexes may have to the inner mitochondrial membrane (see section 4.3.2 
and Hunter & Lindsay, 1986). In this respect, Stanley and Perham (1980) found that the 
PDHC of ox heart was released from membranous material by treatment with Triton X-100, 
indicating some form of attachment of the complex, probably to the mitochondrial inner 
membrane. Another possibility may be that the enzyme possesses anchoring hydrophobic 
polypeptides which reside in the plasma membrane. This is the case for both fumarate 
reductase and succinate dehydrogenase in E. coli, each of which is a dimer linked by two 
hydrophobic polypeptides to the cytoplasmic membrane (Ingledew & Poole, 1984). In 
looking at membrane-bound hydrogenases, Kniittel etal. (1989) showed that the hydrogenase 
from Paracoccus denitrificans partitioned into the detergent phase upon treatment with 
Triton X -l 14. This was in contrast to earlier work from that laboratory (Podzuweit et al., 
1987) which demonstrated that the membrane-bound hydrogenase from Alcaligenes 
eutrophus remained in the soluble phase upon detergent treatment. The enzyme,
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nevertheless, is thought to be an integral membrane protein. They therefore suggested the 
possibility of an intrinsic anchor protein, which could be detached upon purification.
Another possibility raised by this work which might also be relevant to DHlipDH, is that an 
alteration in conformation due to detergent treatment may have exposed hydrophilic residues 
and domains, resulting in preferential partitioning into the aqueous phase. However, 
Podzuweit et al. (1987) found no evidence for this possibility from biochemical, 
immunological or catalytic experiments. Such work suggests that detergent partitioning may 
yield anomalous results, which cannot be explained without further detailed chemical 
characterization of the protein involved.
The level of DHlipDH in sonic extracts of bloodstream forms of Tbbrucei 
compares favourably with results obtained by Danson et al. (0.03 U/mg protein; 1987). The 
specific activity is half that found in Halobacterium halobium (Danson et al., 1986), which 
also lacks the 2-oxo acid dehydrogenase complexes, and is 4-fold lower than in S.cerevisiae 
(Wren & Massey, 1965). S.cerevisiae does possess the enzymes of the citric acid cycle, but 
these are not always fully active, as the organism is capable of fermenting glucose when this 
substrate is supplied in high concentrations (Herbert & Guest, 1975), a process during which 
the citric acid cycle enzymes are less active. Therefore, this is perhaps not the best organism 
for a comparison of DHlipDH activity, but in working with other eukaryotes, it has been 
common to pre-purify mitochondria before purifying DHlipDH, and hence the specific 
activity of the enzyme in cell-free extracts has not been determined.
The inability to detect pyruvate dehydrogenase activity in T.bbrucei concurs with 
the work of Flynn & Bowman (1973), and the lack of 2-oxoglutarate dehydrogenase activity 
is consistent with the bloodstream form being unable to survive when 2-oxoglutarate is 
supplied as a growth substrate (Vickerman, 1965). The BCKDHC has not previously been 
measured in these cells, and it is not surprising that this complex appears absent, as it is 
intramitochondrial and feeds into the citric acid cycle in the mammalian cell (section 1.4.2.3).
In mammalian systems, the PDHC and BCKDHC are regulated by phosphorylation 
(Yeaman, 1989), with specific kinases and phosphatases existing to inactivate and re-activate 
the complexes, respectively. The activity states of the BCKDHC in rat liver, heart and 
kidney are 55 %, 5 % and 71 %, respectively (Patston et al., 1988), indicating that 
phosphorylation is an important regulatory feature of this complex in mammals. Such 
phosphorylation has not been detected in other eukaryotic cells (Yeaman, 1989) and does not 
occur in prokaryotes. In the trypanosome, the majority of glucose metabolism is controlled 
by enzyme synthesis (Fairlamb & Opperdoes, 1986), with mitochondrial switching being 
under genetic regulation (Vickerman, 1965). Therefore, it is unlikely that phosphorylation 
would be used to inactivate the mitochondrial complexes in the bloodstream form cell. To be 
certain of this, however, future assays could be conducted under conditions that promote 
dephosphoiylation (Patston et al., 1988; Moreno-Sanchez & Hansford, 1988).
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In summary, the results presented in this chapter demonstrate that DHlipDH is located 
over the whole of the cytoplasmic face of the plasma membrane. It is probably not attached 
to the membrane by direct anchorage, but rather through interaction with another membrane 
protein. It has been confirmed that this DHlipDH does not participate in the 2-oxo acid 
dehydrogenase complexes.
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CHAPTER 4 : DIHYDROLIPOAMIDE DEHYDROGENASE AND THE 2-OXO ACID 
DEHYDROGENASE COMPLEXES IN PROCYCLIC FORMS OF T.B.BRUCEI
4.1 Introduction
An investigation into DHlipDH in T.b.brucei would not be complete without looking 
at the procyclic form of the parasite. This form possesses a highly-developed mitochondrion, 
and relies upon 2-oxo- and amino-acid oxidation linked to the phosphorylation of ADP at the 
level of the mitochondrial ATPase for production of energy (Opperdoes et al., 1981). The 2- 
oxo acid dehydrogenase complexes, which contain DHlipDH, are intra-mitochondrial in 
other eukaryotes, and therefore their presence might be expected in a mitochondrially-active 
cell.
Whilst the pyruvate dehydrogenase complex (PDHC) and 2-oxoglutarate 
dehydrogenase complex (20GDHC) have been detected in TJb.rhodesiense procyclics (Flynn 
& Bowman, 1973), neither they nor the branched chain 2-oxo acid dehydrogenase complex 
(BCKDHC) or DHlipDH have previously been measured in T.b.brucei. Therefore, the first 
part of this chapter describes the detection and measurement of these enzymes in T.b.brucei 
procyclics.
Secondly, with preliminary evidence of a plasma membrane location for DHlipDH in 
bloodstream form cells (Danson et al., 1987), and the definitive evidence in chapter 3, it is 
necessary to investigate the location of the enzyme and its complexes in procyclics using a 
complete subcellular fractionation. This has been carried out for DHlipDH, the PDHC and 
NADH oxidase. The NADH oxidase activity has been measured because it could interfere 
with DHlipDH and PDHC assays, leading to inaccurate localisation.
4.2 Methods
DHlipDH was assayed as described in section 2.2.6.
4.2.1 Assay of the pyruvate and 2-oxoglutarate dehydrogenase complexes
The pyruvate and 2-oxoglutarate dehydrogenase complexes were assayed under 
identical assay conditions, with the exception of the substrates employed.
The assay mixture, in a total volume of 1 ml, consisted of 50 mM potassium 
phosphate, pH 7.0,2.5 mM NAD+, 0.2 mM thiamin pyrophosphate, 1.0 mM M gC^, 0.13 
mM CoASH, 2.6 mM cysteine-HCl, 0.1 % (w/v) Triton X-100 and 2 mM sodium pyruvate or 
2-oxoglutarate, to which was added an appropriate volume of cell extract. The assay was 
carried out at 30°C and the production of NADH followed by monitoring the increase in
a 340-
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A blank rate of reaction without substrate (pyruvate or 2-oxoglutarate) was 
determined for each sample. This was subtracted from the rate in the presence of substrate to 
yield the specific rate for complex activity.
CoASH and cysteine-HCl were stored together in a separate solution to the other 
assay components, the cysteine-HCl being present to ensure an acid pH for stabilisation of 
CoASH.
4.2.2 Assay of the branched-chain 2-oxo acid dehydrogenase complex
The branched-chain 2-oxo acid dehydrogenase complex (BCKDHC) has a broad 
specificity towards 2-oxo acid substrates (Patston et al., 1988). Therefore, three different 
substrates were used for assays in trypanosomes: ketoleucine (a-ketoisocaproic acid), 
ketoisoleucine (DL-a-keto-P-methyl-n-valeric acid) and ketovaline (a-ketoisovaleric acid).
The assay mixture, in a total volume of 1 ml, contained 30 mM potassium phosphate, 
pH 7.5,1 mM NAD+, 0.4 mM thiamin pyrophosphate, 2 mM MgSO^ 1.1 mM KCN, 2 mM 
dithiothreitol, 0.4 mM CoASH, 2.6 mM cysteine-HCl, 0.1 % (w/v) Triton X-100 and 0.2 mM
2-oxo acid. The assay was carried out at 30°C and monitored by increase in absorbance at 
340 nm due to production of NADH. As with the PDHC & 20GDHC assays, a blank rate 
was determined in the absence of substrate (2-oxo acid), and this was subtracted from the rate 
in the presence of substrate to give the true rate for the complex.
4.2.3 Subcellular fractionation
The same method was used for the subcellular fractionation of procyclic T.b.brucei as 
for the bloodstream forms (section 3.2.1). Cultured procyclic trypomastigotes were disrupted 
by grinding with silicon carbide, and subjected to differential centrifugation followed by 
isopycnic centrifugation in a linear sucrose gradient. The marker enzymes a-glucosidase 
(plasma membrane), acid phosphatase (microsomes), 3'-nucleotidase (plasma membrane), a- 
mannosidase (lysosomes), NADP+-linked isocitrate-dehydrogenase (NADP-EDH, 
mitochondria) and hexokinase (glycosomes) were assayed as described previously 
(Opperdoes & Steiger, 1981; Walter & Opperdoes, 1982; Gbenle et al., 1986). Subcellular 
fractionation and marker enzyme assays were carried out by Mr J. Van Roy, ICP, Brussels, 
and fractions from the gradient, stored in liquid nitrogen, were sent to Bath. DHlipDH, 
PDHC and NADH oxidase activities were measured in Bath. DHlipDH and the PDHC were 
assayed as described in sections 2.2.6 and 4.2.1. NADH oxidase was assayed in 50 mM 
potassium phosphate buffer, pH 7.0, 2 mM EDTA, 0.1 mM NADH at 30°C. The reaction 
was monitored by decrease in absorbance at 340 nm.
42
4.3 Results
4.3.1 The 2-oxo acid dehydrogenase complexes
The levels of the 2-oxo acid dehydrogenase complexes and DHlipDH in the procyclic 
form of T.b.brucei are displayed in Table 4.1.
A blank rate of 1.84 x 10"^ jimol NADH produced/min/mg protein was obtained for 
extracts under the assay conditions for the PDHC, 20GDHC and BCKDHC. This increase in 
A340 was proportional to the amount of extract added. The blank rate has been subtracted 
from each of the values obtained in the presence of substrate to give those shown in Table
4.1.
All three of the branched-chain 2-oxo acids (ketoleucine, ketoisoleucine & 
ketovaline) were equally active as substrates of the BCKDHC.
Of the 2-oxo acid dehydrogenase complexes, the highest level of activity was found 
for the PDHC, with the 20GDHC having 2.7-fold less activity, and the BCKDHC activity 
being a further 6-fold lower. DHlipDH, a component of all of these complexes, has a 20-fold 
higher specific activity than the PDHC, and 14-fold more activity than all three complexes 
together.
4.3.2 Subcellular fractionation
The distribution profiles for DHlipDH, PDHC and NADH oxidase, together with 
marker enzymes for cellular compartments, in post-large-granule extracts of procyclic 
T.b.brucei homogenates after isopycnic centrifugation in linear sucrose gradients are shown 
in Fig. 4.1.
DHlipDH shows two clear peaks of activity at 1.09 g/cm^ and 1.18 g/cm^ in both the 
imidazole- and Tris-based buffering systems. This distribution is identical to that of the 
NADP+-linked isocitrate dehydrogenase (NADP-IDH), which includes a soluble component 
at 1.09 g/cm^ and a peak corresponding to the mitochondrial matrix at 1.18 g/cm^.
There is no significant difference between the distributions of DHlipDH in each of the 
two buffers. This contrasts with the known plasma membrane markers a-glucosidase and 3'- 
nucleotidase, which display density shifts from 1.18 g/cm^ in Sucrose-Imidazole-EGTA 
(SIE) buffer to 1.14 g/cm^ in Sucrose-Tris-EDTA (STE) buffer. Such shifts are 
characteristic of the plasma membrane of both bloodstream and procyclic forms of 
T.b.bruceU the subpellicular microtubular arrays of the cells becoming detached from the 
plasma membrane upon changing from the imidazole- to the Tris-based buffer (Steiger et al.9 
1980; Opperdoes & Steiger, 1981). This difference between results obtained for DHlipDH 
and the plasma membrane markers demonstrates that no DHlipDH is detectable at the plasma 
membrane of procyclic T.b.brucei.
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Table 4*1 Specific activities of dihydrolipoamide dehydrogenase and the 2-oxo acid 
dehydrogenase complexes in the procyclic form of TJb.brucei
En?yme Specific activity
(nmol/min/mg protein)
DHlipDH 400 ± 70
PDHC 2 0 .0  ± 1.0 -
20GDHC 7.5 ±0.7
BCKDHC 1.3 ±0.2
Enzyme activities have been measured according to sections 2.2.6,4.2.1 and 4.2.2, and 
































Fig. 4.1. Distribution profiles of marker enzymes and protein from post-large-granule 
extracts of procyclic TJj.brucei homogenates after isopycnic centrifugation in linear 
sucrose gradients. The marker enzymes present are : acid phosphatase for the 
endoplasmic reticulum; a-mannosidase for lysosomes; a-glucosidase for plasma 
membrane; hexokinase for glycosomes, and isocitrate dehydrogenase for mitochondrion. 
Thick lines represent the distribution in an imidazole-containing gradient, and thin lines 
that in a Tris-containing gradient. The recovery of marker enzymes, NADH oxidase and 
protein was greater than 85 %. Recoveries of pyruvate dehydrogenase complex and 
dihydrolipoamide dehydrogenase were 107 % and 121.2 %, respectively.
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PDHC exhibited only one peak of activity in each sucrose gradient, at 1.18 g/cm^ in 
the SIE gradient, and 1.20 g/cm^ in the STE gradient. This peak coincides with the peaks of 
DHlipDH and NADP-IDH activity which correspond to the mitochondrial matrix. The lack 
of any soluble peak, together with the sharpness of the mitochondrial peak, may indicate that 
the PDHC is present at the mitochondrial membrane in procyclics.
A major peak of NADH oxidase activity was at 1.24 g/cm^ in the imidazole buffer 
and 1.23 g/cm^ in the Tris-based buffer, with an additional small peak in both buffers at 1.08 
g/cm^. The major peaks corresponded to those of hexokinase, a marker for the glycosomal 
compartment, and the minor peak at 1.08 g/cm^ consisted of soluble enzyme activity.
4.4 Discussion
The work presented in this chapter demonstrates the presence of DHlipDH and the 2- 
oxo acid dehydrogenase complexes in the procyclic form of T.b.brucei,
The specific activity of DHlipDH is 4-fold higher than in epimastigotes of T.cruzi 
(Lohrer & Krauth-Siegel, 1990) and in Saccharomyces cerevisiae (Wren & Massey, 1965), 
which possess active citric acid cycles, and 7-fold higher than the activity in Halobacterium 
halobium (Danson et al., 1986), which does not have the 2-oxo acid dehydrogenase 
complexes.
The PDHC activity is 4-fold lower than pyruvate oxidase (determined 
manometrically) in shoit-stumpy bloodstream forms of TJb.rhodesiense (Flynn & Bowman, 
1973), but comparable to levels in other cells such as E.coli (35.6 nmol/min/mg protein; 
Bothe & Nolteemsting, 1975), rat liver (30 nmol/min/mg; Roche & Cate, 1977) and mouse 
and rat brain (4-24 nmol/min/mg; Hinman & Blass, 1981).
The 2.5-fold lower activity of 20GDHC as compared to PDHC in procyclics contrasts 
with the higher levels of 20GDHC found in other organisms including procyclic 
T.b.rhodesiense (1.25-fold more 20GDHC; Flynn & Bowman, 1973) and rat liver (1.77-fold 
more 20GDHC; Roche & Cate, 1977). This unusual difference may reflect the incomplete 
mitochondrial metabolism of procyclics (see section 1.2.3.3). The 20GDHC receives 2- 
oxoglutarate from proline oxidation, and may also obtain it via the action of the NADP+- 
linked isocitrate dehydrogenase (the NAD+-linked enzyme, which normally forms the 
previous step in the citric acid cycle, is absent [see Fairlamb & Opperdoes, 1986]). The 
enzymes succinate thiokinase and succinate dehydrogenase, which follow 20GDHC in the 
cycle, are also present (see section 1.2.3.3). Even with this metabolic context for the enzyme, 
there is surprisingly low activity of 20GDHC in these cells.
The determination of the BCKDHC has not previously been reported in 
trypanosomes, and is evidence that branched-chain amino acids may be catabolised in 
procyclic T.b.brucei. The complex is less active in these cells than the PDHC and 20GDHC,
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which concurs with results from rat tissues, where Patston etal. (1988) found 3-10 
nmol/min/mg BCKDHC and Roche & Cate (1977) measured PDHC activity at 30 
nmol/min/mg (in liver).
At this point it is worth mentioning that both the PDHC and BCKDHC are regulated 
by phosphorylation in mammalian systems (Yeaman, 1989). It is possible, therefore, that 
their levels, as detected in the assays described above, may be underestimates of the true 
activities in the absence of phosphorylation (see section 3.4).
The 20-fold greater specific activity of DHlipDH in comparison to the PDHC in 
procyclics correlates well with results obtained by Komuniecki et al. (1979) working on 
Ascaris muscle (0.038 pmol/min/mg PDHC and 0.80 pmol/min/mg DHlipDH). The greater 
activity of DHlipDH in comparison to the total activity of all the complexes is understandable 
as the enzyme is produced in excess of the other components of the 2 -oxo acid 
dehydrogenase complexes in mammalian mitochondria, where up to 25 % of the enzyme is 
uncomplexed (Lusty & Singer, 1964). Another reason for the higher activity is that the El 
component of the PDHC is the rate-limiting step of the reaction (Cate etal.y 1980), so, when 
E3 is assayed alone, it should show a higher activity than the whole complex.
The glycine cleavage system (GCS) has not been measured in either form of 
Tb.brucei. It is intramitochondrial in other eukaryotes (Motokawa & Kikuchi, 1971), and 
therefore might be expected to be absent from the bloodstream and present in the procyclic 
form of TJb.brucei. Glycine itself is a product of the active threonine catabolism of these 
cells, but appears to be expelled into the surrounding medium as opposed to being 
metabolised further (Linstead et al., 1977). Nevertheless, growth on threonine does induce 
the synthesis of the glycine cleavage system in bacteria (Bell & Turner, 1976), so glycine 
cleavage commonly follows threonine catabolism in these cells. There is an amino acid 
transporter capable of importing/exporting glycine in trypanosomes (Voorheis, 1971).
In rat liver mitochondria, the specific activity of the GCS is 0.09 nmol/min/mg 
protein (Motokawa & Kikuchi, 1971). Therefore, if the enzyme were to perform an 
analogous role in T.b.brucei, it might be present at very low levels in procyclics.
Several anaerobic glycine-utilising bacteria contain high levels of the GCS (Dietrichs 
& Andreesen, 1990), with the DHlipDH of one, Clostridium cylindrosporum, having been 
located to the plasma membrane of the cell (Dietrichs et al., 1991). These organisms, 
however, are anaerobic, and use glycine as their major respiratory substrate, whereas in 
T.b.brucei there is no evidence that the cells use glycine even as a minor nutrient. So, while 
the results from C.cylindrosporum are very interesting from the point of view of there being 
another plasma membrane DHlipDH, they have no bearing on the use of the GCS by 
T.b.brucei.
Further information concerning DHlipDH and the 2-oxo acid dehydrogenase 
complexes has been gained from a full subcellular fractionation of the procyclic cells. This
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has demonstrated that at least the majority of the cellular DHlipDH is within the 
mitochondrion of the procyclic. It is not clear as to whether any DHlipDH exists in any other 
cellular location.
Both DHlipDH and the mitochondrial marker NADP-EDH have two peaks of activity 
in the sucrose gradient, one corresponding to mitochondrial, and the other to soluble, 
material. Opperdoes etal. (1981) detected similar bimodal distributions for threonine 
dehydrogenase and aminoacetone synthase in procyclics. They explained these results by 
suggesting that the highly developed mitochondria of these cells could be easily ruptured by 
grinding with silicon carbide, and enzymes such as those of the threonine pathway, which are 
present in the mitochondrial matrix, could leak out. Both DHlipDH and NADP-IDH may, at 
least in part, be free within the mitochondrial matrix, and therefore able to leak out.
There is much evidence for cytosolic and mitochondrial isoenzymes of NADP-IDH in 
several mammalian systems (Colman, 1983). For example, rat heart has 90 % 
mitochondrial/10 % cytosolic NADP-IDH (Plaut & Gabriel, 1983). The presence of the 
enzyme in both compartments may allow it to act as a flux for reducing equivalents between 
them (Plaut & Gabriel, 1983). In the kinetoplastida, Crithidiafasciculata also has 
mitochondrial and cytoplasmic isoenzymes (Morris & Weber, 1975). Therefore, there is 
clearly a precedent for a cytosolic NADP-IDH in procyclic cells, which may contribute to the 
soluble peak observed in the sucrose gradient.
Looking closer at the distribution profiles for DHlipDH and NADP-IDH (Fig. 4.1), 36 
% of DHlipDH is present in the soluble peak, and the remaining 64 % in the mitochondrial 
peak. In the same gradients, NADP-IDH is 27 % soluble and 73 % mitochondrial.
Therefore, 9 % more DHlipDH than NADP-IDH migrates in the soluble portion of the 
gradient. This difference may not be significant, and could be merely the result of 
differential leakage from ruptured mitochondria, but it does leave open the possibility that a 
proportion of the DHlipDH exists outside of the mitochondrion in vivo. The majority of the 
increase in DHlipDH upon differentiation to the procyclic form can, nevertheless, be put 
down to the switching on of the mitochondrial 2-oxo acid dehydrogenase complexes. This 
highlights a major drawback of the fractionation method, in that if 10 % of the DHlipDH in 
procyclic cells were at the plasma membrane, it would not be possible to observe the 
associated density shift against a high background of mitochondrial DHlipDH.
The distribution profile for the PDHC indicates its presence within the mitochondrion 
of the procyclic T.b.bruceL It has no soluble peak of activity, which is possibly indicative of 
attachment to the mitochondrial inner membrane. The enzymes succinate dehydrogenase, 
oligomycin-sensitive ATPase and glycerol-3-phosphate dehydrogenase, which are all 
components of the respiratory chains of these cells and are also attached to the inner 
membrane, possess distribution profiles identical to that of the PDHC (Opperdoes et al., 
1981).
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Further experiments are required to elucidate whether or not a proportion of procyclic 
DHlipDH is located outside the mitochondrion, and possibly at the plasma membrane. 
Immunocytochemical localisation with antibodies to the bloodstream form DHlipDH would 
be one method. In the absence of suitable antibodies, the technique of digitonin- 
permeabilisation, whereby the plasma membrane can be selectively permeabilised, leaving 
the mitochondrial membrane intact, may allow detection of an extramitchondrial DHlipDH. 
The technique has recently been used successfully to investigate carbohydrate metabolism in 
both bloodstream (Kiaira & Njogu, 1989) and procyclic trypomastigotes (Turrens, 1989). 
Future work must also include the determination of GCS activity in procyclic cells, to 
complete the investigation of the major DHlipDH-containing multienzyme complexes.
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CHAPTER 5 : DETECTION OF LIPOIC ACID
5.1 Introduction
In an investigation into the role of DHlipDH in the bloodstream form of T.b.brucei, it 
is important to look for its presumed substrate, lipoic acid, in these cells.
The presence of lipoic acid would suggest that the enzyme may be performing an analogous 
role to that in the 2 -oxo acid dehydrogenase complexes, in catalysing the interconversion of 
reduced and oxidised lipoic acid/lipoamide. If it were absent, however, then the enzyme 
would have a different substrate in vivo, and be able to catalyse the oxidation of 
dihydrolipoamide as a secondary reaction in vitro. The latter feature is demonstrated by the 
electron-transferring flavoprotein of bacterium W6 , which behaves more like thioredoxin 
reductase than DHlipDH, but can catalyse the oxidation of dihydrolipoamide (Dietrichs et al., 
1990; Meyer et al., 1991). Certainly, the detection of lipoic acid would be suggestive of 
DHlipDH using it as a substrate in vivo. This still, however, gives no indication as to the 
source, or cellular location of the reduced lipoic acid. With the presence of both enzyme and 
presumed substrate within the cell, it becomes less likely that the DHlipDH is merely the 
result of aberrant expression.
Further analysis of the possible linkage of lipoic acid to a protein and any association 
of the cofactor with cell membranes will help to elucidate the role of enzyme and substrate in 
T.b.brucei.
A number of different methods have been developed for the determination of lipoic 
acid in biological systems. Following release of the cofactor from protein by acid or base 
hydrolysis, lipoic acid has been assayed as follows :
a) Manometric assay : Streptococcus faecalis (strain 10C1), grown on lipoic acid- 
deficient medium contains the apoenzymes of the 2-oxo acid dehydrogenases (Gunsalus & 
Razzell, 1957). Addition of lipoic acid activates these enzymes in proportion to the amount 
of cofactor added. Activity is measured by following oxygen consumption manometrically. 
This assay is sensitive between 1 and 10 ng lipoic acid per assay tube.
b) Polarographic assay : The lipoic acid mutant of Escherichia coli K12, W1485//p2, 
contains the apoenzymes of the 2-oxo acid dehydrogenase complexes (Herbert & Guest, 
1968). Therefore, when lipoic acid is supplied to these cells in the presence of pyruvate, 
oxygen consumption increases in proportion to the amount of cofactor added, and this can be 
measured with an oxygen electrode (Herbert & Guest, 1970 & 1975). The sensitivity range 




c) Turbidimetric assay : In this method, the growth of the lipoic acid-deficient E.coli 
K12, W1485/ip2, is proportional to the amount of lipoic acid present. This growth is 
measured turbidimetrically. Growth is proportional to lipoic acid over the range 0.2 - 2.0 ng 
(Herbert & Guest, 1975).
d) Gas chromatography/mass spectrometry (GC/MS): This method differs from the 
three detailed above in being qualitative, but giving an absolute chemical identification of 
lipoic acid (Pratt et al., 1989).
For the purposes of this investigation, the turbidimetric assay was chosen to give a 
quantitative estimation of the lipoic acid content of T.b.brucei bloodstream form and 
procyclic cells. This method was favoured as the most sensitive and most straightforward of 
the quantitative techniques (Herbert & Guest, 1975). Escherichia coli TGI was chosen as a 
control organism, as data already exist for the lipoic acid content of various strains of this 
organism.
GC/MS was used to confirm the chemical nature of the lipoic acid in bloodstream 
forms. This is of particular importance in proving that lipoic acid itself, rather than any 
chemically similar molecule, is present in T.b.brucei. It will not, however, definitively prove 
that lipoic acid is the chemical moiety in vivo because acid hydrolysis may have removed 
certain substituents prior to GC/MS.
At this point it is worth noting that another cellular thiol, glutathione, is replaced by 
trypanothione in all trypanosomatids. Although this has a different function to lipoic acid, 
there is nevertheless a precedent for differences in thiol metabolism in this organism.
5.2 Methods
5.2.1. Biological turbidimetric assay
The biological turbidimetric assay consisted of 3 main procedures: the preparation of 
lipoic acid, the growth of the mutant inoculum, and the assay itself.
5.2.1.1 Preparation of lipoic acid
(a) Standard lipoic acid solution. A standard solution of D,L-a-lipoic acid was 
prepared at 1 mg/ml in 0.2 M potassium phosphate buffer (pH 7.0). This stock solution could 
be stored at 4*C for several months.
(b) Lipoic acid from cellular material. Lipoic acid was liberated from protein by 
acid hydrolysis (Gunsalus & Razzell, 1957). Cells of T.b.brucei bloodstream and procyclic 
forms and E.coli TGI were sonicated for 3 x 30 s at 40 W using a 3 mm probe at 4*C. 
Varying amounts of the sonicates were transferred to glass tubes and hydrolysed in 0.3 ml 6  
M HC1 at 120°C for 2 h in vacuo. As a control, 1 mg bovine serum albumin was also 
hydrolysed under the same conditions. The dried hydrolysates were resuspended in 1 ml
51
0.2 M potassium phosphate buffer (pH 7.0) and filtered through 0.22 pm pore filters to 
remove any insoluble material.
The protein contents of cell sonicates were determined prior to hydrolysis by the 
procedure described in section 2.2.5. Diy weight determinations were carried out by freeze- 
drying cell extracts and drying to constant weight over NaOH and conc. H2SO4  in vacuo.
5.2.1.2. Growth of the inoculum
The mutant inoculum was prepared by transferring a single colony of E.coli K12, 
W1485//p2, to a 5 ml culture of succinate-based minimal salts medium containing 35 mM 
K2 HPO4 , 16 mM NaH2 P0 4 .2 H2 0 , 37 mM NH4 CI, 1 mM Na2 SC>4 , 5 jig thiamin/ml, 0.5 
mM MgCl2 .6H2 0  and 50 mM sodium succinate supplemented with 1 ng/ml lipoic acid. 
Following overnight incubation at 37*C with vigorous shaking, cells were harvested by 
centrifugation at 600 x g, and washed twice with 5 ml portions of sterile 0.9 % saline; the 
cell pellet was resuspended in saline and diluted to an absorbance of approximately 0 .2  at 660 
nm. From this suspension, an inoculum of 0.1 ml was added to each assay tube.
5.2.1.3. Assay of lipoic acid
For the assay of lipoic acid, the following reagents were transferred to a series of 
capped 750 x 10 mm test tubes: 1.0 ml of Basal Growth Medium (Table 5.1), an appropriate 
volume of standard lipoic acid solution or hydrolysed sample, and the required volume of 
water to bring the total volume to 1.8 ml. The tubes were sterilised by autoclaving at 120°C 
for 10 min. Sterile 1 M sodium succinate solution (0.1 ml) and 0.1 ml mutant inoculum were 
added aseptically, and the tubes incubated for approximately 24 h at 37°C with shaking. The 
growth in each tube was determined by measuring the absorbance at 660 nm. From these 
results, a standard curve for lipoic acid was constructed and used to determine the lipoic acid 
contents of individual samples.
5.2.2 Gas chromatographv/mass spectrometry
Gas chromatography/mass spectrometry (GC/MS) of bloodstream forms of T.b.brucei 
was carried out according to the method of Pratt et al. (1989) by Professor K. J. Stevenson at 
The University of Calgary, Calgary, Canada. Cells of Tbbrucei were grown and purified in 
Bath, and sent freeze-dried to Professor Stevenson.
The method can be summarised as follows. Cells were hydrolysed as described in the 
biological method, and any lipoic acid present reduced by slow addition of NaBH4 . The pH 
was lowered to pH 3 with HC1 to remove excess NaBH4 , and the solution then made up to 30 
% (v/v) with respect to ethanol, after which Na2HPC>4 buffer was added and the pH re­
adjusted to pH 9 with NaOH. This solution was added to p-aminophenylarsenoxide- agarose 
and gently agitated overnight. The matrix was then washed with 50 mM-sodium phosphate,
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Table 5.1 Basal growth medium for the growth of the lipoic acid-requiring mutant of 
Escherichia coli K12, W1485///?2
Medium Grams/litre
Casamino acids 4
k 2 h p o 4 14
k h 2 p o 4 6
Na3  citrate.3H20 1
MgS04 .7H20 0 .2 0
(NH^SO^j. 2
L-Asparagine 8
L-Arginine 0 .2 0
L-Glutamate 0 .2 0
Glycine 0 .2 0
L-Histidine 0 .2 0
L-Proline 0 .2 0
L-Tryptophan 0.36
L-Cysteine 0.16
Na thioglycollate 0 .2 0
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pH 7.5, in 30 % (v/v) ethanol, resuspended in the same buffer containing 2,3- 
dimercaptopropane-l-sulphonic acid, and shaken for 3 h. The eluent was collected by 
filtration and the pH adjusted to pH 3 with HC1. The solution was extracted with benzene to 
recover the lipoic acid and the extract was washed with dilute acid to remove any extracted 
2,3-dimercaptopropane-l-sulphonic acid. Extracted lipoic acid was allowed to oxidize 
overnight, yielding a dried extract, and methylated by dissolving in diethyl ether and reacting 
with cold diazomethane. The oxidised lipoic acid methyl ester was applied to a Kratos-MS 
80 GC/MS.
5.3 Results
5.3.1. Biological turbidimetric assay
Using commercially obtained lipoic acid, the growth of the lipoic acid-requiring 
mutant of E.coli was proportional to the amount of cofactor present up to a level of 1.0 ng 
(Fig. 5.1). The amount of lipoic acid in each hydrolysed sample was calculated from the 
growth of the E.coli mutants, using a separate standard curve for each experiment. The lipoic 
acid contents of bloodstream and procyclic Tbbrucei, E.coli TGI and the BSA control are 
displayed in Table 5.2. Those of procyclic T.b.brucei and E.coli TGI are similar, and 7-fold 
greater than the lipoic acid content of bloodstream forms of Tbbrucei.
Each lipoic acid content (± SEM) has been calculated from 7 or more data points. 
Results were independent of protein hydrolysed and quantity of hydrolysate assayed for all 
cell types. At 25 mg of protein, T.b.brucei bloodstream form sonicates showed pronounced 
charring with hydrolysis and reduced lipoic acid recovery after filtration. Therefore, less 
than 2 0  mg protein were hydrolysed in each case.
5.3.2. Gas chromatographv/mass spectrometry
The presence of lipoic acid in the bloodstream form of Tbbrucei was confirmed by 
GC/MS, a procedure which at the same time provided an unequivocal chemical identification 
of the cofactor. Following acid hydrolysis of bloodstream form Tbbrucei cells, any 
compounds containing vicinal thiol groups were separated from other cellular material by 
covalent chromatography on p-aminophenyldichloroarsine-agarose. Compounds such as 
lipoic acid were eluted from the column with 2,3-dimercaptopropane-l-sulphonic acid, 
extracted into benzene, and air-oxidised to the disulphide from. Treatment with 
diazomethane yielded their methyl esters which were subjected to GC/MS as described by 
Pratt etal. (1989).
A peak of oxidised lipoic acid methyl ester was identified in the gas chromatogram 
(Fig. 5.2a) by monitoring the presence of the fragmentation ion (/?z/z=123) and the molecular 
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Fig. 5.1. Standard curve for the growth of the lipoic acid-requiring mutant Escherichia 
coli K12, W1485/ip2, in the presence of increasing concentrations of commercial lipoic 
acid. The mutant E.coli were grown at 37°C for 24 h, with shaking, in a basal growth 
medium containing succinate. The appropriate amount of lipoic acid (ng) was added to 
each assay tube. Growth of cells was assessed turbidimetrically by determining the 
increase in absorbance at 660 nm. A standard curve has been fitted to these points by 
linear regression analysis.
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Table 5.2 Lipoic acid contents of Tbbrucei and E.coli TGI
Organism Lipoic 
ng/mg protein
acid content (± SEM)
ng/mg dry wt.
Tbbrucei (bloodstream) 1.7 ±0.2 1 .2  ± 0 .1
Tbbrucei (procyclic) 17 ±0.5 8 .0  ± 0 .2
E.coli TGI 19 ±1.8 6.5 ±0.6
bovine serum albumin 0 0
Lipoic acid contents have been determined using the biological turbidimetric assay of 
Herbert & Guest (1975), as described in section 5.2.1.
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Fig. 5.2. Gas chromatography/mass spectrometry of oxidised lipoic acid methyl ester 
enriched from T.b.brucei. (a) Gas chromatogram monitored by mass spectroscopy of 
fraction enriched by covalent chromatography on p-aminophenylarsenoxide-agarose.
TIC represents the total ion chromatogram. The profiles obtained by plotting die mass 
ions of mlz -  220 and 123 as a function of time are indicated by 220 and 123, 
respectively, (b) Mass spectrum of the peak eluted at 18.5 min (indicated by arrow) 
containing oxidised lipoic acid methyl ester. The spectrum was generated after 
subtraction of the 18-min baseline. The interpretation of the mass spectrum is described 
in the text, based on the assignment of molecular and fragmentation ions given in Pratt et 
a l  (1989).
57
spectrum (Fig. 5.2b), provide the definitive identification of oxidised lipoic acid methyl ester. 
The expected mass spectral fragmentation pattern, the demonstration of the validity of the 
methodology using commercially available lipoic acid, and the rationale for the interpretation 
of the spectra have been described by Pratt et al. (1989). Thus, the mass spectrum (Fig. 5.2b) 
from the GC/MS analysis of hydrolysed cells of T.b.brucei shows clearly defined peaks at 
m!z -  220,189,155,123,105 and 95, the relative intensities of which are similar to those 
observed with pure lipoic acid. Moreover, the high (m + 2)lm ratio of the molecular ion (mlz 
= 220) is consistent with this species possessing two sulphur atoms. Clearly the presence of 
ions above mlz = 220 indicates that the peak analysed from the GC has a minor contaminant 
in addition to the lipoic acid methyl ester, but this does not detract from the conclusions 
drawn.
5.4 Discussion
The work presented in this chapter represents the first report of the presence of lipoic 
acid in Trypanosoma brucei brucei. Levels of 1.2 & 8.0 ng/mg dry weight for bloodstream 
and procyclic T.b.brucei, respectively, are within the range of values obtained in various 
organisms by Herbert & Guest (1975). The negative result for the bovine serum albumin 
control indicates that individual amino acids, produced by hydrolysis, were not able to 
stimulate the growth of the mutant E.coli.
The lipoic acid content of E.coli TGI (6.5 ± 0.6 ng/mg dry wt.) measured in this assay 
is lower than the range obtained for E.coli W1485 (Table 5.3) by Herbert & Guest (1975), but 
Bothe & Nolteemsting (1975), using the manometric method, detected only 4.1 ng/mg lipoic 
acid in E.coli. Such variation might be expected between different strains and growth 
conditions, but could also result from slightly lower yields after hydrolysis.
The recovery of lipoic acid and its release from protein by hydrolysis are key factors 
affecting the accuracy of lipoic acid determinations, and have been extensively investigated 
by other workers. Gunsalus & Razzell (1957) first showed that autoclaving at 120#C for 2 h 
in 6  M HC1 gave least destruction of lipoic acid, and White (1980) demonstrated that this 
procedure released 95 % of the cofactor from E.coli proteins. A key determinant of lipoic 
acid recovery is the amount of protein hydrolysed with the cofactor. If lipoyllysine alone is 
the starting material, less than 70 % of the lipoic acid is recovered (Hayakawa & Oizumi, 
1989), but the addition of bovine serum albumin to a lipoic acid solution was able to protect 
it against degradation during hydrolysis (Wagner et al., 1956). Herbert & Guest (1975) 
looked at recovery in the presence of E.coli cell extracts. Addition of commercial lipoic acid 
to extracts yielded 90-110 % of the cofactor after hydrolysis. This particular study was 
carried out using the same experimental protocol as detailed in section 5.2.1, and therefore 
allows reasonable confidence in the recovery of lipoic acid from the cells under investigation.
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Table 5.3 Lipoic acid contents of several micro-organisms
Organism Lipoic Acid Content Presence/absence
ng/mg dry wL of PDHC
Escherichia coli W1485a 13-41 +
Bacillus megateriuma 25 +
Pseudomonas aeruginosaa 8.5-9.0 +
Gloecapsa alpicolaa 1.1 -
Clostridium pasteurinunfi 0.05 -
Clostridium kluyverfi 0.15 -
Saccharomyces cerevisiaea 1 .0 + (low)
7.5 +
Ankistrodesmus braunifi 0 .8 -
Halobacterium volcaniic 0 .8 -
a Herbert & Guest (1975); ^ Bothe & Nolteemsting (1975);c Noll & Barber (1988).
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Other methods for releasing lipoic acid from protein include enzymatic cleavage by 
the enzyme lipoamidase, which is present in many species (Koike & Suzuki, 1970), and 
hydrolysis with organic acids (Matarese etal., 1981) or sodium hydroxide (Noll & Barber, 
1988). None of these techniques have been as well characterised in terms of yields and 
optimal cleavage conditions as acid hydrolysis with HC1 or H2 SO4 .
Initial work on determining the lipoic acid contents of hydrolysates was performed 
according to Noll & Barber (1988). This procedure often produced revertants during 
overnight incubation at 37°C in the absence of lipoic acid (an addition to the method of 
Herbert & Guest [1970]). Another problem was the low reproducibility and inaccuracy of 
data. Noll & Barber (1988) used a simplified minimal salts medium for the assay, instead of 
the more complex medium of Herbert & Guest (1970). The latter medium is known to give 
an improved response of the cells to lipoic acid by reducing errors arising from small 
amounts of hydrolysed amino acids affecting growth (Herbert & Guest, 1975). On account 
of these problems, the method of Noll & Barber (1988) was soon abandoned in favour of that 
of Herbert & Guest (1970 & 1975).
Both E.coli TGI and procyclic T.b.brucei possess the enzymes of the citric acid cycle, 
and therefore it is not surprising that they have similar levels of lipoic acid, presumably 
bound to the E2 components of the 2-oxo acid dehydrogenase complexes. The values for 
these two organisms also correlate with those of other organisms using the citric acid cycle, 
including E.coli W1485, Bacillus megaterium and Pseudomonas aeruginosa (table 5.3; 
Herbert & Guest, 1975). In E.coli W1485, a variation in lipoic acid content was observed 
with growth on different substrates, with glycerol resulting in only 13 ng lipoic acid/ mg dry 
wt., whereas pyruvate led to levels as high as 41 ng/ mg dry wt. (Herbert & Guest, 1975).
The levels of the PDHC and 20GDHC closely correlated with lipoic acid contents under all 
growth conditions.
In contrast to the procyclic form, the bloodstream form of T.b.brucei has 7-fold less 
lipoic acid, probably due to the absence of an active citric acid cycle and the 2 -oxo acid 
dehydrogenase complexes. This is the first time lipoic acid has been found in a eukaryotic 
organism lacking the 2-oxo acid dehydrogenase complexes. The low level of lipoic acid is 
comparable to those in Gloecapsa alpicola, a cyanobacterium utilising a ferredoxin-linked 
pyruvate oxidoreductase, and Ankistrodesmus braunii, which contains low levels of the 
PDHC (table 5.3; Herbert & Guest, 1975).
Saccharomyces cerevisiae, when grown in the presence of high concentrations of 
glucose (2 %) ferments this substrate (see Herbert & Guest, 1975). This process does not 
employ the citric acid cycle, and therefore the level of lipoic acid is low, and is similar to that 
in the bloodstream form trypomastigote (table 5.3). When limiting amounts of glucose (0.1 
%) are supplied to S.cerevisiae, the citric acid cycle plays a prominent role in energy 
production, and a correspondingly high level of lipoic acid is observed (table 5.3). This
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illustrates the particular regulation of lipoic acid biosynthesis according to the type of 
metabolism in operation in yeast. Such regulation may be similar to that occurring in 
Tbbrucei.
Halobacterium volcanii utilizes the pyruvate:ferredoxin oxidoreductase system and 
lacks the 2-oxo acid dehydrogenase complexes, and yet has DHlipDH activity (Danson et al., 
1984) and low amounts of lipoic acid (table 5.3; Noll & Barber, 1988). In this respect, it is 
similar to the bloodstream form of Tbbrucei.
Two species of Clostridia have a further 10-fold less lipoic acid than in bloodstream 
forms of Tbbrucei (table 5.3), with similar trace amounts having been found in sulphur- 
metabolising and methanogen archaebacteria (Noll & Barber, 1988). The Clostridia use only 
the pyruvate: ferredoxin oxidoreducatse system to metabolise pyruvate.
GC/MS has provided positive identification of lipoic acid, but it cannot be ruled out 
that the cofactor exists in a modified form in vivo, which is converted to the identified form 
upon hydrolysis.
Following on from the detection and quantitation of lipoic acid in bloodstream form 
Tbbrucei, numerous other experiments can be envisaged. These include the investigation of 
the nature of possible protein attachment and the cellular location of lipoic acid. Preliminary 
acetone-precipitation experiments have demonstrated that the lipoic acid is probably attached 
to protein in vivo in the bloodstream form cell. In procyclics, the cofactor is presumably 
bound to the E2 components of the 2-oxo acid dehydrogenase complexes. Bothe & 
Nolteemsting (1975) were able to release free lipoic acid from cell extracts by boiling, and 
Griffiths et al. (1977) were able to detect the free form in purple membranes from 
H.halobium. Also, gel filtration and partial purification of extracts will show whether the 
lipoic acid is protein-bound. Purification of such a protein, followed by N-terminal 
sequencing would allow cloning of its gene, which may lead to an understanding of its 
function.
A recent technique to produce antibodies to lipoic acid by conjugating it to bovine 
serum albumin (Maclean & Bucher, 1991) may allow immunoprecipitation and 
immunocytochemical localisation of the cofactor. Also, the determination of the lipoic acid 
contents of fractions from a full subcellular fractionation (see Chapter 3) should reveal its 
cellular location.
In summary, lipoic acid is present in both bloodstream and procyclic forms of 
Tbbrucei. In each cell type, it is present in proportional amounts to the enzyme DHlipDH, 
for which it is presumed to be a substrate. In the procyclic cell, the majority of the lipoic acid 
is probably bound to the E2 components of, and functions as a cofactor within, the 2-oxo acid 
dehydrogenase complexes. In the bloodstream form cell, lipoic acid probably acts as an 
enzyme cofactor, but the metabolic process in which it is involved remains unknown.
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CHAPTER 6  PURIFICATION AND PROPERTIES OF DIHYDROLIPOAMIDE 
DEHYDROGENASE FROM BLOODSTREAM FORMS OF TBBRUCEI
6.1 Introduction
The purification of proteins is necessary before detailed structural studies can be 
carried out, and is often a prelude to the cloning of the relevant gene via N-terminal 
sequencing or the production of antibodies.
The first half of this chapter is concerned with the purification of DHlipDH from the 
bloodstream form of T.b.brucei. With the enzyme being in low abundance within the cell 
(0.03 U/mg; Danson et al., 1987), and the labour-intensive method of producing 
trypanosomes in rats, it was important to develop a procedure in which each individual step 
was maximised in terms of its yield.
The particular importance of purifying this enzyme is that, through N-terminal 
sequencing of the pure protein, and deduction of the corresponding DNA sequence, 
oligonucleotide probes can be constructed that will facilitate the identification and sequence 
determination of the DHlipDH gene from trypanosomal DNA. Once the gene for DHlipDH 
has been cloned, more detailed structural and functional studies can be carried out, as 
described in Chapter 8 .
A second use for purified DHlipDH may be for the production of antisera for use in 
immunocytochemical localisation studies. Although such work has not been performed in 
this thesis, the purification of the enzyme enables it to be carried out in the future.
Antibodies could also be used to identify the DHlipDH from a cDNA expression library.
The second half of this chapter is concerned with the investigation of several 
properties of the trypanosomal DHlipDH, with the aim of identifying any similarities to, and 
differences from, other known DHlipDHs. Studies of pH-dependence, temperature stability 
and kinetic parameters have been carried out.
6.2 Methods and Results
6.2.1 The development of a purification procedure for DHlipDH
Following initial disruption of cells by sonication (see section 2.2.3), sonic extracts 
were turbid, especially when high concentrations of cells were used. Some form of 
clarification was necessary before such extracts were amenable to column chromatography.
Centrifugation (8,500 x g for 10 min) brought about some clarification, but up to 30 
% of the enzyme was pelleted with cell debris. Therefore another method was sought that 
would clarify the extract without significant loss of activity.
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Extraction of lipid was attempted by adding chloroform/methanol (2:1) up to a 
concentration of 80 % (v/v). This produced significant clarification, but only 47 % of 
enzyme activity was recovered.
Ammonium sulphate fractionation, used effectively by Komuniecki & Saz (1979) and 
Dietrichs & Andreesen (1990), precipitated the majority of the T.bbrucei enzyme in a 50-75 
% ammonium sulphate cut, but the yield of DHlipDH, after resuspension in buffer, was only 
45%.
Phase partitioning with Triton X-114 (see section 3.2.3 for detailed method), 
separates hydrophilic proteins from hydrophobic proteins and lipid, which are probably major 
sources of turbidity. When applied to cell extracts, a clear aqueous phase was obtained, with 
up to 100 % recovery of DHlipDH (given probable under-estimation in cell-free extracts). 
This was accepted as a first step in the purification procedure.
Following clarification, a good method for obtaining significant purification with 
good yields is affinity chromatography, where the enzyme is selectively bound to a column 
on the basis of its affinity for a particular ligand, which is usually related to one of its 
substrates. In investigating affinity steps for DHlipDH, an ideal situation could be envisaged 
where the enzyme is separated from other proteins on the basis of its affinity for each of the 
physiological substrates NAD+ and dihydrolipoamide (DHlip).
With this in mind, a series of triazene dye columns was surveyed for DHlipDH 
binding. These dyes are related to Cibachron Blue, which is known to bind NAD+- 
dependent dehydrogenases (Thompson & Stellman, 1986). Blue B PGR-10 (from ICI) linked 
to Sepharose 4B was able to bind DHlipDH, and the enzyme could be specifically eluted with 
3 mM NAD+. This specific elution was very dependent upon pH, and only occurred over a 
narrow range of approximately 0.2 pH units. It therefore proved difficult to reproduce 
consistendy. Elution with a 0-1 M NaCl gradient gave a 10-fold purification, which was not 
considered adequate for a first affinity chromatography step.
Separation based upon the affinity of DHlipDH for its lipoyl substrate has been used 
by Schmincke-Ott & Bisswanger (1981) and Richarme (1989), with the latter author 
obtaining a 50-fold purification. Employing the method of Richarme (1989), lipoic acid was 
coupled to EAB Sepharose (Pharmacia) by carbodiimide coupling. T.b.brucei DHlipDH was 
adsorbed to the column at pH 7.8, and eluted with a 0-0.5 M NaCl gradient (elution was 
unsuccessful with any combination of substrates and products). A 7.5-fold purification of 
enzyme was obtained, with a 70 % yield. Once again this level of purification, together with 
the yield of enzyme, made this unacceptable as an initial affinity step.
One further method used by many workers to purify DHlipDH has been calcium 
phosphate-based column chromatography with calcium phosphate-cellulose (Schmincke-Ott 
& Bisswanger, 1981; Koike & Hayakawa, 1970; Komuniecki & Saz, 1979) or hydroxyl 
apatite (Dietrichs & Andreesen, 1990). Hydroxyl apatite chromatography of partially
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purified T.b.brucei DHlipDH gave a broad elution peak with a 50 mM to 0.5 M potassium 
phosphate (pH 7.0) gradient. The enzyme was purified 1.5-fold, with a 49 % recovery.
With both affinity steps and hydroxyl apatite giving poor results, a heat treatment 
similar to those of Komuniecki & Saz (1979) and Oppermann et al. (1991) was attempted. 
This had not been initially favoured because of the possibility that DHlipDH may be 
structurally altered by incubation at high temperatures.
An investigation into the heat stability of DHlipDH from T.b.brucei is detailed later in 
section 6.2.3. When heating at 75*C for 10 min (followed by centrifugation at 8,500 x g for 
10 min) after initial Triton X-l 14 phase partitioning, a 36.5-fold average purification was 
obtained for the heat treatment alone. With yield being a major consideration, the observed 
1 0 0  % yield meant that this step was extremely useful.
To give further separation, a Mono P chromatofocussing step, using Fast Protein 
Liquid Chromatography apparatus (FPLC; Pharmacia-LKB Biotechnology, Milton Keynes, 
U.K.), was added after heat treatment. This enabled separation of proteins on the basis of 
their isoelectric points. A final gel filtration step was added for further purification and 
removal of the polybuffer, which was used to form the pH gradient in the Mono P column. 
Superdex 200 gel filtration on the FPLC was chosen both for rapidity and resolution.
6.2.2 Final purification procedure for DHlipDH
Frozen cell pellets of bloodstream form T.b.brucei were thawed and resuspended in 
25 mM bis-Tris-HCl, pH 7.1. Suspensions were sonicated at 40 W for 3 x 30 s with a 3 mm 
probe, and the cell-free extracts subjected to Triton X-l 14 phase partition as described 
elsewhere (section 3.2.3), with the exception that the Tris buffer used previously was 
replaced by bis-Tris in this procedure.
The aqueous phase from Triton X-l 14 phase partitioning was heated at 75*C for 10 
min, and aggregated material was removed by centrifugation (8,500 x g for 10 min). The 
sample was filtered (0.22 |im pore Durapore filter) and applied to a Mono P 
chromatofocussing column (linked to an FPLC apparatus) pre-equilibrated with 25 mM bis- 
Tris-HCl, pH 7.1. The extract was applied at a flow rate of 0.4 ml/min, and was followed by 
3 ml of the bis-Tris buffer. Polybuffer 74, pH 5 (adjusted with HC1) was then introduced into 
the column, and this generated a pH gradient from pH 7.1 to pH 5 over a total volume of 26 
ml. Peak fractions containing DHlipDH were pooled and passed through a prep grade Hi 
Load 16/60 Superdex 200 gel filtration column (attached to the FPLC) at a flow rate of 1 
ml/min. The column had been pre-equilibrated with 20 mM Tris-HCl, pH 8.0,1 mM EDTA 
or 5 mM sodium phosphate, pH 8.0, the latter being used at a low concentration in 
preparation for N-terminal sequencing.
A calibration curve for gel filtration was constructed from two separate experiments. 
The first contained Blue Dextran & 2,4-DNP-L-lysine, to determine the excluded and
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included volumes of the column, respectively. The second run included the enzymes catalase, 
lactate dehydrogenase, citrate synthase and malate dehydrogenase as molecular weight 
markers. Certain of the enzymes appeared to bind to Blue Dextran, yielding anomalous 
results, and therefore the enzymes were run separately from the volume markers.
The presence of catalase, lactate dehydrogenase, citrate synthase and malate 
dehydrogenase were confirmed by their relevant assays (section 2 .2 .6 ).
The purity of the DHlipDH was assessed following gel filtration by SDS-PAGE using 
an 8-25 % gradient gel with a Pharmacia PhastSystem (section 2.2.7).
The results of a typical purification procedure are displayed in Table 6.1.
Due to the high turbidity of the sonic extract, protein content and DHlipDH activity 
were probably underestimated. Therefore, the activity in the aqueous phase of the Triton X- 
114 extract was taken to be 100 % for the purpose of yield.
A typical elution profile for the Mono P column is displayed in Fig. 6.1. The protein 
content of the eluent from the column could not be measured accurately due to the presence 
of polybuffer, which absorbs at 280 nm. DHlipDH eluted from the Mono P column at pH
6.3. Because enzymes arc eluted from the column when the pH of the buffer reaches their 
isoelectric points, pH 6.3 is the isoelectric point of the T.b.brucei DHlipDH.
An example of an elution profile from the Superdex 200 column is shown in Fig. 6.2. 
In this experiment, DHlipDH eluted in a total volume of approximately 12 ml, at a peak of
67.5 ±1.0 ml. The column was calibrated with protein and chemical markers in order to 
calculate the native molecular weight for DHlipDH. Kd values for each protein were 
calculated using the following equation:
Kd = (Ve -V 0 ) /(V r e -V 0)
where Kd is the distribution coefficient, Ve is the elution volume of the protein, Vq is the 
excluded volume, as determined by the elution volume for Blue Dextran (44.3 ml), and Vre is 
the included volume, as determined by the elution volume for DNP-lys (131.5 ml). Fig. 6.3 
is a plot of log Mj. vs Kd for the four enzymes. A standard curve has been fitted to these 
points by linear regression. From this graph, the experimental Kd value for DHlipDH 
corresponded to a native molecular weight of approximately 107 ± 25 kDa (the error from the 
DHlipDH experiments having been combined with that from the standard curve).
Assessment of protein purity by SDS-PAGE gave a single band after silver staining. 
Using molecular weight markers, a graph of log Mj. vs distance migrated was plotted (Fig. 
6.4), and from this, the sub-unit molecular weight of DHlipDH was calculated to be 53 ± 1.7 
kDa. This result, together with that of the gel filtration, indicates that the enzyme has 2 (± 
0.5) sub-units, and therefore appears to be a dimer of similar Mr sub-units of approx. 53 kDa.
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Table 6.1. Purification of dihydrolipoamide dehydrogenase (DHlipDH) from the 
bloodstream form of T.b.brucei
Fraction Protein Activity Spec.Act. Yield
(mg) (Units) (Units/mg) (%)
Sonic extract* 26.9 0.756 0.028 -
Phase partitioning 23.2 0.943 0.041 1 0 0
Heat-treatment 0.58 0.807 1.39 85.6
Chromatofocussing - 0.731 - 77.5
Gel filtration - 0.326 - 34.6
♦Both protein content and DHlipDH activity were probably underestimated in the sonic 
extract due to its extreme turbidity.
The full purification procedure is described in section 6.2.2. Phase partitioning was carried 
out with Triton X-l 14, with DHlipDH partitioning solely into the aqueous phase. A Mono P 
column (attached to an FPLC apparatus) was used for chromatofocussing. The polybuffer 
used to create a pH gradient absorbs at 280 nm, and therefore an accurate determination of 
protein content was not possible at this stage. Gel filtration was carried out with a HiLoad 
16/60 Superdex 200 column (attached to an FPLC apparatus). The protein content of the 





















Fig. 6.1. Typical elution profile for protein and DHlipDH of bloodstream form 
T.b.brucei from a Mono P chromatofocussing column (attached to FPLC apparatus). 
Triton-partitioned and heat-treated cell-free extract of the bloodstream form of Tb.brucei 
was applied to the column in 25 mM bis-Tris-HCl, pH 7.1 at a flow rate of 0.4 ml/min. 
Polybuffer 74, pH 5, was introduced to the column, generating a pH gradient from pH 7.1 
to pH 5 over a total volume of 26 ml. The protein content of the eluent (—) could not be 
accurately assessed because of the presence of polybuffer, which absorbs at 280 nm. The 
peak of DHlipDH activity (■) was at pH 6.3.
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Fig. 6.2. Typical elution profile for protein and DHlipDH of bloodstream form 
TJb.brucei from a Superdex 200 gel filtration column (attached to FPLC apparatus). 
Cell-free extracts were subjected to Triton X-l 14 phase partitioning, heat treatment and 
Mono P chromatofocussing prior to gel filtration. The column was pre-equilibrated with 
20 mM Tris-HCl, pH 8.0,1 mM EDTA, and the sample was loaded in polybuffer at a 
flow rate of 1 ml/min. Protein (—) content of the eluent was assessed by measuring A2 gQ- 
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Fig. 6.3. Calibration curve for gel filtration on a Superdex 200 column (attached to ah 
FPLC apparatus). The distribution coefficients, Kd, for each enzyme have been 
calculated from elution volumes according to section 6 .2 .2 , and a standard curve has been 
fitted to the data points by linear regression. The data point for the T.b.brucei 
bloodstream form DHlipDH is the average of 6  separate experiments, and yields a native 
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Fig. 6.4. Calibration curve for SDS-PAGE on an 8-25 % gradient gel using the 
Pharmacia PhastSystem. A standard curve has been fitted to the data points by linear 
regression, and this graph yields a sub-unit molecular weight of 53 (± 1.3) kDa for the 
TJb.brucei bloodstream form DHlipDH.
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A total of 5.1 units of enzyme were produced for N-terminal sequencing. The eluent 
from the Superdex column (in sodium phosphate buffer) was concentrated to a volume of 1 
ml, which was freeze-dried, and sent for N-terminal sequencing. Unfortunately no sequence 
information was obtained.
6.2.3 Heat stability
Bloodstream forms of T.b.brucei were sonicated at 40 W for 3 x 30 s in 50 mM 
potassium phosphate, 1 mM EDTA, pH 8.0. Samples of 200 |il of sonic extracts were heated 
for 10 min time periods at temperatures up to 100#C, using a Perkin-Elmer thermal cycler. 
Following heating, samples were centrifuged (8,500 x g for 10 min), and the supernatants 
were assayed for protein content and DHlipDH activity.
The results of the heat inactivation experiment are displayed in table 6.2. The 
DHlipDH is stable up to 70°C, with a small decrease in activity when the temperature is 
raised to 80°C, followed by a sharp decline to no activity at 90°C.
6.2.4 pH Profile
The activity of trypanosomal DHlipDH over a range of pH values from pH 6.5 to pH
8.5 was measured using 50 mM potassium phosphate for pH values up to pH 8.0, and 50 mM 
tetra-sodium pyrophosphate for pH 8.5. The concentrations of substrates used were 1.8 mM 
DHlip and 3.3 mM NAD+.
The activity of trypanosomal DHlipDH over this pH range is displayed in Fig. 6.5. 
Activities were measured in duplicate, with maximal activity being observed at pH 8.0. The 
standard assay for DHlipDH is conducted at pH 7.0, at which the enzyme activity is only 66 
% of that at pH 8.0. The calculated pH optimum can only be considered an operational one 
as two different buffers have been used, which possess different ionic strengths.
6.2.5 Kinetic analysis
Kinetic analysis of DHlipDH was carried out at 37°C, which is the ambient 
temperature of the trypanosome in the host bloodstream. The buffer used was 50 mM 
potassium phosphate, 2 mM EDTA, pH 8.0. A grid was constructed of 8 different 
concentrations of DHlip and 9 concentrations of NAD+. Initial reaction rates were 
determined at each combination of substrate concentration, and kinetic plots were used to 
determine the kinetic parameters. All assays were performed in duplicate.
The kinetic data for DHlipDH in cell-free extracts are displayed as half-reciprocal 
plots, with the concentration of NAD+ being varied at 8 different concentrations of DHlip 
(Fig. 6.6a & b). The data are displayed on two graphs for ease of presentation, and show that 
the enzyme follows Michaelis-Menten kinetics. All kinetic parameters have been determined 
by the direct linear plot of Eisenthal & Comish-Bowden (1974). When data were plotted for
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Table 6.2. Heat-treatment of dihydrolipoamide dehydrogenase (DHlipDH) in cell-free- 
free extracts of bloodstream form T.b.brucei.
Temp. DHlipDH Activitv Protein Spec. Act.of DHlipDH
•c U/ml pg/ml U/mg
4 0.181 1760 0.103
50 0.196 1110 0.176
60 0.202 340 0.593
70 0.198 150 1.32
80 0.166 145 1.14
90 0 145 0
100 0 160 0
Protein content and DHlipDH activity have been measured following centrifugation of 
heated extracts at 8,500 x g for 10 min. Further details of the method and results are 
















Fig. 6.5. pH Profile for DHlipDH from the bloodstream form of T.b.brucei. Each assay 
was conducted at 30°C in 50 mM potassium phosphate (for pH 6.5 to pH 8.0), or 50 mM 
tetra-sodium pyrophosphate (for pH 8.5), containing 1.8 mM dihydrolipoamide and 3.3 





















Fig. 6.6. Half-reciprocal (Hanes-Woolf) plots for the activity of DHlipDH from the 
bloodstream form of T.bbrucei, in the presence of varying concentrations of NAD+, at 8 
different concentrations of dihydrolipoamide. DHlipDH was assayed at 37’C in 50 mM 
potassium phosphate, pH 7.0,2 mM EDTA, with the reaction being monitored by the 
increase in A^mq. The data are displayed on two graphs (a and b) for ease of 
presentation. ‘The concentrations of dihydrolipoamide are : (a) 0.09 mM (■), 0.18 mM 
<$, 0.36 mM (*), and 0.72 mM ft; (b) 0.14 mM <$, 0.27 mM (c*, 0.54 mM ^  and 1.0 
mM &). Data are from duplicate experiments.
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varying [NAD+] or [DHlip], both graphs gave patterns of lines intersecting on the vertical 
axis, which is indicative of a ping-pong mechanism where Ks^ is zero and VaPP/KmaPP is 
independent of the concentration of fixed substrate (Wharton & Eisenthal, 1981).
The rate equation for this mechanism is : va = V . -r
(A) (B)
The slopes at each concentration of DHlip are equal to l/VaPP, and the intercept on 
the vertical axis is equal to Km®/V. A secondary plot of [DHlip]/VaPP against [DHlip] is 
linear (Fig. 6.7) with a gradient of 6.33 min, which is equal to 1/V. The intercept on the 
abscissa of -0.39 mM is equal to -Km^. The calculated kinetic constants from the direct 
linear plot are Km^ (DHlip) = 0.39 ± 0.03 mM; Km® (NAD+) = 0.63 ± 0.01 mM; V =
0.16 ± 0.09 fimol.min'^.
6.3 Discussion
The purification of DHlipDH from bloodstream forms of T.b.brucei has been 
achieved with the high yield of enzyme (34.6 %) that was needed to provide enough protein 
for N-terminal sequencing. Similarly high yields have been obtained by other groups 
working with DHlipDH, including Schmincke-Ott and Bisswanger (1981), who recovered
35.3 % of enzyme activity from E.colU and Lohrer and Krauth-Siegel (1990) who recovered 
26 % from T.cruzL Presumably, this high level of recovery of enzyme from several species is 
an indication of the stability of DHlipDH throughout various purification procedures.
The procedure which has been developed in this work is extremely rapid, being 
capable of completion in 8-10 hours. The major reason for this short timescale is the 
implementation of the FPLC apparatus, through the use of which both the Mono P and 
Superdex 200 separation steps can be completed in less than 3 h. The Superdex gel filtration 
step is also very useful because it enables the final protein to be produced in whichever buffer 
may be required for subsequent experiments.
The failure of the N-terminal sequencing of DHlipDH has a number of possible 
explanations. Insufficient amounts of protein or too high a concentration of buffer salts could 
give unclear results. Alternatively, the N-terminus of the protein could be blocked. Up to 50 
% of all proteins may be N-terminally blocked by formyl, acetyl or other acyl groupings or 
conversion to a pyroglutamyl residue (Aitken et al., 1989). Chemical unblocking can 
occasionally be successful, but it is more usual to form large peptide fragments by cleaving 
with cyanogen bromide, for example, and then separating these fragments for sequencing 
(Aitken et al., 1989). Electroblotting onto Polyvinylidene difluoride membranes enables 
accurate and effecient sequencing, and can be used in future for the trypanosomal DHlipDH 
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Fig. 6.7. Secondary plot to determine the kinetic parameters of DHlipDH from the 
bloodstream form of T.b.brucei. Vapp for each concentration of dihydrolipoamide has 
been calculated from a direct linear plot of therelevant data in Fig. 6 .6 . KmA 
(dihydrolipoamide) = 0.39 (± 0.03) mM; KmB (NAD+) = 0.63 (± 0.01) mM; V = 0.16 
(±0.09) mM.
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To enable the comparison of the properties of T.b.brucei DHlipDH with those of a 
number of different species, table 6.3 displays several important properties of these enzymes 
taken from other published data.
The sub-unit and native molecular weights of the T.b.brucei enzyme are almost 
identical to those of the other DHlipDHs. The only known exception to this 50 kDa 
homodimer structure is the abnormally small DHlipDH of E.acidaminophilum (35.5 kDa per 
S.U.), which behaves more like thioredoxin reductase, with a subsidiary low DHlipDH 
activity (Freudenberg & Andreesen, 1989; Dietrichs eta l., 1990).
An isoelectric point of 6.3 for T.b.brucei DHlipDH is similar to those of other 
cytosolic enzymes of T.b.brucei and other unicellular organisms, and lower than the 8.8-10.2 
range of the glycosomal glycolytic enzymes (Opperdoes, 1987).
A pH optimum of 8.0 for the T.b.brucei DHlipDH is identical to that obtained for the 
E.coli K12 enzyme by Schmincke-Ott & Bisswanger (1981), and similar to values from other 
species. The pH optimum is 0.5 to 1.0 units lower than those of the DHlipDHs from the 
purinolytic anaerobic bacteria (Dietrichs & Andreesen, 1990).
The stability of DHlipDH at high temperatures has been used very effectively by 
Komuniecki & Saz (1979) to purify the Ascaris muscle enzyme. They recovered 100 % of 
enzyme activity after heating at 70°C for 15 min. Similarly, Oppermann et al. (1991) 
retained 91 % of activity after heating at 75#C for 10 min. Therefore, the very high heat 
stability of the T.b.brucei enzyme is in keeping with its stability in other species.
Kinetic analysis of the trypanosomal DHlipDH has yielded kinetic constants for 
DHlip and NAD+ which are similar to those of E.coli K12, S.cerevisiae, pig heart and rat 
liver (see table 6.3), with these being in the millimolar range, and the Km for NAD+ being 
higher than that for DHlip (the only exception to this being the pig heart enzyme). Initial 
kinetic data, with half-reciprocal plots intersecting at the y-axis, are consistent with a ping- 
pong mechanism for the action of the enzyme. A bi-bi ping-pong mechanism was initially 
proposed for DHlipDH by Massey et al. (1960), and has been confirmed for the pig heart 
enzyme by Koike & Koike (1976). Therefore, in this respect, the T.b.brucei DHlipDH is 
similar to those from other species.
In summary, all of the data concerning the size, pH profile, heat stability and kinetics 
of bloodstream form T.b.brucei DHlipDH indicate that it is a normal DHlipDH, despite the 
fact that it may be performing a novel role in metabolic processes in the bloodstream 
trypomastigote.
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Table 6.3. Comparison of some properties of dihydrolipoamide dehydrogenase from 
different organisms




E.coli K12a 56 8 .0 0.28 1.83
S.cerevisiae 51.5 n.d. 0.4 0.7
Pig Heart^e 50 7.9 0.3 0 .2
Rat liver^ 56 8 .0 0.49 0.52
T.cruzi% 55 n.d. n.d. n.d.
T.b.brucei 53 8 .0 0.39 0.63
aSchmincke-Ott & Bisswanger (1981); ^Browning et al. (1988); °Wren & Massey (1966); 
^Williams (1976); eOtulakowski & Robinson (1987); %eed (1973); &Lohrer & Krauth- 
Siegel (1990).
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CHAPTER 7 : INACTIVATION STUDIES USING ARSENICAL REAGENTS
7.1 Introduction
Compounds containing arsenic have been used in Oriental medicine for two to three 
thousand years, and more recendy to treat almost every kind of disease (Webb, 1966).
Arsenite has long been known to have some effect on trypanosomiasis, but for many 
years its high toxicity precluded its use. It was the work of Thomas and Breinl in 1905 which 
renewed interest in the arsenical treatment of trypanosomiasis. They discovered that atoxyl 
(sodium arsanilate) was an effective treatment for murine trypanosomiasis. Ehrlich went on 
to show that pentavalent arsenicals such as atoxyl, must be broken down to their trivalent 
forms in order to be active, and he postulated the presence of arsenoreceptors to explain the 
actions of these compounds. This began the search for the mode of action of arsenicals (see 
Webb, 1966).
Voegtlin et al. (1923) demonstrated that the effect of oxophenarsine on trypanosomal 
motility could be antagonized by various thiols. Trivalent arsenical derivatives were shown 
to form stable complexes with enzymes, coenzymes or other compounds containing two or 
more proximal thiol groups (Johnstone, 1963), and this led to the theory that arsenicals might 
interact with cellular thiols and thereby interrupt oxidative processes. Cellular thiols were 
soon to be considered the major site of arsenical attack (Webb, 1966).
Further metabolic studies by Krebs (see Johnstone, 1963) showed that arsenite 
specifically blocks the oxidation of 2-oxo acids. Peters then demonstrated the extreme 
sensitivity of pyruvate oxidase to arsenicals and suggested this to be due to the presence of 
the dithiol, lipoic acid (Peters et al., 1946).
Two components of the pyruvate dehydrogenase complex possess vicinal thiols: the 
transacetylase component, E2 , through its attached lipoic acid residue, and dihydrolipoamide 
dehydrogenase (DHlipDH), E3, which has an active site dithiol (see section 1.4.1). Both the 
dithiol of DHlipDH (Massey & Veeger, 1960) and the lipoyl dithiol (Stevenson et al., 1978) 
can be modified by arsenicals. Stevenson et al. (1978) showed that in the presence of 
pyruvate and Coenzyme A, a multifunctional arsenoxide formed a stable 6 -membered cyclic 
dithiolarsinite with the substrate-generated dihydrolipoyl domain of E2. The modified lipoyl 
residue can also pass the arsenical to the active site dithiol of E3 (Adamson & Stevenson, 
1981).
For many years, the main arsenical treatment for trypanosomiasis was tryparsamide 
(Thomson, 1989), but resistance to this drug, especially in populations of T.b.gambiense, 
prompted the introduction of melarsen, melaminyl (2,4,6-triamino-S- 
triazinyl)phenylarsonate, which was first developed by Friedheim (1939). Melarsen itself 
was more toxic than tryparsamide, but its conjugate with dimercaprol, melarsoprol, proved to 
have a much lower toxicity, and was of particular value for the treatment of late-stage
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sleeping sickness (Newton, 1963). The active component of melarsoprol, melarsen oxide 
(Mel O), is extremely toxic to the mammalian bloodstream form of Tbbrucei, causing rapid 
loss of motility and subsequent cell lysis. For many years, pyruvate kinase was considered a 
major site of arsenical action in trypanosomes, with the evidence for this largely based upon 
the accumulation of its substrate, phosphoenolpyruvate, in extracts treated with arsenical, 
along with simple kinetic studies which demonstrated enzyme inactivation (Flynn & 
Bowman, 1974). Closer investigation by Van Schaftingen et al. (1987) revealed that the 
inhibition of pyruvate kinase by melarsen oxide was rather poor (Ki > 100 pM), and that 
fructose 2 ,6 -bisphosphate (Fru(2 ,6 )P2 ), a potent stimulator of pyruvate kinase, was depleted 
in arsenical-treated cells. Investigation of 6-phosphofructo-2-kinase (PFK2), the enzyme 
responsible for production of Fru(2 ,6 )P2 , showed that it was potently inhibited by Mel O (Ki 
< 1 pM). Fructose-2,6 -bisphosphatase (Ki = 2 pM) was also much more potently inhibited 
than pyruvate kinase (Van Schaftingen et al., 1987). Although these workers have used the 
word inhibition, the effect of Mel O on these enzymes may, more accurately, be termed 
inactivation.
This work established the point at which Mel O interrupted glycolytic flux, namely at 
PFK2, but there were several arguments against this being the mechanism for the 
trypanocidal action of Mel O. Firstly, the trypanocidal action of Mel O was almost fully 
expressed after 5 min, after which time the level of Fru(2 ,6 )P2  had not changed significantly. 
Furthermore, susceptibility to Mel O was not changed when cells were grown on glycerol, a 
substrate which yielded no Fru(2 ,6 )P2 . Lastly, trypanosomes can adapt to a 70 % decrease in 
ATP without any loss of viability when salicylhydroxamic acid is used to inhibit respiration. 
Therefore, to kill cells by depletion of ATP, melarsen oxide would have to inhibit glycolytic 
flux by more than 70 %. What is seen in vivo is that changes in glycolytic flux parallel cell 
lysis, indicating that pyruvate production is normal in those cells that remain intact (Van 
Schaftingen et al., 1987). All of these results demonstrate that inhibition of glycolysis does 
not appear to be the cause, but rather the consequence, of cell lysis.
In the light of these results, the discovery of the glutathione analogue, trypanothione 
(see section 1.2.2.5), in trypanosomes by Fairlamb etal. (1989) brought cellular thiols back 
to the centre stage of investigations into the mode of action of arsenicals. Mel O forms a 
stable adduct, termed Mel T, with the dithiol form of trypanothione [dihydrotrypanothione, 
Try(SH)2 ]. This adduct accumulates to levels approaching 17 pM (approximately 10 % of 
the intracellular Try(SH)2 ) before cell lysis commences. It has been suggested that Mel T 
exerts a cytotoxic effect on the cell, which results either from sequestration of intracellular 
trypanothione or from the inhibition of trypanothione reductase (Ki = 9 pM). Studies using a 
combination of the ornithine decarboxylase inhibitor a-difluoromethylomithine (DFMO) and 
Mel O have demonstrated a pronounced synergism between the trypanocidal activities of the 
two drugs (Jennings, 1988). DFMO selectively blocks the biosynthesis of spermidine, a
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precursor of trypanothione, in trypanosomes, and therefore a synergism between its action 
and that of Mel O, which sequesters trypanothione, lends further weight to the proposal that 
trypanothione is the primary target for arsenical drugs against African trypanosomes.
The absence of the 2-oxo acid dehydrogenase complexes from the bloodstream form 
of T.b.brucei precludes these most studied targets of arsenical inactivation from investigation 
in this organism, but the recent discovery of DHlipDH (Danson et al.t 1987) and lipoic acid 
(Jackman et al., 1990) re-introduces these species as possible targets for arsenical action.
One aim of the work detailed in this chapter is to investigate DHlipDH as a target for 
trivalent arsenicals in the bloodstream form of T.bbrucei by looking at the inactivation of the 
enzyme with a range of arsenicals including melarsen oxide. The correlation of results on 
DHlipDH inactivation in cell-free extracts and whole cells with those for the immobilisation 
of cells will give some indication of the relevance of DHlipDH as a target for arsenicals in 
these organisms.
Another aim of these studies is to assess the feasibility of using trivalent arsenicals as 
tools for the elucidation of the function of DHlipDH in vivo. In this respect, 
phenylarsenoxide has been used extensively to probe the role of vicinal dithiols in 
mammalian glucose transport (Douen & Jones, 1986) and signal transmission from the 
insulin receptor (Bernier et aL> 1987). Were DHlipDH to be involved in a membrane 
transport or signal transduction mechanism, similar inactivation studies with arsenicals may 
reveal the link between the enzyme and such processes.
Inactivation studies have been used successfully by Richarme (1988) to demonstrate a 
relationship between lipoic acid, DHlipDH and the binding-protein-dependent transport of 
maltose and galactose in Escherichia coli. He used arsenite (Richarme, 1988) and 5- 
methoxyindole-2 -carboxylic acid (a known inhibitor of 2 -oxo acid dehydrogenases; 
Richarme, 1985) as inhibitory probes to prove the link between the enzyme and transport 
mechanisms. Because of the effectiveness of Richarme's studies, 5-methoxyindole-2- 
carboxylic acid has also been investigated as an inhibitor of DHlipDH in bloodstream form 
TJ).brucei as a prelude to functional studies.
7.2 Methods
All of the experiments described in this chapter were performed on the bloodstream 
form of Tb.brucei.
7.2.1 Preparation of stock solutions of arsenicals
Phenylarsenoxide (PAO) and Melarsen oxide (Mel O) were dissolved in 
dimethylformamide (DMF) to concentrations of up to 100 mM. p-Aminophenyldichloro- 
arsine (APDCA) and p-acetylaminophenyldichloroarsine (AAPDCA) were dissolved to
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similar concentrations in 95 % (v/v) ethanol. The structures of these arsenicals are displayed 
in Fig. 7.1.
The concentration of arsenical in each stock solution was determined by titration with 
dihydrolipoamide (DHlip). The arsenical and DHlip form a stable adduct in solution. 
Therefore, if arsenical is mixed with an excess of DHlip, the free DHlip can be titrated 
against DTNB as described in section 2.2.4. From the known concentration of DHlip in the 
stock solution, the concentration of arsenical in the mixture can be calculated.
7.2.2 Inactivation of DHlipDH in cell-free extracts
Cell-free extracts for inactivation studies with arsenicals were prepared by sonication 
of cells suspended in 50 mM KPO4 , pH 7.0,2 mM EDTA. Sonication was carried out at 40 
W for 3 x 30 s using a 3 mm probe. 500 pi diluted sonicate (1.5 mg protein/ ml) was 
incubated with 0.1 % (w/v) Triton X-100,0.5 mM NADH and the appropriate concentration 
of arsenical at 30*C in a microfuge tube. The reaction was started by addition of arsenical, 
and 10 or 20 ill samples were taken at time points and assayed for DHlipDH activity (see 
section 2 .2 .6  for assay details).
7.2.3 Inactivation of DHlipDH in whole, respiring cells
Live cells were pre-incubated at a concentration of 1 x 10^ cells per ml in Krebs 
Ringer buffer containing glucose and sucrose (KRBG; see section 2.2.1) at 30’C for 5 min. 
This pre-incubation period was used to equilibrate the trypanosomal cells to the assay 
temperature of 30*C. The reaction was started by addition of arsenical, and 15 s before each 
time point, the reaction tube was centrifuged at 8,500 x g for 30 s in a bench microfuge. The 
buffer containing arsenical was removed with a Pasteur pipette, and 500 pi ice-cold KRBG 
added. The cell pellet was resuspended and sonicated for 30 s at 40 W using a 3 mm probe.
A sample of 100 pi was removed for assay of DHlipDH. DHlipDH activity was calculated




7 .2 .4  Immobilisation of whole respiring cells
Live cells were pre-equilibrated for 5 min at 30#C in KRBG at a concentration of 1 x 
10? cells per ml. The appropriate volume of arsenical was added to start the reaction, and the 
suspension was mixed by vortexing. A sample of the reaction mixture was transferred to a 
haemocytometer, and the number of motile cells in a 4 x 4 grid was counted at each time 
point using a microscope. At this concentration of cells, approximately 40 were present in 
one grid, the counting of which took about 30 s. Counting was therefore begun 15 s before 
the time recorded. All cells that showed any sign of motility were counted as motile for the 
purpose of these experiments. From the total number of cells in the grid, the percentage of 
total cells that were motile was calculated.
Fig. 7.1. Trivalent arsenical reagents used to inactivate DHlipDH
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7.2.5 Inhibition of DHlipDH in cell-free extracts bv 5-methoxyindole-2-carboxvlic acid
The assay of DHlipDH in the presence of 5-methoxyindole-2-carboxylic acid (MICA) 
was carried out under standard assay conditions, except that, due to the high absorbance of 
MICA at 340 nm, NAD was replaced by its analogue 3-acetyl-NAD. The reaction was 
monitored at 366 nm instead of 340 nm.
7.3 Results
7.3.1 Inactivation of DHlipDH in cell-free extracts
In order to calculate the rate constants for inactivation of DHlipDH in cell-free 
extracts, the first-order rate equation was employed:
In C/Cq = -kt
where Cq is the DHlipDH activity at time 0, C is the activity at time t, and k is the pseudo- 
first-order rate constant for inactivation. C/Cq is the percentage of initial activity at time t, so 
if log C/Cq is plotted against t, the slope of the line is equal to -k/2.303, for each 
concentration of arsenical (or NADH). Assuming that the inactivation proceeds according to 
pseudo-first-order kinetics, k = kf(R), where k* is the true second-order rate constant and (R) 
is the concentration of arsenical. Therefore, k' is equal to the slope of a secondary plot of k 
vs (R).
DHlipDH was inactivated in cell-free extracts of T.b.brucei by all the arsenicals tested 
under the reaction conditions described. Control experiments with DMF and 95 % (v/v) 
ethanol indicated that these did not interfere with enzyme assays. Arsenical inactivation was 
dependent upon the presence of NADH in the reaction mixture, as demonstrated in Fig. 7.2. 
The inactivation rate constant in the presence of 1 mM APDCA alone was only 0.11 min"^, 
but when 0.5 mM NADH was added, the inactivation rate constant increased to 1.5 min'*.
0.5 mM NADH alone inactivated the enzyme with a rate constant of 0.074 min-*.
When measuring the activity of DHlipDH in the presence of arsenical, a short lag 
phase of 2  min was observed in the assay prior to the constant increase in absorbance due to 
production of NADH. This lag period was not seen when no arsenical was present. It may 
reflect a partial re-activation of the enzyme by the substrate, dihydrolipoamide, removing the 
arsenical.
Another difference between the assay reaction profiles of DHlipDH in the presence 
and absence of arsenicals, was a gradual increase in the rate of reaction after approximately 5 
min when arsenicals were added to extracts. The most probable explanation for this is that 
the trivalent arsenical forms a more stable adduct with DHlip than with DHlipDH. Therefore 
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Fig. 7.2. Inactivation of DHlipDH in cell-free extracts of T.b.brucei by 0.5 mM NADH 
(■), 1 mM p-aminophenyldichloroarsine (APDCA;n), and 0.5 mM NADH and 1 mM 
APDCA (A). Each experiment, carried out at 30'C, was started by adding 
NADH/APDCA to cell-free extract (1.5 mg protein/ml in 50 mM potassium phosphate, 
pH 7.0,2 mM EDTA) and samples were taken at time points and assayed for DHlipDH 
activity.
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Having commented on the two major sources of inaccuracy within measurements of 
DHlipDH activity, it is clear that the inactivation rate constants for the arsenicals are only an 
approximation to the true inactivation rate constants in the presence of each arsenical.
For the purpose of brevity, the full details of the inactivation results in this and both of 
the subsequent sections are only shown for PAO. Unless otherwise stated, the three other 
arsenicals behaved in exactly the same fashion as PAO, but obviously possessed different 
inactivation parameters.
Fig. 7.3 shows the effect of varying concentrations of PAO on the activity of 
DHlipDH in cell-free extracts. In each case, the rate of inactivation was approximately 
constant over the first 7.5 min of the reaction, so lines were fitted by linear regression to the 
data points up to this time. When the pseudo-first-order rate constants (k) were plotted 
against the concentration of PAO (Fig. 7.4), a linear relationship between the two parameters 
was obtained, indicating that inactivation was proportional to the amount of arsenical added. 
The slope of the line through these points is equal to the second-order rate constant (k1) for 
the inactivation of DHlipDH. For PAO, this rate constant is 0.027 }j.M"^min" .^
The rate constants for each of the other arsenicals were calculated in the same way, 
and all four are displayed in Table 7.1.
The arsenical possessing the highest rate constant, and therefore the most potent 
inactivator of DHlipDH in cell-free extracts, was PAO. Its rate constant of 0.027 |iM"^min'^ 
is 4-fold greater than that of APDCA, and 5-fold greater than that which was obtained for 
AAPDCA. Mel O was also approximately 5-fold less potent than PAO.
7.3.2 Inactivation of DHlipDH in whole cells
All four trivalent arsenicals were able to inactivate DHlipDH in vivo in whole 
respiring cells of T.b.brucei. Control experiments with DMF and 95 % (v/v) ethanol 
indicated that these solvents did not affect cell motility and viability. When log % initial 
activity of DHlipDH in whole cells was plotted against time, the rate of inactivation was not 
constant over the first 7.5 min. Therefore, in order to calculate the inactivation constants, % 
initial activity was plotted against time (Fig 7.5), and the time taken for 50 % inactivation of 
enzyme activity ^ q )  was determined for each concentration of arsenical.
Although not as accurate as an initial inactivation rate, the t^Q value does give some 
indication of how rapidly inactivation is occurring. Therefore, employing the first-order rate 
equation, In C/CQ = -kt; when t = t5 Q, C/C0  = 0.5. Therefore In C/C0  = -0.693 and 0.693 = 
kt5 Q. The second-order rate constant can be calculated from a secondary plot of IA5 0  vs 
arsenical concentration using the equation 0.693/t5Q = k'(R). The value for PAO, calculated 
from Fig 7.6, is 3.6 x 10"  ^pM’l.min'*.
When the inactivation of DHlipDH by Mel O was attempted over the same 




Fig. 7.3. Inactivation of DHlipDH in cell-free extracts of T.b.brucei by phenylarsenoxide 
(PAO). Cell-free extracts (1.5 mg protein/ml in 50 mM potassium phosphate, pH 7.0,2 
mM EDTA) were incubated at 30*C in the presence of 0.5 mM NADH alone (■), and 0.5 
mM NADH together with 5 mM PAO (a), 10 mM PAO (A) and 20 mM PAO (>0. 
Samples were taken at time points and assayed for DHlipDH activity. To determine the 

















Fig. 7.4. Secondary plot for the inactivation of DHlipDH in cell-free extracts of 
T.b.brucei by phenylarsenoxide (PAO). Initial reaction rates have been determined from 
Fig. 7.3. A regression line has been fitted to the data points, yielding a second order rate 
constant of 0.027 |iM-lmin-l for inactivation by PAO.
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Table 7.1. Second-order rate constants for the inactivation of DHlipDH in cell-free extracts 
of bloodstream forms of T.b.brucei by a range of arsenical reagents
ARSENICAL Rate Constant ( M'^.min'^)
PAO 27 x10”3
APDCA 6 .8  x 1 0 '3
AAPDCA 5.0 x 10"3
MelO 5.0 x 10"3
Inactivation experiments were carried out according to section 7.2.2. For each arsenical, the 
initial rate of inactivation was measured over a range of concentrations, and the second- 
order rate constant was determined from a secondary plot of inactivation rate vs. 
concentration of arsenical (see Figs. 7.3 & 7.4 for PAO). Abbreviations: PAO, 
phenylarsenoxide; APDCA, p-aminophenyldichloroarsine; AAPDCA, p-acetylaminophenyl- 
dichloroarsine; Mel O, melarsen oxide.
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Fig. 7.5. Inactivation of DHlipDH in whole cells of T.b.brucei by phenylarsenoxide 
(PAO). Live cells (10° cells/ml in Krebs Ringer buffer containing glucose and sucrose) 
were incubated at 30*C in the presence of PAO at the following concentrations: 100 /aM 
(■), 200 /aM (a), 250 /aM (a) and 500/aM 0 $. The reaction was started by addition of 
arsenical, and 15 s before each time point, the reaction tube was centrifuged at 8,500 x g 
for 30 s in a bench microfuge. The buffer containing arsenical was removed, and the cell 
pellet was resuspended in 500 / a I  ice-cold buffer and sonicated. A sample of 100 /A  was 
removed for assay of DHlipDH. From these data, the times taken for 50 % of DHlipDH 







Fig. 7.6. Secondary plot for the inactivation of DHlipDH in whole cells of TJb.brucei by 
phenylarsenoxide (PAO). For each concentration of PAO, the time taken for 50 %
for PAO.
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concentration. To investigate this phenomenon further, the graph was extended up to 2 mM 
Mel O (Fig 7.7), a concentration at which results could not be obtained with PAO because of 
the very high rate of inactivation with this arsenical. The data in Fig. 7.7 demonstrate that the 
rate of inactivation of DHlipDH continued to increase with increasing arsenical 
concentration, even up to 2 mM Mel O. If it is assumed that the gradual increase in the rate 
of inactivation between 0.5 and 2 mM Mel O is due to a linear component similar to that 
displayed in Fig. 7.6, then by fitting a regression line to the points between 0.5 and 2 mM 
Mel O, redrawing this line to start from the origin, and subtracting the values from Fig. 7.7, 
two components are resolved in Fig. 7.8. The linear component gives a second-order 
inactivation constant of 6.7 x 10"  ^p.M‘^min‘ ,^ which is 5-fold lower than that for AAPDCA 
(table 7.2). With this component, the concentration of arsenical to which the enzyme is 
exposed appears to be proportional to the external concentration of arsenical. So it can be 
assumed that the Mel O may be diffusing into the cell, but at a much lower rate than the other 
arsenicals. The second component approximates to a rectangular hyperbola, and can be 
analysed according to the equation: IA5 Q = n.M.(Mel 0)/[Kd + (Mel O)], where l/t^Q gives 
an approximation to the rate of inactivation of DHlipDH, n is the number of binding sites for 
Mel O per molecule, M is the macromolecular concentration of the molecule to which Mel O 
binds, Kd is the distribution coefficient, and (Mel O) is the external concentration of Mel O. 
This has the form of a Michaelis-Menten equation. Therefore, from a half-reciprocal plot 
(Fig. 7.9), n.M = 0.18 mM and Kd = 0.21 mM. At low concentrations of Mel O, there is 
some non-linearity, but it is difficult to determine t^Q values at such low concentrations. The 
parameters n.M and Kd may describe a binding site for Mel O which is saturable. This could 
be some form of receptor or transporter for the arsenical, and it appears to be the major route 
of entry for Mel O into the trypanosomal cell. The overall equation describing Fig. 7.7 is the 
sum of the diffusion and Michaelis-Menten processes:
_L = _jL_.[M elO ]+ n.M.TMel Ol
t5 0  0.693 Kd + [Mel O]
To investigate further the presence of a receptor/transporter, a mixture of 2 mM 
melarsen oxide (a concentration at which melarsen oxide inactivation has started to become 
limited) and 0.5 mM PAO was applied to live cells in the normal way, and the inactivation of 
DHlipDH monitored over time (Fig. 7.10). Inactivation of DHlipDH was extremely rapid, 
yielding a pseudo-first-order rate constant, k, of 1.4 min'*. This is greater than would be 
expected if PAO and Mel O were competing for entry into the cell. Indeed, it is even greater 
than the combined rate constants of the two arsenicals (k[PAO] = 0.57, k[Mel O] = 0.17). 
Detailed discussion of this will be left to the section 7.4, but it does mean that the inactivation 
kinetics for Mel O cannot be compared to those of the other arsenicals.
The second-order rate constants for PAO, APDCA and AAPDCA, and the rate 
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Fig. 7.7. Secondary plot for the inactivation of DHlipDH in whole cells of T.b.brucei by 
melarsen oxide (Mel O). Times for 50 % inactivation at each concentration of Mel O 







Fig. 7.8. Secondary plot for the inactivation of DHlipDH in whole cells of T.b.brucei by 
melarsen oxide (Mel O) resolved into two components. A regression line has been fitted 
to the points between 0.5 and 2.0 mM Mel O in Fig. 7.7, yielding a second order rate 
constant of 4.6 x 10"5 mM'^min' 1 for the linear component. This component of the 
inactivation profile has been subtracted from the data in Fig. 7.7, to yield a second 
component which is saturable, and approximates to a rectangular hyperbola.
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Table 7.2. Second-order rate constants for the inactivation of DHlipDH in whole cells of the 
bloodstream form of T.b.brucei by a range of arsenical reagents.
ARSENICAL Rate Constant ( M'^.min'^)
PAO 3.6 xlO "3
APDCA 2 .0  x 1 0 '3
AAPDCA 3.3 x 10"4
MelO 6.7 x 10-5
n.M = 0.18 mM, Kd = 0.21 mM
Live cells of the bloodstream form of T.b.brucei were incubated in the presence of a range 
of arsenical concentrations as described in section 7.2.3. Primary plots (to give t5 Q values), 
followed by secondary plots, allowed determination of the second order rate constants. 
Examples of these for PAO are displayed in Figs. 7.5 and 7.6. The secondary plot for Mel O 
was not linear, and has therefore been resolved into two components, one of which is linear, 
and comparable to those of the other arsenicals, and the other approximates to a rectangular 
hyperbola, the binding kinetics of which are displayed in the table (see section 7.3.2). 
Abbreviations: PAO, phenylarsenoxide; APDCA, p-aminophenyldichloroarsine; AAPDCA, 
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Fig. 7.9. A half-reciprocal (Hanes-Woolf) plot for the determination of the kinetic 
parameters of the saturable component (see Fig. 7.8) of inactivation of DHlipDH in 
whole cells of T.b.brucei by melarsen oxide (Mel O). The pseudo-first order rate 
constant, k, has been calculated from Fig. 7.8 using the equation k = 0.693/t50. 
Regression analysis of this data yields parameters : n.M = 0.18 and Kd = 0.21 mM, from 
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Fig. 7.10. Inactivation of DHlipDH in whole cells of T.b.brucei by melarsen oxide (Mel
O) and phenylarsenoxide (PAO). live  cells (10° cells/ml in Krebs Ringer buffer 
containing glucose and sucrose) were incubated at 3 0 ° C  in the presence of 2 mM Mel O 
<pl), 0.5 mM PAO (■), and 2 mM Mel O and 0.5 mM PAO (A). The reaction was started 
by addition of arsenical, and 15 s before each time point, the reaction tube was 
centrifuged at 8,500 x g for 30 s in a bench microfuge. The buffer containing arsenical 
was removed, and the cell pellet was resuspended in 5 0 0  ml ice-cold buffer and 
sonicated. A sample of 100 ml was removed for assay of DHlipDH.
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PAO (3.6 x 10"^ fiM"lmin"l) is twice that of APDCA, and 10-fold greater than that of 
AAPDCA.
7.3.3 Immobilisation of whole cells
All of the arsenicals under investigation were able to immobilise whole cells of 
TJbbrucei in the micromolar concentration range. As with the inactivation of DHlipDH in 
whole cells, graphs of % initial motility vs time were plotted with different arsenical 
concentrations (see Fig 7.11 for PAO) and t5Q values for each concentration were 
determined. Fig 7.12 shows that IA5 0  was proportional to the concentration of PAO used, 
yielding a second-order rate constant of 0.52 |iM‘*.min'l (slope/0.693). A further 
experiment was carried out with PAO, giving another estimate of the rate constant, and the 
average value of 0.66 fiM ^m in'l is shown in table 7.3. The secondary plots for the other 
three arsenicals were also linear, and all the rate constants are also displayed in Table 7.3.
Mel O was the most potent arsenical for immobilising cells, being approximately 
twice as potent as PAO (rate constants of 1.18 and 0.66 pM'^min"^ for Mel O & PAO, 
respectively). APDCA and AAPDCA were 20- and 40-fold less potent than Mel O, 
respectively.
7.3.4 Inhibition of DHlipDH in cell-free extracts bv 5-methoxvindole-2-carboxvlic acid
DHlipDH was inhibited in cell-free extracts of T.b.brucei by MICA. Inhibition was 
competitive as demonstrated by the parallel lines of the Comish-Bowden plot (Fig. 7.13b; 
Wharton & Eisenthal, 1981) and the Dixon plot (Fig. 7.13a) yielded a Ki of 5.9 mM for 
MICA.
7.4 Discussion
The inactivation of DHlipDH by trivalent arsenicals is thought to occur by 
modification of the active site dithiol (see Fig.7.1; Hill, 1966). The results shown in Fig. 7.2 
demonstrate that NADH is required for enzyme inactivation in cell-free extracts of 
T.b.brucei. This is consistent with DHlipDH operating by a catalytic mechanism of alternate 
oxidation and reduction of an interchain disulphide bond, with reduction by 
dihydrolipoamide or NADH rendering the enzyme susceptible to arsenical inactivation 
(Adamson & Stevenson, 1981). The low rate of inactivation in the absence of NADH shows 
that the vast majority of the enzyme in cell-free extracts is in the oxidised state.
The relative rate constants for inactivation with each arsenical (Table 7.1) are 
probably a function of their chemical structure. PAO, the smallest and most hydrophobic 
arsenical, was the most potent inactivator of DHlipDH. APDCA was 4-fold less potent, 












Fig. 7.11. Immobilisation of live sells of TJb.brucei by phenylarsenoxide (PAO). Live 
cells, at a concentration of 1 x 10® cells/ml, were pre-incubated at 30*C for 5 min. 
Following the addition of PAO, the number of motile cells present in a 4  x 4  grid was 
counted at different time points using a haemocytometer. The concentrations of PAO 
applied to the cells were: 0.3 mM (■), 0.4 mM (d), 0.5 mM (A), 0.7 mM (>$, and 1.0 mM 










Fig. 7.12. Secondary plot for the immobilisation of cells of T.b.brucei by 
phenylarsenoxide (PAO). The t5Q values have been calculated from Fig. 7.11, and a 
straight line fitted to these data points by regression analysis, yielding a second order rate 
constant of 0.521 mM^min' 1 for PAO.
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Table 7.3. Second-order rate constants for the immobilisation of cells of the bloodstream 
form of T.b.brucei by a range of arsenicals
ARSENICAL Second-order rate Constant
( M"*.min'l)




Live cells of the bloodstream form of T.b.brucei were incubated with arsenicals, and the 
motility of the cells monitored using a haemocytometer, as described in section 7.2.4. 
Primary plots were derived from t^g values for immobilisation. Examples of primary and 
secondary plots for PAO are displayed in Figs. 7.11 and 7.12. The second-order rate 
constants have been calculated from the slopes of the secondary plots. Abbreviations:
PAO, phenylarsenoxide; APDCA, p-aminophenyldichloroarsine; AAPDCA, p-acetylamino- 














Fig. 7.13. Inhibition of DHlipDH in cell-free extracts of T.b.brucei by 5-methoxyindole- 
2-carboxylic acid (MICA). The assay of DHlipDH in the presence of MICA was carried 
out at 30°C in 50 mM potassium phosphate, pH 7.0, 2 mM EDTA, 0.4 mM DHlip in the 
presence of 0.25 mM (■), 0.5 mM (a), and 1.0 mM (A) acetyl-NAD+. The absorbance 
change due to the production of acetyl-NADH was monitored at 366 nm. The data have 
been plotted on (a) a Dixon plot, yielding a Ki of 5.9 mM for MICA, and (b) a Comish- 
Bowden plot
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addition of an acetyl group, despite reducing the polarity, reduced the inactivation rate 
constant to 5-fold lower than that for PAO, presumably because it increased the bulk of the 
molecule. Mel O had an equally low potency, even though it is a very much larger molecule 
than AAPDCA.
DHlipDH was inactivated in whole cells by all four arsenicals. It has already been 
shown that the enzyme must be in the reduced state for inactivation to occur. This state was 
produced in cell-free extracts by supplying NADH, but in whole cells DHlipDH is thought 
only to enter the reduced state during a catalytic cycle in vivo. This may indicate that the 
enzyme is turning over in whole cells. It is also possible, however, that the reducing 
environment of the cell may maintain the DHlipDH in its reduced state.
A comparison of the second-order rate constants for inactivation/immobilisation in 
the three different systems with each arsenical (Table 7.4) enables certain conclusions to be 
made about the nature of the inactivation process in vivo.
Excluding the data for Mel O, the lowest second-order rate constants were obtained 
for the inactivation of DHlipDH in live cells. The rate constants for inactivation in live cells 
were 2- to 10-fold lower than the rate constants for inactivation of DHlipDH in cell-free 
extracts, which were a further 10- to 40-fold lower than those for the immobilisation of cells. 
Mel O was different from the other arsenicals because, as has already been mentioned, the 
inactivation of DHlipDH in live cells proceeded, in part, according to Michaelis-Menten 
kinetics, and therefore it cannot be compared with the constants for cell-free extracts and 
motility. Mel O was 240-fold more potent at immobilising cells than inactivating DHlipDH 
in cell-free extracts. This is a 10-fold higher potency ratio than with the other arsenicals.
A combination of possible factors may contribute to the lower rate constants for 
inactivation of DHlipDH in whole cells as compared to cell-free extracts. Firstly, the enzyme 
may be turning over in whole cells, whereas it exists in a constantly reduced, and therefore 
more susceptible, condition in cell-free extracts. A second factor in whole cells is the 
presence of the plasma membrane, which acts as a permeability barrier. This may not be a 
major factor with PAO and APDCA., which are thought to diffuse freely into cells, and for 
which binding reactions within cells are more important than membrane penetration in 
determining their uptake kinetics (Hill, 1966). AAPDCA has a 10-fold reduced potency in 
whole cells, which may be caused, at least in part, by penetration effects.
Mel O possessed completely different kinetics, when compared to the other 
arsenicals, for inactivation of DHlipDH in whole cells. The inactivation process could be 
resolved into two components: a linear component, presumably similar to those for the other 
arsenicals, and a component described by a rectangular hyperbola, which may indicate a 
receptor/transporter mechanism of entry into the cell. The presence of the bulky melaminyl 
residue would dramatically reduce its permeability through membranes, but other workers 
have also shown that it is concentrated by the cell against a concentration gradient (Albert,
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Table 7.4. Comparison of second-order rate constants for the inactivation of DHlipDH in 
cell-free extracts and live cells and the immobilisation of bloodstream form cells of 
T.b.brucei
ARSENICAL RATIO OF INACTIVATION CONSTANTS 
Live Cells Cell-free extracts Motility
PAO 1 7.5 180
APDCA 1 3.4 31
AAPDCA 1 16 120
MelO - (1) (240)
Treating PAO, APDCA & AAPDCA separately, each constant has been divided by that for 
inactivation of DHlipDH in live cells. For Mel O, the values are displayed in brackets 
because they are divided by the inactivation constant for DHlipDH in cell-free extracts. 
Abbreviations: PAO, phenylarsenoxide; APDCA, p-aminophenyldichloroarsine; AAPDCA, 
p-acetylaminophenyldichloroarsine; Mel O, melarsen oxide.
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1973; Flynn & Bowman, 1974) and that uptake is via a carrier-mediated mechanism (Ojeda 
& Flynn, 1982). Furthermore, Ojeda & Flynn (1982) showed that the melaminyl residue of 
melarsen oxide was required for this uptake process. This presence of a carrier may explain 
the very different behaviour of Mel O in inactivating DHlipDH in live cells. The Kd of 
0.21 mM and n.M of 0.18 mM, determined from kinetic plots, may therefore describe a 
transporter for Mel O.
The immobilisation of cells was achieved at lower arsenical concentrations than the 
inactivation of DHlipDH in vivo. PAO, APDCA & AAPDCA were 12- to 32-fold more 
potent at immobilising as compared to inactivating DHlipDH in vivot and the order of 
potency was PAO > APDCA > AAPDCA. This is the same order of potency as for 
inactivation of DHlipDH in cell-free extracts. Presumably this is because the chemical 
structural differences mentioned earlier for inhibition of DHlipDH also apply for the 
interactions of the arsenicals with the cellular targets involved in immobilisation.
It is interesting that the concentrations of arsenicals used to inactivate DHlipDH are 
considerably higher than those which immobilise cells. This indicates that the DHlipDH may 
still be turning over, or may be reduced, when the cells have lost their motility.
When Mel O is administered therapeutically, concentrations between 0.6 and 6 pM 
can be achieved in the blood of host animals (Hill, 1966). This would be sufficient to 
immobilise trypanosomes, but would not inactivate DHlipDH over the timescales used in 
these experiments.
One major limitation of the experimental data for live cells presented in this chapter is 
that the timescales of exposure to arsenicals are very short, ranging up to 20 min. The 
concentration of arsenical needed to kill trypanosomes over a short period of time is known 
to be much greater than that required for longer term killing (Hill, 1966). For example, the 
results in this chapter show that 1 |iM PAO immobilised trypanosomes in 5-10 min, whereas 
18 nM PAO is able to kill trypanosomes in 6 h (King & Strangeways, 1942). Trypanosomes 
in the bloodstream of their host organism will be exposed to arsenicals for long periods of 
time, and therefore lower doses of arsenical will be effective. Over longer timescales, and at 
lower concentrations, the arsenicals may have different potencies at different sites, and the 
inactivation of DHlipDH, because it could be a cumulative process, may become more 
relevant. However, this is only speculation, and the likelihood is that the results obtained 
give a fair indication of the relative potencies of the arsenicals for the different cellular 
targets.
According to Hill (1966), the trypanocidal activity of arsenicals occurs in three
phases:
1) fixation of arsenical - rapid & reversible
2) secondary chemical reactions
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3) death process within cells - cells begin to swell, become distorted, and eventually
lyse.
Various indicators of cell viability have been used by workers testing trypanocidal 
drugs. Motility is not the most direct method, as cells remain intact after immobilisation, and 
indeed can still be resuscitated by cysteine or dimercaprol after immobilisation with PAO 
(Eagle et al., 1946). Nevertheless, Ercoli et al. (1980) found that determinations of 
immobilisation and parasite number led to similar comparative results using a range of 
trivalent antimonials against T.venezuelense. More direct measurements of cell lysis were 
carried out by Yarlett et al. (1991), recording lysis spectrophotometrically by reduction in 
A5 0 O’ Vs11 Schaftingen et al. (1987), who used release of pyruvate kinase as a measure of 
lysis, and Betbeder etal. (1990), who measured reduction in cell number microscopically. A 
common viability assay for cultured animal cells involves the uptake of fluorescein diacetate 
and the exclusion of propidium iodide by live cells (see Mishell & Shiigi, 1980). With this 
technique live cells fluoresce green, and non-viable cells are stained red. This assay was 
attempted, but the trypanosomes appeared to lyse under assay conditions, and all fluoresced 
red.
As has already been mentioned, it is important with arsenical studies to assess the 
long-term effects of low concentrations upon cells. The motility determinations employed in 
this chapter could not be extended over longer time periods because of the depletion of 
glucose from the medium, which is known to affect arsenical reactions (Hill, 1966). Instead, 
other groups have assessed the longer-term effects by measuring the infectivity of treated 
trypanosomes (Loiseau et al., 1988; Betbeder et al., 1990), and the production of pyruvate by 
cells in continuous culture, followed with a pH indicator (Zinsstag et al., 1991).
In conclusion, both the short- and long-term effects of the arsenicals on DHlipDH 
activity and cell viability should be assessed to give a complete picture of the relationship 
between these two phenomena. However, such studies were not practicable within the 
timescale of this project, and short-term work is sufficient to give an indication of the relative 
arsenical potencies.
As mentioned in the introduction to this chapter, several other trypanosomal enzymes 
are inhibited by melarsen oxide, including phosphofructo-2-kinase, for which Mel O has a Ki 
of < 1 pM (Van Schaftingen et al., 1987), and fructose -2,6-bisphosphatase (Ki = 2 pM).
These enzyme studies were superseded by the work of Fairlamb et al. (1989) on 
trypanothione, who showed that this thiol forms a stable adduct with melarsen oxide (termed 
Mel T), which is the only acid-soluble form of Mel O in T.b.brucei (Fairlamb & Henderson,
1987). The conjugate has a Ka of 1.21 x 10^ M"*, and its concentration reaches 17 pM 
(equivalent to approximately 10 % of cellular trypanothione) when cell lysis occurs. It is a 
potent inhibitor of trypanothione reductase (Ki = 9 pM), so at its maximum level of 17 pM 
within the cell, Mel T is significantly inhibiting trypanothione reductase.
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It is not possible directly to compare the second-order rate constants for inactivation 
of DHlipDH by arsenicals, with the Ki values for the inhibition of the other enzymes or the 
Ka for the affinity of Mel O with trypanothione, but the interaction with trypanothione 
appears to be much more relevant to cell lysis. Nevertheless, any role for DHlipDH in the 
toxicity of arsenicals to trypanosomes should not be ruled out too quickly, as it represents a 
significant difference between the enzymology of the parasite and its host. It is also worth 
bearing in mind that because the DHlipDH is not inactivated at concentrations of arsenicals 
sufficient to immobilise the cells, the enzyme could still be essential to the cell. In this case, 
a specific inhibitor of DHlipDH could be developed which would cause cell lysis.
Because cell lysis follows immobilisation even with the high concentrations of 
arsenicals used to inhibit DHlipDH in vivo, it may be possible to carry out functional studies 
on transport processes and signal transduction pathways in T.b.brucei using trivalent 
arsenicals as inhibitory probes.
The other possible inhibitor of DHlipDH which could be used for functional studies is 
MICA. Its Ki of 5.9 mM for T.b.brucei DHlipDH compares favourably with those for the rat 
liver (Ki = 3 mM) (Reed & Lardy, 1970) and E.coli (Ki = 6 mM) (Richarme, 1985) enzymes. 
The mechanism of MICA inhibition is very different from that of arsenicals, in that it 
probably forms an inhibitory complex with the FAD cofactor of DHlipDH (Reed & Lardy, 
1970). MICA may therefore prove useful in functional studies, but trypanothione reductase 
is also a flavoprotein, and may be inhibited by this compound.
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CHAPTER 8 GENERAL DISCUSSION AND CONCLUSIONS
Dihydrolipoamide dehydrogenase (DHlipDH) was discovered in the bloodstream 
form of T.b.brucei in the absence of the 2-oxo acid dehydrogenase complexes by Danson et 
al. (1987). In that report, it was shown to co-purify with plasma membranes and to be 
inactivated by a trivalent arsenical in a substrate-dependent process. This was a particularly 
interesting discovery in that it was the first time that DHlipDH had been found in a 
eukaryotic cell in the absence of the 2-oxo acid dehydrogenase complexes, and the first time 
that this enzyme had been located to the plasma membrane of a eukaryote. The aim of this 
project has been to proceed from these initial discoveries into gaining a greater understanding 
of DHlipDH in T.b.brucei.
8.1 Summary of Chapters 3 to 7
From the work of chapter 3, it is clear that the bloodstream form of T.b.brucei 
possesses a DHlipDH solely located over the inner surface of its plasma membrane, and that 
this enzyme is not attached to the membrane by any form of lipid or hydrophobic anchor.
The situation is very different in the procyclic form of the parasite (chapter 4), where 
the enzyme is definitely in the mitochondrion, but it was not possible to demonstrate whether 
any remained at the plasma membrane. The procyclic mitochondrion contains active 2-oxo 
acid dehydrogenase complexes, the presence of which accounts for at least the majority of 
the DHlipDH in these cells. The level of DHlipDH is 13-fold higher in the procyclic cell 
than in the bloodstream form trypomastigote.
Lipoic acid, the presumed substrate of DHlipDH, is present in both forms of the 
parasite (chapter 5), with the procyclic cell possessing 10-fold more of this cofactor than the 
bloodstream form cell. The increase in lipoic acid parallels that of DHlipDH, the ratio of 
enzyme to cofactor remaining approximately constant through these two stages of the 
lifecycle (0.018 & 0.024 U DHlipDH /  ng lipoic acid in bloodstream form and procyclic 
cells, respectively). In the procyclic cell, it is thought that the majority of the lipoic acid and 
DHlipDH are components of the mitochondrial 2-oxo acid dehydrogenase complexes. Their 
respective levels are therefore optimised for the complexed situation. In the bloodstream 
form, a comparable ratio of enzyme to cofactor might suggest that a structurally similar 
complex to the 2-oxo acid dehydrogenase complexes contains the DHlipDH and lipoic acid 
in these cells, because, if the cofactor were free, much higher quantities of it would be 
required for efficient catalysis by the same amount of enzyme.
Production of lipoyl-bearing proteins and DHlipDH is probably co-ordinately 
regulated in both prokaryotic and eukaryotic systems, but the situation has only been clearly 
worked out in E.coli. Here, the Ipd gene, which encodes E3, is regulated both by the PDHC 
{ace E and ace F genes) operon and a secondary promoter of the Ipd gene (Patel & Roche,
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1990). It is therefore likely that DHlipDH and lipoic acid are produced in a coordinated 
fashion in the mitochondrion of the procylic cell. No such suppositions can be made 
concerning the bloodstream form cell.
Focussing in further upon the bloodstream form DHlipDH, it appears, in terms of its 
size, stability and kinetics, to be very similar to the DHlipDHs associated with the 2-oxo acid 
dehydrogenase complexes of other species. The bloodstream form DHlipDH has also been 
purified to homogeneity in preparation for N-terminal sequencing and further analysis 
(chapter 6).
Experiments in chapter 7 demonstrated that the DHlipDH could be inactivated in vivo 
by a series of arsenical reagents. This might indicate that the enzyme is catalytically turning 
over in the living cell, but it may be possible for the DHlipDH to be maintained in the 
reduced state by a reducing environment within the cell. This result, together with the 
demonstration of the presence of lipoic acid in proportional amounts to DHlipDH, and the 
fact that this DHlipDH appears to be similar to those of other species, strongly suggests that 
the enzyme is not a metabolic aberration, sent to the plasma membrane by faulty processing 
or targetting. Instead, it may have a membrane function, possibly involving another 
protein/enzyme complex containing lipoic acid.
Further studies with the arsenical reagents demonstrated that DHlipDH is probably 
not a major target for arsenical drugs such as melarsen oxide, and is inactivated only after 
cells have been immobilised by these compounds. These studies do not, however, rule out 
the involvement of DHlipDH in arsenical toxicity, as the enzyme is located at the plasma 
membrane of the cell, whereas trypanothione reductase, thought to be the major arsenical 
target, is cytoplasmic (Smith et al., 1991). DHlipDH may therefore be one of the first vicinal 
dithiol-containing molecules to be seen by arsenicals entering the cell. In addition, lipoic 
acid is able to form stable adducts with trivalent arsenicals. The reduction potential of lipoic 
acid (EQ = - 0.288 v) is such that it could receive an arsenical like melarsen oxide from its 
dimercaprol conjugate near the cell surface, and then pass it on to trypanothione, which has a 
lower reduction potential (EQ = - 0.242 v; Fairlamb & Henderson, 1987).
Until the functions of DHlipDH and lipoic acid have been elucidated, it remains to be 
seen how they may relate to arsenical toxicity in vivo.
With the numerous other cellular targets for arsenical reagents, it is unlikely that these 
reagents will prove useful as inhibitory probes for the function of DHlipDH, as it will be 
difficult to differentiate the DHlipDH-related effects from those involving other molecules.
8.2 Previous reports of DHlipDH activity in trypanosomes
The de-repression of mitochondrial enzymes during transformation from the 
bloodstream form of TJbbrucei has been investigated by Vickerman (1965) using the 
NADH-diaphorase test Diaphorase is a secondary activity of DHlipDH (Massey, 1960), in
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which the enzyme uses NADH as substrate and nitro-blue tetrazolium as electron acceptor. 
Activity is indicated by blue-black deposits of formazan dye. Small amounts of activity were 
observed in microbodies in long-slender bloodstream forms, but these were put down to the 
activity of another enzyme (Vickerman, 1965). Significant deposits were seen in the 
mitochondria of short-stumpy forms, which coincided with the ability to survive on 2- 
oxoglutarate.
The reverse reaction of DHlipDH (NADH-dependent lipoate reductase) has been 
measured in T.b.rhodesiense by Ryley (1962). He observed activity in bloodstream forms 
and procyclics, with slightly higher levels in the latter. These results cannot, however, be 
considered definitive because a pleomoiphic population of bloodstream form cells was used, 
a significant proportion of which would be short-stumpy cells with active mitochondria. This 
is in contrast to the purely monomorphic long-slender bloodstream forms of T.b.brucei 
EATRO 427 used in this project (see section 2.1.2). In addition, trypanosomal cells were 
probably not adequately separated from blood cell material by the technique of blood cell 
lysis; column chromatography, as employed in this thesis, does give complete separation.
8.3 Possible functions of the plasma membrane DHlipDH
8.3.1 Multicrayro complex functions
In considering the possible function(s) of DHlipDH and lipoic acid in vivo, the first 
possibility is that they are part of a dehydrogenase multienzyme complex. The most 
prominent of these (apart from the 2-oxo acid dehydrogenase complexes) is the glycine 
cleavage system (GCS), which has been discussed in section 1.4.2.4. The GCS is particularly 
important in the metabolism of glycine-utilising and purinolytic anaerobes (Dietrichs & 
Andreesen, 1990). The latter produce glycine (which is further catabolised by the GCS) and 
formate from purines. As TJbbrucei produces significant quantities of glycine from 
threonine catabolism, and has an active purine salvage pathway, it would be possible for the 
GCS to be involved in the metabolism of these cells. There are also examples of plasma 
membrane DHlipDHs involved in the GCS in the purinolytic Clostridium cylindrosporum 
(Dietrichs et al.y 1991), and the glycine-utilising Eubacterium acidaminophilum 
(Ffeudenberg et al., 1989), but these are prokaryotic cells, and the GCS has never been found 
outside the mitochondrion in eukaryotes.
Other DHlipDH-containing complexes include the lactate-degrading system of 
Butyribacterium rettgeri (Wittenberger & Haaf, 1964) and the acetoin dehydrogenase system 
of Pelobacter carbinolicus (Oppermann et al., 1991). Both of these are rather specialised, 
but they do demonstrate that DHlipDH is not confined to the four most common complexes, 
but could be part of a complex catalysing a completely different dehydrogenase reaction.
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8.3.2 Thiol: protein disulphide interchange
DHlipDH and lipoic acid form part of an active system of flavoenzymes that 
maintains redox balance and catalyses reductive processes in many cell types (see Freedman, 
1979). Lipoic acid is able to reduce the major intracellular thiol, glutathione (Bast & Haenan, 
1988), and thereby contributes to the maintenance of redox balance and to reduction of 
oxidative stress (see Meister & Anderson, 1983). DHlipDH may also affect oxidative stress, 
as it has a significant oxidase activity capable of producing reactive superoxide radicals 
(Bando & Aik, 1991; Grinblat etal., 1991). In the trypanosome, glutathione is replaced by 
trypanothione, and the cell is much more vulnerable to reactive oxygen species. In this 
environment, lipoic acid and DHlipDH may have considerable influence upon redox levels.
Lipoic acid and DHlipDH can also catalyse the NADH-dependent reduction of 
thioredoxin (Holmgren, 1979; Spector et al., 1988). This enzyme and its homologue, 
glutaredoxin, are capable of reducing a wide variety of cellular substrates, including insulin, 
glutathione, oxidised lens protein and ribonucleotides (Holmgren, 1988). Thioredoxin is also 
an important regulator of enzyme activity. It reduces photosynthetic fructose-1,6- 
bisphosphatase, and protein disulphide isomerase (Holmgren, 1979; Lundstrom & Holmgren, 
1990), which catalyses thiol; protein disulphide interchange associated with the biosynthesis 
of secretory proteins such as insulin (Freedman et al.t 1988; Tang et al., 1988). With 
thioredoxin being membrane-bound in both mammals (Lundstrom & Holmgren, 1990) and 
Ejcoli (Bayer et al., 1987), it can be speculated that a plasma membrane DHlipDH may 
interact with this protein in trypanosomes, with significant effect upon cellular reductive 
processes.
The reaction mechanism for each of the interactions described above is thiol: protein 
disulphide exchange. This mechanism has also been implicated in several other cellular 
processes, including receptor signal transduction and transport phenomena (Robillaid & 
Konings, 1982; Malbon et al., 1987). Furthermore, it has been suggested that DHlipDH and 
lipoic acid may be connected with several of these phenomena. This is of particular 
relevance to the trypanosomal situation, where a plasma membrane-associated function for 
the enzyme and cofactor is being sought
The insulin receptor represents the most studied example of sulphydryl involvement 
in receptors and transmission. When insulin binds to its receptor, the two undergo disulphide 
exchange, which activates the post-receptor transmission pathway (Clark & Harrison, 1983). 
A further site of sulphydryl involvement has been detected downstream of a tyrosine 
phosphorylation step by inactivation studies with phenylarsenoxide (Bernier et al., 1987). 
These studies demonstrated that a vicinal dithiol is required for internalisation of the insulin- 
receptor complex, which is essential for subsequent translocation of glucose transporters to 
the plasma membrane (Frost & Lane, 1985; Douen & Jones, 1986).
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The precise molecular details of the transduction pathway have not been elucidated, 
but a number of steps must require protein disulphide interchange (Maturo et al., 1983). 
Although no role is suggested for DHlipDH, this system illustrates how such an enzyme 
catalysing thiol: disulphide exchange might have a role in transmission/transduction.
Robillard and Konings (1982) have proposed that in solute transport, the affinities of 
substrate binding sites are regulated by interchange between a dithiol and a disulphide 
located at different depths in the membrane. This is evidenced by the ability of 
phenylarsenoxide and other sulphydryl reagents to inhibit the phosphoenolpyruvate- 
dependent transport of hexoses in E.coli (Robillard & Konings, 1982) and glucose transport 
in 3T3-L1 adipocytes (Douen & Jones, 1986). A similar situation is seen with the 
mitochondrial proton-pumping NAD+ transhydrogenase, which also operates by thiol: 
disulphide interchange (Persson & Rydstrom, 1987).
8.3.3 Solute transport
Besides the possible role of DHlipDH in thiol: protein disulphide interchange-related 
transport processes (section 8.3.2), the enzyme itself has been implicated in several solute 
transport mechanisms:
a) Ubiquinone-mediated transport of proline in E.coli is NADH-dependent, and it is 
thought that reduction of endogenous membrane-bound quinones by DHlipDH stimulates 
solute uptake in vivo (Owen et al., 1980).
b) Binding-protein-dependent transport of maltose, ribose and galactose in E.coli is 
energised by dihydrolipoamide and NAD+ (Richarme, 1988). Furthermore, lipoic acid has 
been shown to stimulate aggregation of maltose-binding proteins, resulting in inhibition of 
binding (Richarme, 1986). Studies with strains deficient in the 2-oxo acid dehydrogenase 
complexes (Richarme, 1987) and with inhibitors of these complexes (Richarme, 1985; 
Richarme & Heine, 1986) have demonstrated a clear link between complex activity and 
transport However, according to recent work, the DHlipDH involved in transport may be 
distinct from the Ipd gene product (the DHlipDH of the complexes), and may be associated 
with the mgl gene product which forms part of the binding-protein-dependent transport 
system (Richarme, 1989).
8.3.4 Electron transport
The link between the mitochondrial ATP synthase and the respiratory chain may 
involve, amongst other components, lipoic acid (Partis et al., 1977). This is present in 
stoichiometric amounts in ATP synthase preparations (Griffiths, 1976), and is required for 
the oxidative phosphorylation of NADH, succinate or D-lactate by the mitochondria of 
several cells. Indeed, in isolated mitochondria, dihydrolipoic acid stimulates ATP synthase 
by up to 45 %, and decreases ATPase activity by 36 % (Zimmer et al., 1991). In parallel to
I l l
the increase in ATP synthesis, oligomycin-sensitive mitochondrial -SH groups are activated 
at 2-4 nmol lipoic acid/  mg protein. An analogous role for the cofactor has been postulated in 
the purple membranes of Halobacterium halobium, where photoreduction of lipoate might 
form the link between bacteriorhodopsin and the ATP synthase (Griffiths et al., 1977).
In summary, DHlipDH and lipoic acid have been implicated in several redox and 
transport processes in different cell types, and with thiol: disulphide interchange proving a 
common feature of transduction pathways, there remain a wide variety of possible roles for 
the enzyme and its cofactor in the bloodstream form of Tbbrucei.
8.4 A general plasma membrane location for DHlipDH ?
In addition to the anaerobes C.cylindrosporum and E.acidaminophilum and 
bloodstream form Tbbrucei, the DHlipDH of Thermoplasma acidophilum appears to be 
associated with the plasma membrane of the cell (Danson, 1988). Rat adipocytes, which 
possess functional mitochondria, may also have a proportion of their DHlipDH in this extra- 
mitochondrial position (Danson, 1988). These findings beg the question as to whether a 
plasma membrane DHlipDH is a generalised phenomenon in most cell types, or whether it 
could be restricted to cells carrying out certain mechanistically similar processes, such as 
those involving particular thiol: disulphide interchange reactions.
One further implication of the discovery of a plasma membrane DHlipDH concerns 
the autoimmune disease, Primary Biliary Cirrhosis (PBC). In this disease, antibodies are 
produced which are directed mainly against components of the 2-oxo acid dehydrogenase 
complexes (Krams et al., 1989). In particular, antibodies are reactive against the lipoyl 
domains of the £2 and protein X components, but they have also been detected against the 
E l-a  polypeptide (Fregeau et al., 1990). Immunisation with purified recombinant 
transacetylase yielded anti-mitochondrial antibodies (AMAs), but did not precipitate the 
disease, indicating that other factors such as genetic susceptibility must be involved (Krams 
et al., 1989). Indeed, AMAs may only be produced as a result of tissue damage. One major 
drawback of the theory that antibodies cause the disease has always been that the 
autoantigens are intra-mitochondrial, and are therefore not exposed to antibody-producing 
cells. With these new discoveries of plasma membrane DHlipDHs, it is possible that they 
may be accompanied by lipoyl-bearing proteins and El-like enzymes, and these might 
become exposed on the cell surface under certain conditions, eliciting an antibody response. 
In this context, Fusey et al. (1990) have already suggested a bacterial aetiology for PBC, and 
Uzoegwu et al. (1987) have looked for proteins reactive with PBC sera in various 
endoparasites. Stercorarian trypanosomes and procyclic cells of T.b.brucei contained 
antigenic proteins, but bloodstream forms of Tbbrucei showed no significant reactivity. The 
possible antigenic aetiology of PBC remains uncertain, but further studies with bacteria and
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parasites may yet demonstrate that unusually located "mitochondrial” antigens elicit the 
initial antibody response.
8.5 Towards an understanding of DHlipDH in T.b.brucei
Several questions remain to be answered concerning DHlipDH in T.b.brucei. These 
concern the situation in the procyclic cell, intracellular targetting, and the genetic origin of 
the DHlipDH(s).
8.5.1 DHlipDH in procvclic cells
Whilst DHlipDH has been localised solely to the plasma membrane of the 
bloodstream form cell of T.b.brucei, the situation in the procyclic cell remains unclear (see 
section 4.4). This is because it was not possible to show by subcellular fractionation whether 
a small proportion of the DHlipDH was present at the plasma membrane of the cell. If there 
is a plasma membrane-DHlipDH in these cells, this would be very unusual, as there are few 
enzymes located in both the mitochondrion and the plasma membrane of an organism. If 
there is no plasma membrane DHlipDH in procyclics, then presumably this DHlipDH only 
has a function in the bloodstream form. Therefore, the possible functions of the enzyme are 
narrowed down to those which occur in one form, but not the other. Indeed, several 
membrane processes are very different between the two forms, with receptor-mediated 
endocytosis stopping in the procyclic cells, VSG being swapped for procyclin, and glucose 
transport changing (see section 1.2.2).
8.5.2 Intracellular targetting
With the small size of the eukaryotic mitochondrial genome, it is thought that the 
majority of constituent polypeptides are encoded in the nucleus and are synthesized on free 
ribosomes in the cytosol (see De Marcucci et al., 1988). The tiypanosomes are no exception 
in this respect, with the kinetoplast DNA encoding only cytochromes, ATPase and a few 
other polypeptides (Simpson, 1987). In other eukaryotes, nuclear-encoded polypeptides are 
targetted to the mitochondrion by means of an N-terminal signal peptide, which may also 
serve to regulate uptake, maintain hydrophobic proteins in their soluble state, interact with 
soluble cytosolic recognition factors, and prevent premature aggregation. Such extensions 
have been demonstrated for the mammalian PDHC and 20GDHC components, with pie-E3 
having an extra 15-20 amino acids (Mr = 1500-3500) in each case (see De Marcucci et al.,
1988). The N-terminal extension to the pre-E3 is cleaved by a specific matrix protease 
during or shortly after entry into the mitochondrial matrix ( t ^  approx. = 5-10 min; Hunter & 
Lindsay, 1986). The dimeric DHlipDH then interacts with the E2 or protein X components 
of the 2-oxo acid dehydrogenase complexes.
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Targeting to the plasma membrane is reasonably well understood for secretory and 
integral membrane proteins, but for those loosely associated with the membrane, the position 
remains unclear. It is presumed, however, that interaction with cytoplasmic factors such as 
chaperones is essential for correct processing and targeting (see Rhee & Hunter, 1990; Ellis 
& van der Vies, 1991).
8.5.3 The genetics of DHlipDH
In T.b.brucei, there are two basic models which can be considered for the encoding of 
the enzyme, namely that the plasma membrane and mitochondrial DHlipDHs could be 
encoded by one gene or by two separate genes.
The one gene model: If there were one gene for DHlipDH in T.b.brucei, then the decisive 
event for protein targeting must occur either at the DNA, RNA or protein level. Some form 
of genetic rearrangement at the DNA level could occur to ensure that the correct leader 
sequence is attached to the active gene. Indeed, the gene could be transposed, or copied, in 
the bloodstream form cell, to an active expression site, such as one of those for VSG 
production. These expression sites contain several developmentally regulated genes (see van 
der Ploeg, 1987; Revelard et al., 1990).
Alternatively, messenger RNA splicing may mediate differential targeting. An 
example of this is the mitochondrial and cytosolic fumarases of Saccharomyces cerevisiae, 
which are encoded by a single nuclear gene, FUM1 (Wu & Tzagoloff, 1987). Almost every 
imaginable pattern of alternative splicing has been reported in different organisms, and the 
process is often associated with stage-specific expression (Maniatis, 1991), making it a clear 
possibility for the trypanosomal DHlipDH.
The two gene model: With two genes for DHlipDH, one could contain the mitochondrial 
leader, and the other a signal for the plasma membrane. The citrate synthases of S.cerevisiae 
are examples of mitochondrial and non-mitochondrial proteins encoded by separate 
homologous genes (Rosenkrantz et al., 1986). These differ markedly in their N-termini, with 
CIT1 having a 38-residue mitochondrial target sequence, and CIT2 having a different 20- 
amino acid N-terminal extension, the function of which is unknown. There are also examples 
of homologous genes in T.b.brucei. Glycosomal and cytosolic phosphoglycerate kinase 
genes, together with a third homologous gene, are encoded in a tandem array in a 
multicistronic transcription unit (Gibson et al., 1988). This is processed into individual 
mRNAs by splicing and addition of mini-exons.
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8.6 Future work
The beauty of the trypanosomal DHlipDH system is that one can study the enzyme in 
two separate cellular locations within one organism, but at different stages in its lifecycle. 
This allows studies at both the genetic and protein levels which are not possible in other 
organisms, and provides an excellent model system for looking at developmental regulation.
8.6.1 Enzymological studies
Within the procyclic cell, it remains to be seen whether a DHlipDH is present at the 
plasma membrane. Immunocytochemical localisation and digitonin-permeabilisation studies 
should provide an answer to this question (see section 4.4).
Purification of DHlipDH from the bloodstream form cell remains a priority, as protein 
sequence data are vital to genetic investigations on the enzyme. It will also be useful to 
purify the DHlipDH from the mitochondria of procyclics in order to gain further sequence 
data for genetic analysis.
8.6.2 Genetic studies
Probably the best route to structural and functional studies on the trypanosomal 
DHlipDH(s) is via cloning and sequencing of the gene(s) for the enzyme(s).
With the use of oligonucleotide probes, it should be possible to identify the gene(s) 
for DHlipDH in the genome of T.b.brucei. A probe derived from the N-terminal amino acid 
sequence of the bloodstream form DHlipDH, when applied to genomic digests should 
identify the correct gene by Southern analysis. If the one gene model were true, this gene 
might contain an upstream mitochondrial leader sequence separated from the gene by a splice 
or recombination site. With the two gene model, some other signal for the plasma membrane 
might be present, but there would be no mitochondrial leader. This is not a watertight 
method for distinguishing between the models, but the use of homologous probes, based upon 
conserved sequences from other DHlipDHs, should help to identify the one or two genes 
involved.
During the writing of this thesis, a gene encoding a DHlipDH has been identified in 
the genome of T.b.brucei using homologous probes (A.J.Else, University of Bath, personal 
communication). These were a 43mer constructed from part of the FAD domain (E.coli 
residues 40 to 54), and a 29mer from part of the central domain {E.coli residues 318 to 327), 
of DHlipDH (see Carothers et al., 1989 for sequence alignments). The N-terminal sequence 
of the bloodstream form DHlipDH will be a useful tool in determining whether this gene 
encodes a plasma membrane DHlipDH. Indeed, any protein sequence data from either the 
plasma membrane or mitochondrial enzymes would be very helpful in this respect.
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8.6.3 Structural and functional studies
Once the gene for the bloodstream form DHlipDH has been identified and cloned, it 
should be possible to express the enzyme in E.coli, as a prelude to structural studies such as 
nuclear magnetic resonance or X-ray crystallography. Antibodies to the pure enzyme can be 
raised and used for immunocytochemical localisation and rapid purification through 
immunoprecipitation.
It should also be possible to use the gene for functional studies. Specific mutations 
could be made in vitro to produce inactive enzyme. The mutant gene could be recombined 
back into the genomes of live trypanosomes by homologous recombination, so that it replaces 
the existing gene. The effect of this mutation upon the survival of the cell and several 
cellular functions could be assessed (see Eid & Sollner-Webb, 1991). The same effect would 
be produced by making antisense RNA to a particular region of the gene, and introducing this 
into the cell, so that it binds to the DHlipDH gene and blocks its transcription (see Kinsman 
& Kinsman, 1988).
8.6.4 Developmental regulation
Another interesting direction for future research into DHlipDH in T.b.brucei could be 
to look at the developmental switching of the enzyme in its different locations. A technique 
for differentiating bloodstream to procyclic cells in vitro has been developed by Overath et 
al. (1987). Differentiation is triggered by the addition of citrate/cw-aconitate to the growth 
medium, and alteration of the temperature from 37*C to 26*C. Using this method, Durieux et 
al. (1991) followed alterations in carbohydrate catabolism and citric acid cycle enzymes over 
a 28 day time period. Whilst citrate synthase, isocitrate dehydrogenase (NAD4), succinate 
dehydrogenase and fumarase were not detectable in bloodstream trypomastigotes, they all 
appeared after 24 h differentiation, except citrate synthase, which took 48 h to appear. The 
activities of all of the citric acid cycle enzymes then increased steadily up to 28 days post­
stimulation. It would be very interesting to follow DHlipDH activities and locations and 
mRNA levels with this method, through which a greater understanding of switching events 
could be gained. There are problems, however, with the procedure, as significant levels of 
citrate synthase and NAD+-dependent isocitrate dehydrogenase were detected in in vitro- 
produced procyclics. Citrate synthase activity is very low (Jenkins et al., 1988), and NAD- 
IDH is not present in "true" procyclics (Fairlamb & Opperdoes, 1986). This suggests that the 
metabolic switching in vitro is not properly regulated, perhaps because the environment of 
the cells does not have the correct stimulating and modulating factors.
With cunent gene cloning and enzymological approaches to investigating the unusual 
DHlipDH of bloodstream form trypomastigotes, it should not be long before both the 
structure and function of this enzyme have been elucidated. The trypanosome, however,
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remains a confounding organism to those who attempt to study i t  With its unique 
combination of metabolic laziness and creative complexity, it still manages to evade attack 
from mammalian and insect hosts and drug designers around the world. The plasma 
membrane DHlipDH is perhaps a minor peculiarity when compared to the variable surface 
glycoprotein or glycosomal compartmentation, but even such small discoveries may prove 
essential to the war against this debilitating parasite, and to the gaining of a greater 
understanding of biological systems.
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